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Fruit juice-drug interactions involving drug transporters have been variously studied 
with citrus fruit juices. The collective data led us to hypothesize that the modulating 
activity of citrus fruit juices on cellular transport and metabolic pathways is dependent 
on the dominant flavonoid pattern and taxonomy of the citrus fruits. This hypothesis 
has important implications given the difficult task of compiling complete constituent 
profiles for fruit juice, and the limited success in identifying the active transporter-
modulating component(s) in the juice.  
 
The hypothesis was verified by evaluating the activity of grapefruit, pummelo, 
orange, lime and lemon fruit juices on various cellular transport pathways and 
CYP3A4-mediated metabolism. Grapefruit and pummelo are classified under the 
neohesperidosyl species based on dominant flavonoid pattern, while lime and lemon 
belong to the rutinosyl species. Classification of these fruits based on taxonomy 
yielded parallel groupings. Orange, on the other hand, belongs to the same taxonomic 
family as grapefruit and pummelo, but is classified as a rutinosyl species with lime 
and lemon based on dominant flavonoid glycosylation pattern. Orange was included 
to test the relative importance of these two classification principles in drug 
interactions.  
 
Data on [14C]-mannitol, [3H]-propranolol and R-123 transport profiles across the 
Caco-2 cell monolayers suggest that the effects of the citrus fruit juices on the 
paracellular and transcellular diffusive pathways, and on P-gp mediated efflux 
activity, respectively, are in agreement with the hypothesis. Lime and lemon juices 
consistently showed a stronger tendency to modulate the intercellular tight junction 
 ix
compared to grapefruit, pummelo and orange juices. The basal-to-apical propranolol 
flux was also more sensitive to lime and lemon juices, although all 5 fruits did not 
modulate the transcellular absorption of propranolol to a great extent. Grapefruit and 
pummelo juices modified the R-123 efflux and cellular accumulation profiles in a 
manner that implicate P-gp inhibition. Orange juice also inhibited R-123 efflux, but 
its effects on the cellular accumulation of R-123 were not in agreement with P-gp 
inhibition. The fruit juice-mediated P-gp activities were further verified by bi-
directional digoxin transport across the MDR1-transfected L-MDR1 cells, and similar 
conclusions were reached. The hypothesis could also be extended to the pOCT2-
mediated transport in the LLC-PK1 cells. Grapefruit, pummelo and orange juices 
produced pOCT2-mediated R-123 transport and cellular accumulation profiles that 
were comparable to those induced by TEA, an established OCT inhibitor. In contrast, 
the overriding influence of lime and lemon juices was to enhance the bi-directional 
transport of R-123 through the paracellular transport pathway. This was true also for 
digoxin transport across the L-MDR1 cell monolayers. The collective transport data 
suggest that the taxonomic classification of orange juice has a greater influence on its 
capacity to modulate cellular permeation. 
 
On the other hand, the hypothesis could not be applied to predict the modulating 
effects of the citrus fruit juices on the cellular P-gp and pOCT2 expression in cells or 
P-gp and mRNA levels in rodent tissues. Neither can it be used to predict the 
modulating effects of the fruit juices on CYP3A4-mediated metabolism of 
midazolam, which appeared to be more closely related to the furanocoumarins content 
of the fruit juices.  
 x
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 of pOCT2 using [PT2]. Upper bands, OCT2; lower bands, β-actin.  
 β-actin was used to confirm equal protein loading. (b) Optical density of  
 OCT2/β-actin bands as quantified by densitometric analyses. Data represent  
 mean ± SEM, n = 3. * p < 0.05 compared with control cells (C). 
 
5.1. HPLC chromatograms of (a) midazolam (MDZ; Rt = 10.63 min) and   150 
 (b) 1’-hydroxymidazolam (1’-OH MDZ; Rt = 7.93 min) in heat-inactivated  
 HIM systems.  
 
5.2. HPLC chromatograms of incubation mixtures containing (a) human   151 
intestinal microsomes (HIM) with 8 μM of MDZ, (b) MDZ alone,  
(c) HIM alone, and (d) HIM with 8 μM of MDZ and 10 μM of  
ketaconazole. HPLC analysis was performed after 10 min of incubation  
at 37oC.  Peaks were assigned to the following compounds:  
1’-hydroxymidazolam (1’-OH MDZ; Rt = 7.93 min), midazolam  
(MDZ; Rt = 10.63 min), norclomipramine HCl as internal standard  
(IS; Rt = 16.53 min) and ketaconazole (Keto; Rt = 23.78 min). 
 
5.3. Effects of citrus fruit juices on the amount of (a) 1’-OH MDZ formed   154 
and (b) MDZ remaining after 8 μM of MDZ was incubated for 10 min  
in human intestinal microsome (HIM) system. From left to right: HIM  
without inhibitor (Control), HIM with ketoconazole (Keto; 10 μM),  
grapefruit (GFJ), pummelo (PJ), orange (OJ), lime (LiJ) or lemon juices  
(LJ). Citrus fruit juices were applied at 5 (n=2) or 12.5% v/v (n=1).  
Data are presented as mean ± SEM, except data for juices at 12.5% v/v.  
 
5.4. Metabolism of midazolam (Mw = 362.25) by CYP3A.    158 
 
9.1. Standard curves of (a) MDZ and (b) 1’-OH MDZ concentrations versus 243 
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1.1. ORAL DRUG BIOAVAILABILITY 
1.1.1.   Introduction 
A drug can be administered into the human body via various routes, such as by oral 
ingestion, injection, inhalation or contact with the skin or mucosal membrane in the 
rectum, nose and cornea (Fig. 1.1). Except when the drug is introduced directly into 
the blood stream, it will enter the systemic circulation by passing through an epithelial 
barrier, a process known as absorption. Once in the blood, the drug distributes rapidly 
between the plasma and other body compartments. Most drugs readily cross the 
capillaries to reach the extracellular fluid, with lipid-soluble drugs capable of 
permeating cell membranes also accessing the intracellular fluid of organs and tissue. 
Concurrently, the drug undergoes elimination either directly through an excretory 
route, e.g. via the urine, or indirectly through metabolism via enzymatic or 
biochemical transformation by the liver (Fig. 1.2). The net contribution of these 
pathways results in drug clearance from the circulation (Gunaratna, 2000). Because of 
the biodistribution and clearance pathways, only a fraction of the drug in the blood 
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Figure 1.2. Biodistribution and 
clearance pathways of an 






The most convenient and acceptable route of drug administration is orally by tablets, 
capsules or syrups. However, the oral route presents the greatest number of barriers 
for a drug to be absorbed at therapeutic levels. Oral bioavailability is defined as the 
fraction of an oral dose that reaches the systemic circulation (Ferrec et al., 2001). 
Therapeutic failure results when the desired drug bioavailability is not reached, either 
because absorption is incomplete, or because the drug is metabolized during its first 
pass through the gut wall or liver before reaching the systemic circulation. 
 
1.1.2. Drug Transport Pathways 
One of the barriers that reduce the bioavailability of peroral drugs is the epithelial 
cells that line the gastrointestinal tract (GIT). These cells are tightly connected to each 
other, and most drug molecules must traverse at least two cell membranes (inner and 
outer) to pass from one side of the cells to the other. Drugs can be transported across 
the cells by one or more of these routes: passive diffusion via the paracellular or 
transcellular routes, transcytosis and active carrier-mediated transcellular route (Fig. 
1.3).  
 









Figure 1.3. Routes of transport of drug molecules across the intestinal epithelium. (1) 
paracellular passive diffusion; (2) transcellular passive diffusion; (3) transcytosis; (4) 
carrier-mediated uptake at the apical domain followed by passive diffusion across the 
basolateral membrane (Ref. Ferrec et al., 2001). 
 
Passive diffusion is the most important transfer process for the majority of clinically 
important drugs administered orally. It involves the movement of a substance down 
an electrochemical gradient, and is driven by the concentration gradient or 
thermodynamic solute potential difference across the cell membrane. Passive 
diffusion is characterized by non-saturable kinetics, it does not require metabolic 
energy nor can it be inhibited by structural analogues (Artursson et al., 1996a). The 
rate of diffusion is described by the Fick’s Law (Dawson, 1991; Tukker, 2003), and is 
determined primarily by the physicochemical properties of the drug (e.g. pKa, 
lipophilicity, molecular size, hydrogen bonding potential), and the properties of the 
epithelial membrane. In the absorptive epithelium, drug diffusion can occur across the 
cell membranes (transcellular route), or through the intercellular tight junctions (the 
paracellular route) (Artursson et al., 1996a).  
 
Lipophilic drugs (log P < 5) that distribute readily into the cell membranes of the 
epithelial monolayers are assumed to be transported exclusively by the passive 
transcellular route (Tukker, 2003). This is because the surface area of the brush border 
membrane in the small intestine is more than 1000-fold larger than the paracellular 




surface area (Pade and Stavchansky, 1997; Pappenheimer and Reiss, 1987). There are 
two potential mechanisms for transcellular passive diffusion. The drug molecule can 
distribute into the apical cell membrane and diffuse within the membrane to the 
basolateral side, or diffuse across the apical cell membrane and enter the cytoplasm 
before exiting the cell across the basolateral side (Burton et al., 1993). Most (> 80%) 
approved drugs which are rapidly and completely absorbed after oral administration 
are transported by the passive transcellular route (Brennan, 2000).  
 
On the other hand, hydrophilic drug molecules that are not distributed to cell 
membrane to a large extent and are not substrates of active transporters are limited to 
the paracellular route of transport across the epithelial membrane (Artursson et al., 
1996a,b). The paracellular pathway is defined by a series combination of tight 
junctions and lateral intercellular space. Access to this pathway is limited due to the 
small paracellular surface area and the tight junctions that gate its entrance. The pore 
diameter of the tight junctions in the small intestine is estimated to be less than 10 Å 
(Jung et al., 2000), restricting the paracellular passage to drugs with molecular weight 
(Mw) less than 180 Da and molecular radii less than 4 Å (Yee and Day, 1999).  
 
Active transport processes involve carrier-mediated solute translocation that is driven 
by energy derived from cellular metabolism. It is associated with saturation kinetics, 
substrate specificity, dependence on metabolic energy, and may function against a 
concentration gradient (Artursson et al., 1996a). Solute transport coupled directly to 
the metabolic energy constitutes primary active transport and a classic primary active 
transport carrier is the Na+/K+-ATPase. Many active transport systems also convert 
chemical energy into chemical potential energy by contributing to the potential 




difference across the cell membranes. Solute transport coupled to such a potential 
generated by cellular metabolism is referred to as a secondary active transport 
process. Active transport of drugs is mediated by drug-binding membrane 
translocators. It is saturable at high drug concentrations and can be inhibited by other 
substrates and metabolic inhibitors.  
 
Macromolecules and small particles can be transported across epithelial cells by 
vesicular transport mechanisms, i.e. transcytosis. This is initiated by receptor-
mediated or adsorptive endocytosis at the apical cell membrane, followed by vesicle 
migration across the cell, and exocytosis at the basolateral membrane. The 
transcytotic route is less attractive compared with other routes of absorption because 
of its low transport capacity (Artursson et al., 1996b). It has, therefore, been 
considered to be a viable delivery route only for highly potent drugs, such as peptide 
antigens, which are excluded from the other transport pathways due to their large size 
(de Aizpurua and Russel-Jones, 1988). 
 
1.1.3. Drug Efflux Systems - The P-glycoprotein (P-gp) 
Efflux transporters that extrude intracellular drugs back into the intestinal lumen or 
secrete drugs already in the blood back into the lumen present a formidable barrier to 
drug absorption. These transporters are localized in the apical and basolateral 
membranes of epithelia in many tissues, most notably the excretory organs such as the 
liver, kidney and intestine (Kunta and Sinko, 2004). Efflux transporters in the 
intestine are believed to act as the first line of defence by limiting the absorption of 
potentially toxic xenobiotics (Chan et al., 2004). Efflux transporters are also 




overexpressed in many tumours, where they confer resistance to a diverse range of 
chemotherapeutic agents (Chan et al., 2004).  
 
Efflux transporters are principally ATP-binding cassettes (ABC) transport proteins, 
and are divided into subfamilies where the P-glycoprotein (multidrug resistance 
protein, P-gp), multidrug resistance associated proteins (MRP), and breast cancer 
resistance protein (BCRP) are the distinctive members (Chan et al., 2004; Wagner et 
al., 2001). A characteristic feature of these transporters is a highly conserved (30-50% 
sequence identity among members) ATP-binding cassette of 200-250 amino acids, 
consisting of two nucleotide-binding domains (NBDs) located in the cytoplasm 
(Higgins et al., 1986; Hyde et al., 1990). The ABC transporters generally comprise 12 
transmembrane (TM) regions split into 2 ‘halves’, each with an NBD, although there 
are exceptions, as illustrated in Fig. 1.4. The transporters are conserved between 
species, and many orthologues of the human proteins have been identified and 
characterized in other mammals, most notably rodents. Among the ABC transporters, 
the P-gp is the most studied and well-characterized (Kunta and Sinko, 2004).  
 
The P-gp is a 170-180 kDa phosphorylated and glycosylated plasma membrane 
protein (Klein et al., 1999; Müller, 2005). It is a product of the multidrug resistance 
(MDR) gene family (Chin et al., 1989; Ueda et al., 1986). Among the genes that code 
for this protein, the MDR1 in humans is closely related to the mdr1 and mdr3 (also 
known as mdr1b and mdr1a, respectively) in rodents (Fardel et al., 1996), and all 3 
are involved in drug resistance (Ho et al., 2003). The human MDR2 gene is more 
homologous to the rodent mdr2 gene (Schinkel et al., 1991), both of which do not 
confer drug resistance (Schinkel et al., 1991).  






Figure 1.4. Transmembrane arrangement of ABC efflux transporters. (a) P-gp 
(MDR1), MDR3, MRP4, MRP5, and MRP8, have 12 TM (transmembrane) regions 
and two NBDs (nucleotide binding domains).  (b) Typical MRP transporters (MRP1-3 
and 6-7) have 5 extra TM regions towards the N terminus. (c) ‘Half-transporters’ such 
as BCRP have six TM regions and one NBD (Ref. Chan et al., 2004). 
 
The P-gp consists of two homologous halves of 610 amino acids, joined by a flexible 
linker consisting of 60 amino acids. Each half has an N terminal hydrophobic domain 
containing six TM domains followed by a hydrophilic domain containing a NBD, 
which binds ATP and its analogues. Both halves are essential, as the inactivation of 
either site inhibits substrate-stimulated ATPase activity (Ho et al., 2003) (Fig. 1.5a).  















   
















Figure 1.5. (a) Predicted structure of P-gp. P-gp is composed of two cytoplasmic 
ATP-binding domains (NBD) and two membrane domains (MD) containing six 
predicted transmembrane helices. There are three glycosylation sites on the first 
extracellular loop. (b) In cells that do not express P-gp, cytotoxic agent enters the cells 
by diffusion through the plasma membrane. In the cytosol, they can exert their 
cytotoxic effects and lead to cell death (white arrows). In MDR cells overexpressing 
P-gp, drugs appear to be extruded directly from the lipid phase and cannot accumulate 
in the cell (grey arrow). P-gp function requires ATP hydrolysis. However, the 
coupling with drug transport is unclear as P-gp displays a constitutive ATP hydrolysis 
activity in the absence of any identified ligand. The two NBDs appear non equivalent 
but cooperate during ATP hydrolysis (Ref. Ferté, 2000). 
 
Kinetic data indicating non-competitive interactions between P-gp substrates and 
inhibitors (Litman et al., 1997; Pascaud et al., 1998), together with photoaffinity 
labeling studies (Dey et al., 1997), have suggested the presence of at least 2 distinct 




substrate binding sites that show overlapping substrate specificities and positive 
cooperativity. A third drug-binding (non-transporting) site with positive allosteric 
properties for drug transport has also been reported (Shapiro and Ling, 1998). 
Ultimately, the inhibition data obtained from P-gp interaction studies depends on the 
substrate used (Schwab et al., 2003). 
 
In humans, P-gp was first described in tumor cells, where it contributes to multidrug 
resistance by promoting the efflux of a range of structurally unrelated anticancer 
drugs (Fromm et al., 1999). Exceptionally high P-gp expression is constitutive in 
tumors that arise from tissues known to physiologically express the transporter, such 
as carcinomas of the colon, kidney, liver and pancreas (Goldstein et al., 1989; Huang 
et al., 1992; Kramer et al., 1993). The multidrug resistance phenotype shows 
decreased intracellular drug accumulation (Holmes and West, 1994), which often 
leads to treatment failure and poor prognosis for cancer and AIDS (Fojo et al., 1987).  
 
Besides tumor cells, P-gp is also constitutively expressed in a wide range of normal 
tissues in both humans and rodents. It is localized on the villus tip of the  brush border 
membranes of several tissues with excretory function, such as the small and large 
intestines (brush border membrane of enterocytes), liver (canalicular membrane of the 
hepatocytes), kidney (brush border membrane of proximal tubule cells), and blood-
brain barrier (capillary endothelial cells) (Fromm, 2000, 2003; Fromm et al., 1999). 
The polarized, apical membrane location suggests an excretory or barrier role for P-gp 
in mediating the efflux of xenobiotics and toxins into the intestinal lumen, bile, urine 
and blood, respectively (Ernest and Bello-Reuss, 1998; Gatmaitan and Arias, 1993; 
Hunter et al., 1993a,b; Mayer et al., 1996; Schinkel, 1999; Terao et al., 1996; 




Thiebaut et al., 1987; Tsuji and Tamai, 1996). P-gp in the intestinal enterocytes may 
therefore limit the bioavailability of peroral drugs (Arimori and Nakano, 1998; Chan 
et al., 2004; Fromm, 2000; Huisman et al., 2001; Kunta and Sinko, 2004). However, 
the P-gp is not uniformly distributed along the length of the GIT. It is maximally 
expressed in the colonic epithelial cells with a gradual decrease in expression 
proximally into the ileum, followed by the jejunum, duodenum and stomach (Ayrton 
and Morgan, 2001; Ho et al., 2003; Wagner et al., 2001). The high expression of P-gp 
in the ileum and the distal colon (Makhey et al., 1998; Sababi et al., 2001; Yumoto et 
al., 1999) counteracts the relatively high transcellular permeability of drugs and 
xenobiotics in these regions (Stephens et al., 2002; Ungell et al., 1998) to ensure the 
overall bioavailability for P-gp substrates remains low (Kunta and Sinko, 2004).  
 
P-gp-mediated drug efflux is an ATP-dependent phenomenon that can occur against 
steep concentration gradients (Ferté, 2000). Two mechanisms have been proposed to 
explain how P-gp performs its function. In the “hydrophobic vacuum cleaner” model, 
P-gp binds directly with substrates in the plasma membrane and pumps them out of 
the cell (Gottesman and Pastan, 1993). According to the “flippase” model, P-gp binds 
with substrates in the inner leaflet of the plasma membrane and flips them to the outer 
leaflet from which they diffuse into the extracellular medium (Higgins and 
Gottesman, 1992).  
 
A variety of structurally and pharmacologically unrelated hydrophobic compounds, 
such as anticancer agents, steroid hormones, calcium channel blockers, 
immunosuppressants and β-blockers, have been identified as P-gp substrates (Hunter 
et al., 1993a; Terao et al., 1996). However, a defined structure-activity relationship for 




P-gp substrates remains elusive (Chan et al., 2004), as the substrates have been found 
to range in size from 300 to 2000 Da, and they can be basic, uncharged, or acidic 
(Gottesman and Pastan, 1993; Ueda et al., 1997). The only commonality was their 
amphipathic nature (Chan et al., 2004; Ferté, 2000).  
 
Some interacting compounds, structurally diverse from P-gp substrates, may inhibit 
the P-gp function (Schwab et al., 2003). Inhibitors have been classified as 
competitive, non-competitive and cooperative inhibitors (Ayesh et al., 1996; Litman 
et al., 1997). For instance, cyclosporin A is a competitive inhibitor of verapamil 
(Litman et al., 1997) as both compounds compete for the same binding site on the P-
gp (Ayesh et al., 1996). Vanadate is a non-competitive inhibitor of verapamil (Litman 
et al., 1997) as it interacts with the catalytic domain of the P-gp ATPase, and not with 
the P-gp binding site (Senior et al., 1995). Verapamil, on the other hand, is a 
cooperative inhibitor of progesterone as it increases the affinity of progesterone for 
the P-gp site where it stimulates the ATPase (Litman et al., 1997). Some compounds, 
the so-called non-transported substrates, such as midazolam, nifedipine and 
ketoconazole (Polli et al., 2001), may bind with P-gp without being transported. P-gp 
does not influence the pharmacokinetics of P-gp inhibitors or non-transported 
substrates, but these compounds may modify the pharmacokinetics of co-administered 
P-gp substrates (Schwab et al., 2003). Inhibition of P-gp function results in increased 
intestinal absorption, and decreased excretory efflux in the kidney and biliary tract for 
P-gp substrates (Schinkel et al., 1995). Bioavailability of P-gp substrates will also be 
moderated upwards at higher doses as a result of transporter saturation (Wagner et al., 
2001). 
 




1.1.4. Drug Uptake Systems – The Organic Cation Transporters (OCT)   
Besides the ABC transporter families, the human body is equipped with another 
important group of membrane transporters that mediates the uptake, elimination and 
distribution of drugs, environmental toxins and metabolic waste products (Koepsell, 
2004; Sai, 2005). According to the guidelines of the Human Genome Organization 
(HUGO) Nomenclature Committee (http://www.gene.ucl.ac.uk/nomenclature/), these 
transporters are classified as solute carrier (SLC), by far the largest superfamily of 
transporters with about 225 members (Jonker and Schinkel, 2004; Sai and Tsuji, 
2004). Within the SLC superfamily, the solute carrier family 21 (SLC21) and 22 
(SLC22) have been identified, and both are found to mediate the transport of a variety 
of structurally diverse organic anions, cations, and uncharged compounds (Jonker and 
Schinkel, 2004).  
 
The SLC21 family of organic anion transporting polypeptides (OATP) currently 
consists of 9 members in humans (Hagenbuch and Meier, 2003; Tirona and Kim, 
2002). They transport a range of relatively large (usually > 450 Da), mostly anionic, 
amphipathic compounds, including bile salts, eicosanoids, steroid hormones, and their 
conjugates (Hagenbuch and Meier, 2003). The SLC22 family currently consists of 12 
members in humans and rats (Koepsell and Endou, 2004), and encompasses the 
organic cation transporters (OCT) (Koepsell et al., 2003), organic anion transporters 
(OAT) (Sweet et al., 2001), carnitine transporter (OCTN) (Wu et al., 1998), urate 
anion-exchanger (URAT) (Enomoto et al., 2002), and some gene products of 
unidentified function (Koepsell, 2004).  
 




Approximately 50% of clinical drugs are polar and, with pKa ranging from 8 – 12, are 
positively charged at physiological pH (Koepsell, 1998; Zhang et al., 1998). 
Examples include quinidine, cimetidine, morphine and acebutolol. These structurally 
and pharmacologically diverse compounds, together with certain toxins (e.g. 
paraquat) and endogenous amines (e.g. choline and dopamine), are collectively 
classified as organic cations (OC). They do not permeate cell membranes freely, and 
their transport in or out of cells are mediated by the polyspecific OCT (Ciarimboli and 
Schlatter, 2005; Koepsell, 2004; Koepsell et al., 2003). The OCT (OCT1, 2 and 3) are 
expressed in various tissues, such as the intestine, liver and kidney (Katsura and Inui, 
2003; Koepsell, 1998; Zhang et al., 1998) and have extensively overlapping substrate 
specificity.  
 
The rodent rOCT1 is the first member of the OCT family to be cloned (Gründemann 
et al., 1994). Two additional subtypes, rOCT2 and rOCT3, and the OCT homologs 
from humans and other species have since been identified (Koepsell et al., 2003; 
Koepsell and Endou, 2004). The expression and function of the OCT are subtype-, 
tissue- and species-specific (Koepsell et al., 2003). For example, rOCT1 is expressed 
abundantly in the kidney, intestine, and liver, but not in the colon, skin, spleen, 
choroid plexus and brain (Gorboulev et al., 1997; Gründemann et al., 1994; Koepsell 
et al., 2003; Meyer-Wentrup et al., 1998). In contrast, the rabbit OCT1 is expressed 
primarily in the liver, as is the case of hOCT1. OCT2, on the other hand, appears to 
have similar tissue distributions in the human and the rat where it localizes to the 
basolateral membrane of renal proximal tubules (Dresser et al., 2000; Gorboulev et 
al., 1997; Karbach et al., 2000; Okuda et al., 1996; Sugawara-Yokoo et al., 2000). In 
humans, hOCT1 and hOCT2 are predominantly expressed in the excretory organs 




(Koepsell, 1998; Zhang et al., 1998), with hOCT1 localized in the liver (Gorboulev et 
al., 1997) and hOCT2 in the kidney (Gorboulev et al., 1997; Koepsell et al., 1999; 
Motohashi et al., 2002). In contrast, hOCT3 mRNA has been detected at high levels in 
a wide number of tissues, including the aorta, skeletal muscle, prostate, adrenal gland, 
salivary gland, liver, term placenta and fetal lung (Verhaagh et al., 1999). However, 
the hOCT3 mRNA level in the kidney appears to be about 10% that of hOCT2, but is 
more than 10 times greater than that of OCT1 (Motohashi et al., 2002). Such organ-
specific distribution of OCT could in part be responsible for the organ-specific 
transport mechanisms of an OC, which determines the final distribution of an OC 
between the extracellular and intracellular spaces in different tissues.  
 
Most information on OCT has been obtained from the kidney (Burckhardt and Wolff, 
2000; Koepsell et al., 1998), which expresses this transporter in abundance (Koepsell, 
2004; Sweet and Pritchard, 1999). In humans, high levels of hOCT2, with a lower 
expression of hOCT1, have been found in the basolateral membrane of the renal 
proximal tubule, rendering this the primary site for OCT-mediated renal tubular 
secretion (Fig. 1.6) (Masereeuw and Russel, 2001; Wright, 2005). 
Immunohistochemical studies have further revealed that hOCT2 is also located at the 
apical membrane of the distal tubule, indicating a role in the reabsorption of OC 
(Gorboulev et al., 1997). Less data are available regarding the role of the OCT in the 
intestine. hOCT1 has been found to localize in the basolateral membrane of the small 
intestine (Katsura and Inui, 2003) where it mediates the uptake of OC from the blood 
into the intestinal lumen. hOCT2 mRNA has also been detected in the small intestine 
by reverse transcription-polymerase chain reaction (RT-PCR) (Gorboulev et al.,  
 























Figure 1.6. Organic cation secretion across the epithelium of the proximal renal 
tubule in three simplified steps: (i) potential-dependent facilitative diffusion across the 
basolateral membrane, (ii) intracellular sequestration, and (iii) secretion across the 
apical membrane. Two putative reabsorption pathways are also shown (Ref. Zhang et 
al., 1998).     
 
 
1997). The intestinal OCT is believed to play a role in limiting the absorption and/or 
promoting the secretion of OC. 
 
Several properties are common to the OCT regardless of subtype or species-
differentiation. They are: (a) OCT translocate a variety of organic cations with widely 
differing molecular structures, (b) OCT translocate OC in an electrogenic manner. 
Electrogenicity of transport has been shown for rOCT1, rOCT2 and rOCT3 (Busch et 
al., 1996; Gründemann et al., 1994; Kekuda et al., 1998; Nagel et al., 1997; Okuda et 
al., 1999), as well as for hOCT1 and hOCT2 (Busch et al., 1998; Dresser et al., 2000, 
2001; Gorboulev et al., 1997), (c) OCT-mediated transport is independent of Na+ and 
Cl-  (Busch et al., 1996; Gorboulev et al., 1997; Kekuda et al., 1998). (d) OCT can 




translocate OC across the plasma membrane in either direction, as has been 
demonstrated for rOCT1, rOCT2, hOCT2 and rOCT3 (Busch et al., 1996, 1998; 
Kekuda et al., 1998; Nagel et al., 1997). 
 
1.1.5. Drug Metabolism – The Cytochrome P450 3A4 (CYP3A4)    
Net absorption of a drug from the intestinal lumen to portal blood can be limited by 
significant first-pass metabolic elimination of the drug by enzymes in the GIT (lumen 
and mucosal epithelium) and the liver (Benet et al., 1996a; Fisher et al., 1999; 
Guengerich, 1995). One of the most important classes of drug–metabolizing enzymes 
in humans is the cytochrome P450 (CYP) enzymes (Guengerich, 1995). CYP belongs 
to a large multigene family (encoded by the P450 gene) that has been divided into 
families that share > 40% amino acid sequence homology (as designated by a 
number), and subfamilies that share > 70% amino acid homology (as designated by a 
letter, followed by another number to denote the sequence of recovery) (Gonzalez, 
1988; Gunaratna, 2000). They are membrane bound, heme-containing proteins (MW 
~50 kDa) (Gunaratna, 2000) found in the endoplasmic reticulum of cells throughout 
the body (Ghosal et al., 1996; Gunaratna, 2000). Approximately 70 human CYPs have 
been identified, out of which six (CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1 
and CYP3A4) are major drug metabolising enzymes (Gunaratna, 2000).  
 
The CYP enzymes metabolise a diverse array of clinically important, structurally 
 diverse drugs, most of which are lipophilic (Table 1.1). Some drugs are metabolised 
by more than one isozyme, e.g. propranolol is metabolised by CYP1A2 and CYP2D6. 
Most CYP enzymes also exhibit multiple-substrate metabolism, which can give rise to  
 









CYP1A2 Amitriptyline, Betaxolol, Caffeine, Clomipramine, Clozapine, 
Chlorpromazine, Fluvoxamine, Haloperidol, Imipramine, Olanzapine, 
Ondansetron, Propranolol, Tacrine, Theophylline,  Verapamil, (R)-
Warfarin 
CYP2A6 Coumarin, Betadiene, Nicotine 
CYP2C9 Amitriptyline, Diclofenac, Demadex, Fluoxetine, Ibuprofen, Losartan, 
Naproxen, Phenytoin, Piroxicam, Tolbutamide, (S)-Warfarin 
CYP2C19 Amitriptyline, Citalopram, Clomipramine, Diazepam, Imipramine, 
Omeprazole 
CYP2D6 Amitriptyline, Betaxolol, Clomipramine, Codeine, Clozapine, 
Desipramine, Fluoxetine, Haloperidol, Imipramine, Methadone, 
Metoclopramide, Metoprolol, Nortriptyline, Olanzapine, Ondasetron, 
Paroxetine, Propranolol, Risperidone, Sertraline, Timolol, Venlafaxine 
CYP2E1 Acetaminophen, Caffeine, Chlorzoxazone, Dextromethorphan, Ethanol, 
Theophylline, Venlafaxine 
CYP3A4/5 Alprazolam, Amiodaron, Amitriptyline, Astemizole, Bupropion, 
Buspirone, Caffeine, Carbamazepine, Cerivastatin, Cisapride, 
Clarithromycin, Clomipramine, Codeine, Cyclosporine, 
Dexamethasone, Dextromethorphan, Diazepam, Diltiazem, Donepezil, 
Doxycycline, Erythromycin, Estradiol, Felodipine, Fluoxetine, 
Imipramine, Lansoprazole, Lidocaine, Omeprazole, Orphenadrine, 
Paroxetine, Progesterone, Quinidine, Rifampin, Sertraline, Sibutramine, 




drug-drug, food-drug and environmental toxin-drug interactions. Some compounds, 
not necessarily substrates, can act as CYP inducers or inhibitors. An enzyme inducer 
such as rifampin (Hosagrahara et al., 1999; Kolars et al., 1992) increases the specific 
enzyme level by modulating the gene expression, and this can result in lower systemic 
levels of a drug (Hebert et al., 1992; Holtbecker et al., 1996). On the other hand, an 
enzyme inhibitor such as grapefruit juice (Lown et al., 1997a; Schmiedlin-Ren et al., 
1997) decreases the enzyme protein level and causes higher systemic levels of a drug, 
which can lead to enhanced efficacy or toxicity (Bailey et al., 1995; Yee et al., 1995). 




These factors thus contribute to variable drug bioavailability and may adversely affect 
therapeutic outcome.  
                                           
CYP3A4 is the most abundant CYP expressed in the human liver and small intestine 
(Guengerich, 1999; Peters and Kremers, 1989; Watkins et al., 1987). It contributes to 
the metabolism of approximately 50% of the clinically available drugs (Guengerich, 
1999; Gunaratna, 2000), and more than half of the drugs absorbed in the GIT (Benet 
et al., 1996a; Doherty and Charman, 2002; Raeissi et al., 1999). 
Immunohistochemical studies have shown that CYP3A4 comprises on average 70% 
of the total CYP protein in the human small intestine (Watkins et al., 1987), and this 
concentration is approximately 80-100 % of that in the liver (Paine et al., 1997). 
CYP3A4 protein concentration and enzymatic activity in the intestinal and hepatic 
microsomes are comparable (Watkins et al., 1987), and the two forms of CYP3A4 
have identical cDNA (Lown et al., 1998), although they are not co-ordinately 
regulated (Lown et al., 1994). The collective data suggest that the intestinal CYP3A4 
contributes equally to the first pass metabolism of orally administered drugs as the 
hepatic CYP3A4.  
 
Unlike the P-gp, the CYP3A4 protein and catalytic activity decrease longitudinally 
along the small intestine, with the highest concentration observed at the duodenum, 
followed by jejunum and ileum (Paine et al., 1997; Peters and Kremers, 1989). Within 
the intestines, epithelial cells located closer to the villus tip have the highest CYP 
concentration, while cells located in the crypts have the lowest (Kaminsky and Fasco, 
1991). Factors such as species specificity, genetic polymorphism, gender or hormonal 
control, age, disease, and environmental inducers, such as caffeine or concomitant 




drug therapy, can influence CYP3A4 expression and function. Inter-individual 
amounts of CYP3A4 expressed in the liver and small intestine have been found to 
vary by 10-100-fold and up to 30-fold, respectively (Lown et al., 1994; Wacher et al., 
1998). The molecular basis for the wide inter-individual variation remained 
unexplained.  
 
1.1.6. Synergistic role of P-gp and OCT 
OC transport in the renal proximal tubule cells occurs via the electrogenic pH-
independent transport systems at the basolateral membrane and proton-organic cation 
exchangers (OC/H+) at the brush border membrane (Pritchard and Miller, 1993; 
Ullrich, 1994). Luminal OC/H+ exchange appears to be the rate-limiting step 
(Pritchard and Miller, 1993; Schäli et al., 1983), with binding to the OC/H+ exchanger 
profoundly influenced by substrate hydrophobicity (Wright et al., 1995). On this 
basis, OC can be classified into “type I” and “type II”. Type I OC are comparatively 
small (Mw < 400) monovalent compounds that enter the renal proximal tubule cells 
via electrogenic facilitated diffusion at the basolateral membrane, and exit the apical 
membrane via electroneutral exchange for H+. This group is exemplified by 
tetraethylammonium (TEA), tributylmethylammonium (TBuMA), and procainamide 
ethobromide (Suhre et al., 2005). Type II OC are usually bulkier (Mw > 500) and 
frequently polyvalent, and they include d-tubocurarine, vercuronium, and 
hexafluorenium (Wright, 2005; Wright and Dantzler, 2004). Type II OC are 
comparatively more hydrophobic, and are not substrates of the luminal H+/cation 
antiporter (Koepsell et al., 1998, 1999). They appear to diffuse across the basolateral 
membrane into the renal cells via the same mechanisms as type I OC, but they exit by 
apical secretion mediated by P-gp (Miller, 1995).  




P-gp in the renal brush-border therefore plays a complementary role in the secretion 
of OC. The P-gp and OCT at the brush border membrane have similar substrate 
specificities (Holohan et al., 1992; Smit et al., 1998b), and a number of OC, e.g. 
quinidine, verapamil and cimetidine, may be secreted by the combined action of the 
P-gp and hOCT1, or by P-gp and hOCT2 (Sakaeda et al., 2002). This overlap in 
substrate selectivity for parallel transport pathways is not unusual (van Montfoort et 
al., 2001; Smit et al., 1998a), although it is possible for one transport pathway to 
predominate. For example, the basolateral-to-apical (BA) transport of cadmium is 
mediated by endogenous P-gp and OCT in the porcine kidney, LLC-PK1 cells (Endo 
et al., 2002; Kimura et al., 2005) but is predominantly mediated by P-gp in the P-gp-
overexpressed derivative cell line, LLC-GA5-COL 150 cells. Consequently, OCT 
inhibitors had no effect on the BA flux of cadmium across the LLC-GA5-COL 150 
cells (Kimura et al., 2005). This has implications on drug elimination in normal 
kidney tissues (exemplified by LLC-PK1 cells) and diseased kidney tissues with over-
expressed P-gp (exemplified by LLC-GA5-COL 150 cells).  
 
1.1.7.   Synergistic role of P-gp and CYP3A4 
Benet and coworkers were among the first to hypothesize that the P-gp and CYP3A4 
act co-ordinately to lower the oral bioavailability of many drugs (Benet et al., 1996b, 
1999, 2004; Benet and Cummins, 2001; Wacher et al., 1996). This is because the two 
proteins share considerable overlap in substrate specificity (Ho et al., 2003; Kim et 
al., 1999; Schuetz et al., 1996; Wacher et al., 1995), with the substrate of one protein 
inadvertently a substrate or inhibitor of the other (Wacher et al., 1995; Wandel et al., 
1999). The two proteins are also jointly present in significant amounts in the villi of 
the small intestine (Benet et al., 1999; Ho et al., 2003), the P-gp on the apical brush 




border membranes (Thiebaut et al., 1987), and CYP3A4 in the endoplasmic reticulum 
just below the brush border membrane (Watkins, 1997). One proposal is that P-gp 
facilitates repeat enzyme exposure through the recycling of drug via diffusion and 
active efflux (Fig. 1.7) (Benet et al., 2004; Benet and Cummins, 2001; Wacher et al., 
1998). Drug molecules that escape CYP3A4 metabolism in the enterocytes are 
transported back into the lumen by the P-gp. They then re-enter the enterocytes by 
passive diffusion, resulting in repeated exposure to the metabolic enzyme (Fig. 1.7) 
(Fromm, 2003; Ho et al., 2003; Ito et al., 1999; Suzuki and Sugiyama, 2000). 
Consequently, even low levels of intestinal CYP3A may be significant in reducing 
drug bioavailability in subjects with active intestinal P-gp (Lown et al., 1997b). 
Selective inhibition of P-gp may thus decrease the extent of CYP3A4-mediated drug 
metabolism. This was demonstrated in a clinical study, where the co-ingestion of 10 
mg/kg Sandimmune®, a cyclosporine product, with 2.6 IU/kg tocopheryl 











Figure 1.7. Schematic diagram illustrating the synergistic role of CYP3A4 and P-gp. 
After being taken up by enterocytes, some of the drug molecules are metabolized by 
CYP3A4. Drug molecules which escaped metabolic conversion are secreted from the 
cells into the lumen via the P-gp, and may re-encounter the CYP3A4 following 
reabsorption into the cells (Ref. Suzuki and Sugiyama, 2000). 
 




increase in the cyclosporine area under the plasma concentration-time curve (AUC) in 
10 healthy volunteers. Cyclosporine is a bisubstrate of P-gp and CYP3A4, while 
TPGS is a water-soluble form of vitamin E that inhibits the P-gp (Dintaman and 
Silverman, 1999) but has no effect on CYP3A metabolism (Chang et al., 1996).  
 
1.2. FRUIT JUICE-DRUG INTERACTIONS 
The practice of administering medicine with meals in order to aid patient compliance 
(Haynes et al., 1976) can create opportunities for food-drug interactions. Food-drug 
interactions can be defined as food-induced alterations in the pharmacokinetic and/or 
pharmacodynamic profile of drugs, some of which may be clinically significant. Food 
-drug interactions can occur at the absorption, distribution, metabolism and/or 
elimination phases. For an orally administered drug, food has the greatest effect on its 
absorption and metabolism in the GIT.  
 
Among all food, fruits have a high potential for food-drug interactions since they are 
widely available and frequently consumed, either as whole fruits, meal condiments, 
fruit juices, flavoured processed drinks, or preserved snacks. The recent fortification 
of juices with calcium has increased the intake of citrus juices, such as grapefruit and 
orange juices, particularly among the middle-aged and elderly populations, who are 
also the people more likely to require medications (Kane and Lipsky, 2000). Besides 
grapefruit and orange, lime, lemon and pummelo are tropical fruits of the genus 
Citrus that are also widely consumed, in particular by Asian populations.  
 
Most citrus fruits are acidic, and may affect drug bioavailability by decreasing the pH 
of GI fluids (Basu, 1998). However, mounting evidence has suggested that citrus fruit 




juices can interact with metabolic enzymes and/or carrier proteins in the GIT to 
modify therapeutic outcomes. Of the citrus fruit juices, grapefruit juice has been the 
most widely investigated for drug interactions.   
 
1.2.1.   Grapefruit juice-drug interactions 
More than a decade ago, grapefruit juice was discovered by chance to increase the 
oral bioavailability of felodipine when the juice was used to mask the taste of ethanol 
in a clinical study (Bailey et al., 1991). Since then, grapefruit juice has been found to 
modulate the functions of the CYP3A4 enzymes (Bailey et al., 1991, 1994, 1998b, 
2000; Greenblatt et al., 2003; Kupferschmidt et al., 1995; Lundahl et al., 1995, 1997, 
1998; Veronese et al., 2000, 2003), P-gp (Honda et al., 2004; Romiti et al., 2004; 
Spahn-Langguth and Langguth, 2001; Tian et al., 2002; Xu et al., 2003) and MRP2 
efflux transporters (Honda et al., 2004), and the OATP (Banfield et al., 2002; Dresser 
et al., 2002; Lilja et al., 2003).  
 
1.2.1.1.   Clinical significance and relevance 
Co-administered grapefruit juice has been shown in clinical trials (Bailey et al., 
1993b; Dahan and Altman, 2004; Dresser and Bailey, 2003; Fuhr, 1998; Kane and 
Lipsky, 2000; Lundahl et al., 1995, 1997, 1998; Saito et al., 2005) to change the 
pharmacokinetic parameters of some 40 peroral drugs (out of 59 studied). Based on 
the changes in AUC and Cmax, the juice-drug effects have been classified into Group I 
(> 30% increase in either AUC or Cmax), Group II (no change) and Group III (> 20% 
decrease in either AUC or Cmax) (Saito et al., 2005).  
 




The majority of the 34 drugs (Table 1.2) in Group I undergo substantial presystemic 
metabolism by CYP3A4, suggesting that grapefruit juice enhanced the bioavailability 
of drugs that undergo extensive CYP3A4 metabolism (Di Marco et al., 2002; Edgar et 
al., 1992; Fuhr, 1998; Lilja et al., 1998; Takanaga et al., 2000a; Veronese et al., 
2003). However, given the extensive overlap in tissue distribution and substrate 
specificities between CYP3A4 and P-gp, scientists have speculated very early on that 
grapefruit juice may interact with the intestinal P-gp. This was confirmed when 
grapefruit juice was found to increase the AUC and/or Cmax of cyclosporine in kidney 
transplanted patients (Min et al., 1996b) and healthy volunteers (Ducharme et al., 
1995; Yee et al., 1995), two groups of patients in which the bioavailability of peroral 
  
Table 1.2.   Drugs demonstrating increased oral bioavailability with grapefruit juice. 
Anti-infective agents Central nervous system agents 
    Artemether     Buspirone 
    Erythromycin     Carbamazepine 
    Halofantrine     Diazepam 
    Praziquantel     Midazolam 
    Saquinavir     Scopolamine 
Anti-inflammatory agents     Sertraline 
    Methyprednisolone     Triazolam 
    Prednisone Corticosteriods 
Antilipemic agents      17β-estradiol 
    Atorvastatin     Progesterone 
    Lovastatin     Ethinylestradiol 
    Simvastatin Gastrointestinal agents 
Cardiovascular agents     Cisapride 
    Amiodarone Histamine H1 antagonists 
    Felodipine     Terfenadine 
    Nicardipine Immunosuppressive agents 
    Nifedipine     Cyclosporine 
    Nimodipine Others 
    Nisolidpine     Caffeine 
    Nitrendipine     Dextromethorphan 
    Verapamil  
    Propafenone  
 




cyclosporine is affected by intestinal P-gp efflux rather than by CYP3A4 metabolism 
(Fricker et al., 1996; Lown et al., 1997b). The same results were not observed when 
cyclosporine was co-administered with Seville orange juice, a CYP3A4 inhibitor but 
not a P-gp modulator (Edwards et al., 1999).  
 
On the other hand, 14 drugs (including alprazolam, quinine, quinidine, indinavir, 
clarithromycin and amlodipine) which are primarily metabolized by CYP3A4, did not 
register changes in AUC and Cmax when co-administered with grapefruit juice (Cheng 
et al., 1998; Ho et al., 1999; Josefsson et al., 1996; Min et al., 1996a; Penzak et al., 
2002; Yasui et al., 2000). It was postulated that these Group II drugs might be 
metabolized by hepatic CYP3A4 and not by the intestinal CYP3A4 (Saito et al., 
2005). Drugs that are metabolized by several enzymes, including CYP3A4, may also 
fail to show a clinical interaction with grapefruit juice (Saito et al., 2005). For 
example, the pharmacokinetic parameters of losartan, a substrate of both CYP3A4 
and CYP2C9, was barely affected by grapefruit juice (Zaidenstein et al., 2001).     
  
There exists a possible third mechanism for the clinical grapefruit juice-drug 
interactions as categorized by drugs in Group III. Grapefruit juice at 5% has been 
found to markedly reduce human OATP function in OATP-transfected HeLa cells but 
not P-gp function in Caco-2 and L-MDR1 cells (Dresser et al., 2002). For bisubstrates 
of OATP and P-gp, e.g. fexofenadine (Banfield et al., 2002; Dresser et al., 2002) and 
celiprolol (Lilja et al., 2003), it implied that their reduced oral bioavailability in the 
presence of grapefruit juice might be mediated by the more potent effect of the juice 
on OATP function. However, the clinical relevance of the effects of grapefruit juice 




on drug uptake transport systems has yet to be established across a range of substrate 
drugs (Dresser and Bailey, 2003).  
 
In terms of dose, it has been shown that the ingestion of a single glass (250 ml) of 
regular strength grapefruit juice was enough to change a therapeutic outcome (Lilja et 
al., 2000a; Lundahl et al., 1998; Rau et al., 1997). In addition, the juice does not have 
to be taken simultaneously with the interacting drug to produce a clinical effect. The 
CYP3A4 inhibitory activity of grapefruit juice has been shown to persist for up to 24 
h (Lundahl et al., 1995), and even up to 3 days (Greenblatt et al., 2003; Takanaga et 
al., 2000a) post-ingestion. Nevertheless, a washout period of 24 h is generally 
regarded as adequate to prevent a potential grapefruit juice-drug interaction (Lilja et 
al., 2000b). There was no evidence of cumulative effect when grapefruit juice was 
consumed daily for up to 14 days (Lundahl et al., 1998).  
 
1.2.1.2.   Mechanism of interactions  
Grapefruit juice inhibits CYP3A4 metabolism by both reversible, competitive (Bailey 
et al., 2000; Greenblatt et al., 2003; Guo et al., 2000) and non-competitive (Greenblatt 
et al., 2003; Paine et al., 2004), and irreversible (mechanism-based) (Bailey et al., 
2000, 2003; Greenblatt et al., 2003; Guo et al., 2000; Lown et al., 1997a; Schmiedlin-
Ren et al., 1997) inhibition of the enzyme. It is proposed that during the mechanism-
based inhibition, CYP3A4 metabolically activates grapefruit juice component(s) to 
reactive intermediates that irreversibly inactivate CYP3A4 by covalent binding 
(Dresser and Bailey, 2003; Silverman, 1988a,b).  The structurally modified CYP3A4 
then undergoes rapid proteolysis within the cells (Dresser and Bailey, 2003) that leads 
to marked reduction in the enterocyte CYP3A4 protein expression (Lown et al., 




1997a; Schmiedlin-Ren et al., 1997). As the CYP3A4 mRNA level remained 
unchanged (Lown et al., 1997a), the mechanism of inhibition is likely to be post-
transcriptional, possibly through an accelerated degradation of the CYP3A4 protein 
(Bailey et al, 1998b). Recovery of CYP3A4 activity thus requires de novo enzyme 
synthesis (Bailey et al, 1998b), which probably accounts for the persistent effect of 
grapefruit juice for up to 3 days post consumption (Greenblatt et al., 2003; Takanaga 
et al., 2000a). Grapefruit juice is believed to contribute insignificantly to competitive 
(reversible) inhibition of CYP3A4 activity in vivo (Bailey et al., 2000, 2003), 
although the relative clinical importance of the two mechanisms remains to be 
clarified (Bailey et al., 2003; Saito et al., 2005). 
 
Grapefruit juice acts predominantly on the intestinal CYP3A4 (Di Marco et al., 2002; 
Kolars et al., 1991; Lown et al., 1997a; Uno et al., 2000; Wu et al., 1995). Hepatic 
CYP3A4 activity is inhibited only when grapefruit juice is consumed at large 
quantities (6-8 glasses of normal strength juice per day or 1 glass of double-strength 
juice 3 times a day) (Lilja et al., 2000a; Rogers et al., 1999; Veronese et al., 2000, 
2003). There is no evidence of hepatic CYP3A4 inhibition when the juice is 
consumed at up to 3 glasses a day at normal strength (Greenblatt et al., 2003; Lown et 
al., 1997a; Uno et al., 2000). This might account for why grapefruit juice elevated the 
bioavailability of a wide range of peroral drugs but had no effect on the 
pharmacokinetics of these drugs when they were injected intravenously (Ducharme et 
al., 1995; Kupferschmidt et al., 1995, 1998; Lundahl et al., 1997; Rashid et al., 1995).  
 
Grapefruit juice also inhibits P-gp located mainly in the intestinal wall (Saito et al., 
2005). Although the inhibitory effects of grapefruit juices on P-gp activity have been 




widely-studied in vitro (Ohnishi et al., 2000; Romiti et al., 2004; Spahn-Langguth and 
Langguth et al., 2001; Takanaga et al., 1998; Tian et al., 2002; Xu et al., 2003), the 
contribution of grapefruit juice to the bioavailability of P-gp substrates is not well-
established (Dresser and Bailey, 2003; Saito et al., 2005; Zhou et al., 2004). 
Nevertheless, it has been shown that thrice daily ingestion of 8 oz (Lown et al., 
1997a) or 300 ml (Schwarz el al., 2005) of grapefruit juice for 6 days did not alter the 
intestinal P-gp expression. At least 2 studies have demonstrated the predominance of 
P-gp inhibition relative to CYP3A4 modulation by grapefruit juice (Edward et al., 
1999; Lown et al., 1997b). For drugs which are substrates of both the P-gp and 
CYP3A4, inhibition of intestinal P-gp by the co-administered grapefruit juice could 
therefore lead to fewer encounters with the CYP3A4 enzyme and a lower degree of 
drug metabolism. The resultant accumulation of intracellular drug will, in turn, 
saturate the CYP3A4 enzyme, which is concomitantly down-regulated by repeated 
exposure to the juice (Eagling et al., 1999).  
 
The influence of grapefruit juice on multiple drug transporters and metabolic enzymes 
can make it difficult to interpret experimental data. Transporters such as the OATP 
and P-gp are both located on the apical membrane of the enterocytes, but they result 
in opposing vectors for uptake into the portal circulation and efflux back into the 
lumen, respectively (Walters et al., 2000). Co-inhibition of these transporters can 
therefore produce different outcomes depending on the predominating influence. In 
one study involving the rat model, co-administered grapefruit juice was found to 
double the Cmax for peroral talinolol and enhanced the AUC value by 1.5-fold. As the 
juice did not affect the terminal talinolol t1/2 and talinolol is a P-gp substrate, the 
enhancement was attributed to grapefruit juice-mediated inhibition of intestinal P-gp 




function (Spahn-Langguth and Langguth, 2001). A recent clinical study, however, 
showed the AUC and Cmax values for peroral talinolol to be reduced by more than 
55% when it was co-ingested with a glass of grapefruit juice (300 ml). As repeated 
ingested of the juice at 900 ml/day for 6 days did not alter the MDR1 mRNA and P-gp 
levels in duodenal biopsy specimens, the results were explained on the basis of a 
preferential inhibition of an intestinal uptake process (Schwarz et al., 2005). Being a 
weak base (pKa 9.4), talinolol may well be a potential substrate of the OCT, like 
metoprolol (Dudley et al., 2000). To date, however, there is no data providing direct 
evidence that grapefruit juice modulates the function of the OCT. 
 
1.2.1.3.   Causative constituents 
The major constituents of grapefruit juice are the flavonoids, a class of polyphenolic 
compounds known to inhibit oxidative drug metabolism. For this reason, they were 
initially considered to be the causative constituents responsible for the juice-mediated 
inhibition of the CYP3A4 enzyme (Buening et al., 1981). Of the flavonoids, naringin 
is the most prevalent in grapefruit juice (Kuhnau, 1976), presenting at concentrations 
of up to 1200 mg/l (Ho et al., 2000). However, naringin does not appear to be capable 
of producing a clinical drug interaction when it is administered at concentrations 
found in commercial grapefruit juice (Bailey et al., 1992, 1993a,b, 1998a; Edwards 
and Bernier, 1996). Its aglycone, naringenin, is a much more potent enzyme inhibitor 
(Guengerich and Kim, 1990) except that it is not normally present in grapefruit juice. 
Although naringenin is formed in vivo, probably in the small intestine following juice 
consumption (Cheng et al., 1971; Fuhr and Kummert, 1995), it is reported to cause 
competitive, not mechanism-based, inhibition of CYP3A4 metabolism (Bailey et al., 
2000). Other flavonoids, such as quercetin and kaempferol, are active CYP3A4 




inhibitors in vitro (Ho et al., 2001; Miniscalco et al., 1992), but they are present only 
in trace amounts in grapefruit juice (Kuhnau, 1976) and they do not exhibit significant 
in vivo activity (Rashid et al., 1993).  
 
Grapefruit juice also contains furanocoumarins (psoralens), which have been shown 
to be mechanism-based inactivators of CYP enzymes (Cai et al., 1993; Guo et al., 
2000; Guo and Yamazoe, 2004; Schmiedlin-Ren et al., 1997) and inhibitors of P-gp 
(Eagling et al., 1999; Ikegawa et al., 2000; Ohnishi et al., 2000; Wang et al., 2001). 
Of particular interest is 6’,7’-dihydroxybergamottin (DHB), which caused a dose-
dependent decrease in the activity (Bailey et al., 2000; Schmiedlin-Ren et al., 1997) 
and protein concentration (Schmiedlin-Ren et al., 1997) of CYP3A4 in the Caco-2 
cell model. DHB is present in abundance in grapefruit juice (Gray, 1983), its 
concentrations (∼27.4 μM) exceeding the IC50 for loss of CYP3A4 activity 
(Schmiedlin-Ren et al., 1997). Moreover, the mechanism of action of DHB on 
CYP3A4 mirrored that of grapefruit juice (Kakar et al., 2004; Schmiedlin-Ren et al., 
1997). A recent clinical study involving the co-administration of felodipine and 
furanocoumarin fractions, which contained comparable DHB concentration as 
grapefruit juice, to 5 healthy adults supported the notion that DHB contributed to the 
grapefruit juice-felodipine interaction (Kakar et al., 2004).  
 
Another furanocoumarin of interest is bergamottin, a more lipophilic analog of DHB 
and the major furanocoumarin (10 μg/ml) in grapefruit juice. Bergamottin 
demonstrated a time- and concentration-dependent, mechanism-based inhibition of 
CYP3A4 in vitro (He et al., 1998). However, diluted lime juice containing the same 
level of bergamottin as grapefruit juice, but without the DHB, could only partially 




reproduce the effect of grapefruit juice on felodipine AUC (Bailey et al., 2003). 
Hence, it cannot be concluded that bergamottin is the primary constituent in grapefruit 
juice that is responsible for the inhibition of CYP3A4 activity (Bailey et al., 2003).  
 
Other furanocoumarin dimers isolated from grapefruit juice have also been reported to 
inhibit human CYP3A4 in vitro (Fukuda et al., 1997; Guo et al., 2000; Guo and 
Yamazoe, 2004; Ho et al., 2001; Schmiedlin-Ren et al., 1997). Bergapten, which is 
also found in Seville (sour) orange, exhibits mechanism-based inhibition of CYP3A4 
in vitro. However, bergapten has only one-third the potency of DHB, and a grapefruit 
juice preparation with no detectable level of bergapten could still significantly 
increase the AUC and Cmax of felodipine (Malhotra et al., 2001). Another bergamottin 
derivative, epoxybergamottin, also demonstrates mechanism-based inhibition of 
CYP3A4 in vitro (Bailey et al., 2000). However, it is present in minor quantities in 
grapefruit juice (Guo et al., 2000), is chemically unstable, and rapidly converts to 
DHB in the GIT (Bailey et al., 2000). Two dimers, GF-I-1 (4-[[6-hydroxy-7-[[1-[(1-
hydroxy-1-methyl)ethyl]-4-methyl-6-(7-oxo-7H-furo[3,2-g][1]benzopyran-4-yl)-4-he-
xenyl]oxy]-3,7-dimethyl-2-octenyl]oxy]-7H-furo[3,2-g][1]benzopyran-7-one) and GF 
-I-4(4-[[6-hydroxy-7-[[4-methyl-1-(1-methylethenyl)-6-(7-oxo-7H-furo[3,2-g][1]ben- 
zopyran-4-yl)-4-hexenyl]xy]-3,7-di-methyl-2-octenyl]xy]7H-furo[3,2g][1]benzopyran 
-7-one), are minor constituents in grapefruit juice that reportedly could reduce 
CYP3A4 activities through both competitive and mechanism-based inhibition (Guo et 
al., 2000). Although both dimers are at least 100 times more potent than DHB or 
bergamottin in vitro (Guo et al., 2000; Guo and Yamazoe, 2004; Tassaneeyakul et al., 
2000), further information, including clinical data, on these compounds are lacking. 
 




It is probable that more than one component in grapefruit juice may act to inhibit 
CYP3A4 activity (Dahan and Altman, 2004; Evans, 2000; Guo et al., 2000). A study 
which evaluated the effects of flavonoids, furanocoumarins and related compounds on 
CYP3A4-mediated metabolism of quinine in human liver microsomes has found 
bergapten and methoxalen to be the most potent, with IC50 of 19-36 μM and 35-39 
μM, respectively (Ho et al., 2001). Flavonoids, including quercetin, fisetin, chrysin, 
naringenin and galangin, were moderate inhibitors, with IC50 ranging from 41 to 136 
μM, while naringin and hesperidin were poor inhibitors, with IC50 of 1349 and 601 
μM, respectively. Further studies will be required to evaluate the clinical significance 
of these interactions, and to investigate whether the juice components act 
synergistically on CYP3A4 activity. At least one study has shown that all the major 
furanocoumarins have to be present in order to elicit the maximal effect on CYP3A4 
activity observed with grapefruit juice (Guo et al., 2000). Moreover, the inhibitory 
activity could not be clearly correlated with the content of any one specific grapefruit 
juice constituent, although the potency was well correlated with total furanocoumarin 
content in the juice.  
 
Flavonoids in grapefruit juice are also considered to be responsible for its P-gp 
activity (Eagling et al., 1999; Takanaga et al., 1998). However, it is suspected that the 
major P-gp inhibitor in grapefruit juice is different from the major CYP3A4 inhibitor 
(Ohnishi et al., 2000; Takanaga et al., 1998). This is because the ethyl acetate extract 
of grapefruit juice significantly lowered P-gp efflux in Caco-2 cells, while the 
methylene chloride extract had higher inhibitory effect on CYP3A4 activity (Ohnishi 
et al., 2000). Nevertheless, the identification of the major constituent(s) in grapefruit 
juice that contributes to its P-gp activity is proving to be as elusive as that for its 




CYP3A4 activity. For instance, naringin and naringenin have been shown to inhibit 
the transport of P-gp substrates (Dresser et al., 2002; Eagling et al., 1999; Takanaga et 
al., 1998), but they are not present in sweet orange juice (Kuhnau, 1976), which also 
attenuates P-gp activity. In contrast, some furanocoumarins, such as bergamottin, 
DHB and bergapten, have been shown to lower P-gp activity in vitro (Eagling et al., 
1999; Ikegawa et al., 2000; Ohnishi et al., 2000; Wang et al., 2001), but their presence 
in Seville (sour) orange juice (Edwards et al., 1999; Malhotra et al., 2001) does not 
confer the juice with P-gp modulating activity (Edwards et al., 1999; Malhotra et al., 
2001).  
 
To complicate matters, some components of grapefruit juice, e.g. bergamottin and 
DHB, appear to inhibit P-gp-mediated drug efflux as well as CYP3A4-mediated drug 
metabolism (Eagling et al., 1999; Ohnishi et al., 2000; Wang et al., 2001), while 
others, such as bergaptol, inhibits P-gp efflux without affecting CYP3A4 activity 
(Ohnishi et al., 2000). Flavonoids such as quercetin and kaempferol showed a 
biphasic effect on P-gp efflux, causing inhibition or enhancement depending on their 
concentration (Shapiro and Ling, 1997; Takanaga et al., 2000b). In addition, 
flavonoids can alter drug permeability by modulating the phospholipid packing 
density in cell membrane (Clarke et al., 1990) or drug transporter expression (Kioka 
et al., 1992). Not surprisingly, these have confused efforts to identify the major 
causative agents responsible for the clinical grapefruit juice-drug interactions.   
 
The on-going efforts to identify the causative constituent(s) in grapefruit juice 
underscore the desire to predict fruit-drug interactions based on the constitution of the 
fruit (Bailey et al., 1998b). Non-toxic levels of the causative constituent(s) may also 




be incorporated into pharmaceutical formulations to increase drug bioavailability. 
This is especially useful for drugs that are currently administered by intravenous 
injections because they undergo complete first-pass metabolism mediated by 
CYP3A4 in the GIT (Bailey et al., 1994). However, until the causative constituent(s) 
are fully isolated and defined, both in terms of identity and degree of activity in vivo, 
the exploitation of grapefruit juice as an adjuvant in drug therapy will remain an 
unsafe practice.  
 
1.2.2. Other potential citrus fruit juice-drug interactions 
Besides grapefruit juice, the potential of orange juice (Bailey et al., 1991; Dresser et 
al., 2002; Honda et al., 2004; Lilja et al., 2004; Takanaga et al., 2000b; Tian et al., 
2002), lime juice (Bailey et al., 2003; Xu et al., 2003), lemon juice (Xu et al., 2003), 
pummelo juice (Egashira et al., 2003, 2004; Fujita et al., 2003; Grenier et al., 2006; 
Hou et al., 2000; Xu et al., 2003), and Seville (sour) orange juice (Di Marco et al., 
2002; Edwards et al., 1999; Malhotra et al., 2001) to modulate drug bioavailability 
has been studied .  
 
1.2.2.1.   Orange juice (Sweet) 
Unlike grapefruit juice, orange juice does not affect the oral bioavailability of 
CYP3A4 substrates like felodipine and nifedipine (Bailey et al., 1991). As such, it 
was often used as a negative control for the study of CYP3A4 inhibition by grapefruit 
juice (Edwards et al, 1996; Kakar et al., 2004; Malhotra et al., 2001). However, the 
ethyl acetate extract of orange juice (Honda et al., 2004; Ikegawa et al., 2000; Tian et 
al., 2002) and its polymethoxylated flavones (Takanaga et al., 2000b) are potential 
inhibitors of P-gp. More recently, orange juice was shown to have a stronger 




inhibitory effect on OATP than on P-gp in vitro (Dresser et al., 2002), leading to 
speculation that it may predominantly inhibit OATP-mediated transport in vivo. 
Clinical studies have indeed shown orange juice to reduce the AUC and Cmax of 
fexofenadine by up to 30% (Dresser et al., 2002), and the Cmax, AUC and urinary 
excretion of celiprolol by 89%, 83% and 77%, respectively (Lilja et al., 2004).  
 
The major P-gp inhibitors in orange juice are believed to be a class of flavonoids 
known as the polymethoxylated flavones (PMF) (Fig. 1.8), in particular  
3,3’,4’,5,6,7,8-heptamethoxyflavone (HMF) and 4’,5,6,7,8-pentamethoxyflavone 
(tangeretin) (Ikegawa et al., 2000; Takanaga et al., 2000b). Tangeretin was 
crystallized from tangerine oil (Nelson, 1934) while HMF was identified in the 
neutral fraction of orange peel oil (Swift, 1967). A minor P-gp inhibitor, 3’,4’,5,6,7,8-
hexamethoxyflavone (nobiletin) (Takanaga et al., 2000b), was first isolated from 
orange peel (Tseng, 1938). The PMF are also found in grapefruit juice, but at lower 














Figure 1.8. Chemical structures of polymethoxylated flavones (Ref. Mouly et al., 
1998). 
 




1.2.2.2.   Pummelo juice 
Pummelo juice exhibits concentration-dependent inhibition of P-gp transport activity 
(Xu et al., 2003) and CYP3A4-mediated metabolism (Egashira et al., 2003, 2004; 
Grenier et al., 2006). Pummelo juice has been shown to possess similar drug transport 
modulating activities as the grapefruit juice (Egashira et al., 2003; Fujita et al., 2003; 
Guo et al., 2000; Xu et al., 2003), which should not be surprising since the grapefruit 
is believed to be a hybrid of the pummelo and sweet orange (Albach and Redman, 
1969; Ameer et al., 1996; Berhow et al., 1998; Scora, 1975).  
 
1.2.2.3.   Lime and lemon juices 
Unlike the grapefruit and pummelo juices, lime and lemon juices did not appear to 
modulate P-gp transport activity. They have been shown to enhance the apical-to-
basal (AB) digoxin fluxes in Caco-2 cell monolayers without reducing the basal-to-
apical (BA) digoxin transport (Xu et al., 2003). The mechanism might be associated 
with cell damage as both juices decreased the transepithelial electrical resistance 
(TEER) and viability of Caco-2 cells at concentrations above 5%. Lime juice showed 
mechanism-based inhibition of CYP3A4 activity in vitro, but did not affect the 
clinical pharmacokinetic parameters of felodipine when administered at 
concentrations that contained the same levels of bergamottin as grapefruit juice 
(Bailey et al., 2003).  
 
1.2.2.4.  Other citrus fruit  juices 
Seville (sour) orange is mainly used for confectionary products such as marmalade. 
Due to its sour taste, its juice is not fit for drinking. However, several studies 
conducted with Seville (sour) juice have shown it to have similar drug interaction 




effects as grapefruit juice. When adjusted to contain the same total concentration of 
bergamottin and DHB, Seville (sour) orange juice was found to increase the AUC of 
felodipine, a CYP3A4 substrate, to a comparable level as grapefruit juice (Malhotra et 
al., 2001). Seville (sour) orange is also considered to exhibit mechanism-based 
inhibition because it decreases the enterocyte concentration of CYP3A4. Unlike 
grapefruit juice, however, the Seville (sour) orange juice did not inhibit intestinal P-
gp-mediated transport of cyclosporine (Edwards et al., 1999).  
 
The juice of tangerine, a kind of Mandarin orange, contains tangeretin as the major 
flavonoid. Tangeretin is considered to be one of the major constituents causing sweet 
orange juice-mediated P-gp inhibitory activity (Ikegawa et al., 2000; Takanaga et al., 
2000b). While the tangerine juice has not been studied for its P-gp interactions, 
tangeretin has been shown to potently stimulate midazolam metabolism by human 
liver microsomes and cDNA-expressed CYP3A4 (Backman et al., 2000). As a result, 
tangerine juice decreased the AUC of peroral midazolam by about 40% over the first 
1.5 h and increased the tmax by 2-fold. It did not, however, affect the total AUC, Cmax 
nor the AUC ratio of the main metabolite to midazolam (Backman et al., 2000).  
 
1.3.   STATEMENT OF PURPOSE 
Fruit juice-drug interactions involving the transport activities of the P-gp and OATP 
have been variously studied with the juices of grapefruit, pummelo, orange, lime and 
lemon. An interesting phenomenon emerging from the collective data of these studies 
is the correlation between the classification of the citrus fruits according to their 
dominant flavonoid pattern and/or taxonomy and the drug transport modulating 
activities of the fruit juices. This hypothesis was first proposed by our laboratory (Xu 




et al., 2003), when it was noted that the grapefruit and pummelo could be categorized 
into one group, and the lime and lemon in another, based on the effects of their juices 
on the TEER, cytotoxicity and P-gp-mediated digoxin transport in the Caco-2 cell 
model. Like grapefruit juice, pummelo juice exhibited concentration-dependent 
inhibition of the P-gp transport activity (Xu et al., 2003). The grapefruit is believed to 
be a hybrid of the pummelo and sweet orange (Albach and Redman, 1969; Berhow et 
al., 1998), and both the pummelo (Citrus grandis) and grapefruit (Citrus paradisi) 
have been categorized under the neohesperidosyl species, as they contain dominant 
neohesperidosides like naringin, neohesperidin and neoeriocitrin (Fig. 1.9; right 
panel) (Kanes et al., 1993; Mouly et al., 1993). The neohesperidosyl species is 
distinguished by a bitter taste due to the presence of a high percentage of naringin, 
which is also responsible for the distinctive smell of the grapefruit and pummelo 
(Kane and Lipsky, 2000; Mizelle et al., 1965). Unlike the grapefruit and pummelo 
juices, lime and lemon juices did not show typical P-gp inhibiting activity. Both juices 
enhanced the A-to-B digoxin fluxes in the Caco-2 cell monolayers without reducing 
the B-to-A digoxin transport (Xu et al., 2003). In addition, lime and lemon juices also 
caused the widening of the paracellular transport pathway in the Caco-2 cell 
monolayers, a phenomenon not associated with the grapefruit and pummelo juices. 
Lime and lemon have been classified under the rutinosyl species as they contain 
predominant rutinosides like hesperidin, eriocitrin and narirutin (Fig. 1.9; left panel) 
(Kanes et al., 1993; Mouly et al., 1993). Lime (Citrus aurantifolia) is considered to be 
a trihybrid cross involving the citron, pummelo and a species of Microcitrus, while 
the lemon (Citrus limon) is probably derived from citron, lime and another 
unidentified gene source, and it carries a greater proportion of the citron genes. Thus, 
the categorization of the fruit juices with regards to their effects on the TEER and P-




gp mediated digoxin transport in the Caco-2 cell model was in line with the 
classification of the fruits according to dominant flavonoid pattern and taxonomy. It 
was also interesting that data across laboratories showed grapefruit juices to exert 
similar modulating effects on drug transport and metabolism despite being produced 
in different countries. These grapefruit juices were unlikely to share the same 
constituent profiles due to variation in cultivars, as well as cultivation, processing and 
storage conditions. This led us to believe that the diversification in the constituent 
profile of the citrus fruits might be less important than their dominant flavonoid 
pattern and taxonomy in influencing the biological activities of the fruit juices.  
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Figure 1.9. Chemical structures of (left panel) rutinosyl species: (a) hesperidin, (b) 
eriocitrin, and (c) narirutin; and (right panel) neohesperidosyl species: (a) naringin, 
(b) neohesperidin, (c) neoeriocitirn (Ref. Mouly et al., 1993). 
 




This projects set out to evaluate the hypothesis that the modulating activity of citrus 
fruit juices on cellular transport and metabolic pathways was dependent on the 
dominant flavonoid pattern and taxonomy of the citrus fruits. The hypothesis has 
important implications given the notoriously difficult task of compiling a complete 
constituent profile for a fruit and the limited success in identifying the active 
component(s) in citrus fruits responsible for the drug transport-modulating activity 
(Miniscalco et al., 1992; Rashid et al., 1993). Moreover, the synergism in activity 
exhibited by components in the whole juice as compared to individual, isolated 
components (Guo et al., 2000) also implies that the modulating activities of the citrus 
fruit juices cannot be simply apportioned to the major components in these juices. 
 
To test the hypothesis, 5 citrus fruit juices were evaluated. These were the juices of 
pummelo, grapefruit, orange, lime and lemon. Of the 5 cultivated citrus, only the 
pummelo meets sufficient biological criteria to be regarded as a true species (Barret 
and Rhodes, 1976). Grapefruit is suggested to be a hybrid of the pummelo and sweet 
orange, while the latter is believed also to possess pummelo characteristics. Lime is 
considered to be a trihybrid cross involving the citron, pummelo and a species of 
Microcitrus, whereas lemon is probably derived from citron, lime and another 
unidentified gene source. Based on dominant flavonoid pattern, grapefruit and 
pummelo are classified under the neohesperidosyl species as they contain dominant 
neohesperidosides, like naringin, neohesperidin and neoeriocitrin (Fig. 1.9; right 
panel) (Kanes et al., 1993; Mouly et al., 1993). Lime and lemon belong to the 
rutinosyl species, which contain predominant rutinosides, like hesperidin, eriocitrin 
and narirutin (Fig. 1.9; left panel) (Kanes et al., 1993; Mouly et al., 1993). 




Classification of grapefruit, pummelo, lime and lemon according to the dominant 
flavonoid pattern is similar to that based on taxonomy.  
 
The inclusion of orange was designed to test the relative importance of these two 
classification principles in drug interactions, for orange is grouped with grapefruit and 
pummelo based on its taxonomy (Barret and Rhodes, 1976), but is classified as a 
rutinosyl, together with the lime and lemon, based on its dominant flavonoid 
glycosylation pattern (Kanes et al., 1993; Mouly et al., 1993). Indeed, orange juice 
exhibits some characteristics of drug interactions that are similar to those of the 
grapefruit and pummelo juices, e.g. the inhibition of P-gp efflux and OATP influx 
(Dresser et al., 2002). Unlike the grapefruit juice, however, orange juice does not 
inhibit CYP3A4-mediated metabolism (Takanaga et al., 2000b; Tian et al., 2002). It 
would therefore be interesting to use the orange to test the relative importance of the 
dominant flavonoid pattern and taxonomy of a citrus fruit in influencing drug 
interactions.  
 
To prove the hypothesis, studies were conducted with the following specific 
objectives: 
1. To evaluate the cytotoxicity of the citrus fruit juices on the in vitro cell models 
used (ie. Caco-2, L-MDR1 and LLC-PK1 cells).  
2. To evaluate the modulating activities of the citrus fruit juices on the paracellular 
transport pathway in Caco-2 cells. 
3. To evaluate the modulating activities of the citrus fruit juices on the transcellular 
passive transport pathway in Caco-2 cells. 




4. To evaluate the effects of the citrus fruit juices on the function and expression of 
the P-gp efflux transporter. 
5. To evaluate the effects of the citrus fruit juices on the function and expression of 
the OCT uptake transporter. 
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This project set out to evaluate the hypothesis that the modulating activity of citrus 
fruit juices on cellular transport and metabolic pathways was dependent on the 
dominant flavonoid pattern and taxonomy of the citrus fruits. In this section, we 
proposed to test the validity of the hypothesis by examining the effects of grapefruit, 
pummelo, orange, lime and lemon juices on the paracellular and transcellular passive 
transport pathways, as well as the P-gp-mediated efflux transport, in the Caco-2 cell 
model.  
 
Caco-2 cells are derived from a human colon adenocarcinoma. They are an 
established cell line for intestinal permeation studies when cultured on semipermeable 
membranes, as they differentiate into a highly functionalized epithelial barrier with 
remarkable morphological and biochemical similarities to the small intestinal 
columnar epithelium (Hidalgo et al., 1989) (Table 2.1). Upon reaching confluence, 
they further differentiate into enterocyte-like cells, form tight junctions and express 
many transporters normally found in the small intestine (Tsuji and Tamai, 1996). As 
such, they are applied extensively to predict and characterize the mechanisms of drug 
transport (Artursson, 1991), and the relative contributions of the paracellular and 
transcellular passages in drug absorption. Apparent permeability coefficients (Papp) of 
drugs derived from transport studies using the Caco-2 cell line have been shown to 
correlate with human intestinal drug absorption (Artursson and Karlsson, 1991; Yee, 
1997). For this reason, drug permeation across the Caco-2 cell monolayers is often 
performed to estimate the fraction of drug absorbed in the GIT (Hunter et al., 1993a). 
Caco-2 cells are also applied to generate mechanistic data for drug absorption and for 
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intestinal permeability screening in preclinical drug selection (Delie and Rubas, 
1997).  
 
Table 2.1.   Characteristics of Caco-2 cells (Ref. Ferrec et al., 2001).  
Origin Human colorectal adenocarcinoma 
State of growth  Monolayer epithelial cells 
Differentiation 21 days after confluence in standard culture medium 
Morphology Polarised cells, with tight junctions, apical, brush border 
Electrical 
parameters High electrical resistance 
Digestive enzymes Typical membranous peptidases and disaccharidases of the small intestine 
Active transport Amino acids, sugars, vitamins, hormones 
Membrane ionic 
transport 
Na+/K+ ATPase, H+/K+ ATPase, Na+/H+ exchange, NaI/K+/Cl- 
co-transport, apical Cl- channels  
Membrane non-ionic 
transporters 
Permeability-glycoprotein, multidrug resistant associated 
protein, lung cancer associated resistance protein 
Receptors Vitamin B12, vitamin D3, epidermal growth factor, sugar transporters (GLUT1, GLUT3, GLUT5, GLUT2, SGLT1) 
 
 
The passive transcellular diffusive pathway is important for drug transport across the 
intestinal epithelium because more than 80% of the clinically significant drugs with 
Mw > 200 Da and molecular radii > 15 Å are absorbed via this route when 
administered orally (Brennan, 2000; Kerns, 2001). The paracellular route normally 
plays a minor role in intestinal drug translocation (Ward et al., 2000), but can become 
an important route if the intercellular tight junction is compromised (Sawada et al., 
2003). For this section of the study, the tight junction integrity across confluent Caco-
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2 cell monolayers was evaluated by monitoring the transepithelial electrical resistance 
(TEER) values (Markowska et al., 2001; Ward et al., 2000) and the transport of [14C]-
mannitol (Fig. 2.1a), a paracellular transport marker (Balimane et al., 2004; 
Markowska et al., 2001; Pade and Stavchansky, 1997; Yee, 1997). [3H]-propranolol 
(Fig. 2.1b) was used as a marker for the passive transcellular transport pathway 
(Markowska et al., 2001; Violini et al., 2002). Bi-directional [14C]-mannitol and [3H]-
propranolol permeability were quantified by determining the apparent permeability 







      (a)     (b) 
Figure 2.1. Structure of (a) mannitol (Mw = 182.17) and (b) propranolol (Mw = 
259.3). (Source from http://www.sigmaaldrich.com).  
 
Although fruit juices consumed orally are unlikely to present in the same composition 
in the blood, mannitol and propranolol transport was carried out in the BA direction to 
determine whether the fruit juices would exhibit similar activities for cell membranes 
of different constitutions (van Meer and Simons, 1986). Caco-2 cells are polarized 
when cultured on porous supports for 3 weeks (Ward et al., 2000), and they show 
differential apical and basal membrane constitutions (Pade and Stavchansky, 1997; 
Ward et al., 2000), with evidence of P-glycoprotein (P-gp) expression on the apical 
surface (Hunter et al., 1993b). To further validate the application of the project 
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hypothesis to P-gp-mediated efflux activity, the cellular accumulation of rhodamine-
123 (R-123), a well-established P-gp substrate, was measured (Wigler, 1996).  
 
We also delineated the general toxicity of the fruit juices from their effects on the 
specific drug transport pathways by performing the MTT assay on exposed cells 
(Scudiero et al., 1988). The MTT assay is a sensitive and reliable colorimetric assay 
that quantitatively measures the viability, proliferation and activation of cells 
(Mosmann, 1983; Scudiero et al., 1988). The assay is based on the principle that 
mitochondrial dehydrogenase enzymes in living cells are capable of converting the 
yellow, water-soluble 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) salt into an insoluble, purple formazan crystal. The quantity of crystals 
produced can be quantified by colorimetric techniques after solubilizing the cells and 
dissolving the formazan crystals with an organic solvent, and it is found to be directly 
proportional to the number of viable cells in a wide range of cell lines (Denizot and 
Lang, 1986; Mosmann, 1983; Scudiero et al., 1988; Sladowski et al., 1993). This 
capacity to differentiate between living and dead cells by a simple experimental 
procedure has made the MTT assay a popular method for the evaluation of in vitro 
cytotoxicity of samples (Mosmann, 1983; Scudiero et al., 1988). 
 
2.2. METHODS AND MATERIALS 
2.2.1. Materials 
[14C]-mannitol (53.7 mCi/mmol) and [3H]-propranolol (24.4 Ci/mmol) were 
purchased from PerkinElmer LifeSciences (Wellesley, MA, U.S.A.); minimum 
essential medium (MEM), fetal bovine serum (FBS), trypsin-EDTA, and phosphate 
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buffered saline (PBS, pH 7.4) were from Gibco BRL Life Technologies (Grand 
Island, NY, U.S.A.); penicillin, streptomycin, sodium bicarbonate (NaHCO3), non-
essential amino acid (NEAA), dimethylsulfoxide (DMSO), Hank’s balanced salt 
solution (HBSS), N-[2-hydroxyethyl]piperazine-N’-[2-ethanesulfonic acid] (HEPES), 
dextran, rhodamine-123 and bovine serum albumin (BSA) were from the Sigma-
Aldrich, Inc. (St. Louis, MO, U.S.A.); propranolol HCl was from Beacon Chemical 
Pte Ltd (Mount Vernon, NY, U.S.A.); sodium hydroxide (NaOH), sodium lauryl 
sulphate (SDS) and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) were from BDH Chemicals Ltd (Poole, England); Sodium chloride (NaCl) 
was from Merck (Darmstadt, Germany); Triton X-100 was from Bio-Rad 
Laboratories, Inc. (Hercules, CA, U.S.A.); 96-well plates were from Nunc™ 
(Roskilde, Denmark); liquid scintillation cocktail BCS was from Amersham 
Biosciences UK Limited (Little Chalfont, Buckinghamshire, England) and 
Transwell™ polycarbonate cell culture inserts (12 mm diameter, 0.4 μm pore size) 
were from Corning Costar Corp. (Bedford, MA. U.S.A.). Caco-2 cells of passage 18 
were obtained from the American Type Culture Collection (ATCC; Rockville, MD, 
U.S.A.), while lime, lemon, orange, grapefruit and pummelo were purchased from a 
local supermarket.  
 
2.2.2. Cell Culture 
Caco-2 cells (passage 47-56) were seeded onto Transwell™ cell culture inserts at a 
density of 105 cells/insert and cultured at 37oC in 5% CO2 / 95% humidified air in the 
CO2 incubator (NuAire, Plymouth, MN, U.S.A.) in MEM supplemented with 10% of 
FBS, 1% of NEAA, 100 μg/ml of penicillin, 100 μg/ml of streptomycin and 7.5% of 
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NaHCO3. Medium was replaced every second day and the integrity of the cell 
monolayers was confirmed by TEER measurements (Millicell®-ERS, Millipore, 
Bedford, MA, U.S.A.) on Days 21-28. Confluent cell monolayers in culture medium 
with TEER values greater than 300 Ω.cm2, after correction for resistance in control 
blank wells, were used in the transport experiments.  
 
2.2.3. Dosing solutions 
Control dosing solutions for paracellular and transcellular diffusion studies were 
prepared by dissolving [14C]-mannitol (10 μM, 0.54 μCi/ml) and [3H]-propranolol (10 
μM propranolol HCl, 0.54 μCi/ml), respectively, in HBSS-HEPES transport medium 
(HBSS with 10 mM HEPES and adjusted to pH 7.4 with 5 N NaOH), while that for P-
gp-mediated efflux studies contained R-123 (5 μM) in HBSS-HEPES. Fruit juices, 
hand-squeezed from fresh unblemished fruits sliced in the radial direction and filtered 
(11-µm), were separately added to the dosing solutions to give final concentrations of 
5 to 50% v/v. The dosing solutions were adjusted to pH 7.4 with 5 N NaOH. 
 
2.2.4. Permeability Studies 
Culture medium was aspirated from the apical (A) and basal (B) chambers, and the 
cells were washed and equilibrated with prewarmed HBSS-HEPES (A, 0.5 ml; B, 1.5 
ml) at 37oC for 30 min. Cell monolayers in prewarmed HBSS-HEPES with TEER 
greater than 200 Ω.cm2 were used for [14C]-mannitol and [3H]-propranolol transport 
studies. Experiments were initiated by exchanging the HBSS-HEPES in the A or B 
chamber with an equal volume of dosing solution. Transport experiments were carried 
out at 37oC in 5% CO2 / 95% air. At predetermined times of 30, 60, 120 and 180 min, 
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50 μl-aliquots were withdrawn from the receiver chamber and these were immediately 
replenished with an equal volume of prewarmed HBSS-HEPES. The transport 
experiments were terminated by replacing the dosing solutions with HBSS-HEPES. 
TEER was again measured after the cells had been incubated for 30 min at 37°C. 
Samples withdrawn from the receiver chamber were incubated overnight with 5 ml of 
scintillation fluid and the radioactivity was measured using a liquid scintillation 
counter (LS 3801, Beckman Instruments, Inc., CA, U.S.A.).  
 
Change in monolayer TEER induced by each sample was calculated as TEER (% 
initial) = TEERfinal /TEERinitial x 100 (where TEERinitial and TEERfinal were the 
respective TEER values measured before and after the drug transport experiment) and 
expressed as a percent of the change in TEER for the control sample. Apparent 
permeability coefficient (Papp) was calculated as Papp = (dQ/dt)/(A.Co) (cm/s) where 
dQ/dt (nmol/s) was the flux rate, A (cm2) was the effective surface area of the cell 
monolayer (1.13 cm2), and Co (nmol/ml) was the initial drug concentration in the 
donor chamber. Net efflux was expressed as the quotient of Papp (BA) to Papp (AB).  
 
2.2.5. Reversibility of juice effects on paracellular transport pathway 
Further experiments were carried out to determine whether the detrimental effects of 
the lime and lemon juices on the paracellular transport pathway were reversible. For 
these experiments, Caco-2 cell monolayers cultured on Transwell™ inserts were 
exposed to 10% of the juices for 3 h, then allowed to recover in culture medium for 24 
h after juice removal. TEER changes and mannitol transport profiles were monitored 
immediately after juice exposure, and compared with the data obtained 24 h after 
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juice removal. TEER and mannitol permeability were measured according to the 
methodology described in Section 2.2.4. Control cells were subjected to the same 
experimental protocols, except that HBSS-HEPES (pH 7.4) was used instead of the 
fruit juice.    
 
2.2.6. R-123 efflux and cellular accumulation 
Experimental protocols to study R-123 efflux were similar to those described in 
Section 2.2.4 except that the R-123 dosing solution was added only to the B chamber, 
while the fruit juices were added to both A and B chambers to ensure total inhibition 
of P-gp activity. Samples for analysis were withdrawn from the A chamber. At the 
end of the transport experiment at 180 min, the Caco-2 cell monolayers were washed 
with ice-cold PBS, and solubilized with 1% Triton X-100. Cellular debris was 
removed by centrifugation at 10,000 x g for 5 min at 4°C (Hettich Zentrifugen, 
Tuttlingen, Germany), and the supernatant was measured for R-123 fluorescence 
intensity (λex 485 nm, λem 535 nm, Spectra Fluor plate reader, Tecan, Austria) and 
total protein content (Bio-Rad protein assay, BSA as calibration standard). R-123 
cellular accumulation was normalized with respect to protein content per well.  
 
2.2.7. Cytotoxicity Studies 
Citrus fruit juices were mixed at 10 to 50 % with HBSS-HEPES and adjusted to pH 
7.4 with 5 N NaOH. The osmotic pressures of the solutions before and after pH 
adjustment were measured (Vapro® Vapor Pressure Osmometer 5520, Wescor Inc., 
Longan, U.S.A.). Control samples included HBSS-HEPES (no treatment) and 0.1% 
dextran and 0.1% SDS in HBSS-HEPES (negative and positive controls, 
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respectively). To delineate the effects of osmotic pressure from the intrinsic 
cytotoxicity of the citrus fruit juices, the Caco-2 cells were also exposed to 350, 450, 
550 and 650 mosm/kg HBSS-HEPES adjusted with NaCl. 
 
Caco-2 cells (passage 52) were seeded onto 96-well plates at 1x104 cells per well, and 
incubated with 100 μl of culture medium in 5% CO2 / 95% air at 37°C for 48 h. The 
spent medium was replaced with 150 μl of control or juice samples (n = 5), and the 
cells were incubated for a further 4 h at 37oC. The MTT assay was performed by 
aspirating the samples and incubating the cells with 100 μl of MTT solution (5 mg/ml 
in PBS, pH 7.4) for 4 h at 37°C. Extracellular MTT was removed by washing the cells 
with 150 μl of PBS, and the intracellular formazan crystals extracted into 100 μl of 
DMSO were quantified by measuring the cell lysate absorbance at 590 nm (Spectra 
Fluor plate reader). Cell viability was calculated as a percent based on the absorbance 
measured relative to the absorbance obtained from cells exposed only to HBSS-
HEPES.  
 
2.2.8. Statistical Analyses 
Experiments were repeated at least three times and the data expressed as mean ± SD. 
Differences between mean values were analysed by One-way ANOVA with the 
Tukey’s test applied for paired comparisons (SPSS 10.0, SPSS Inc., Chicago, IL). A p 
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2.3.1. [14C]-mannitol Transport 
Caco-2 cell monolayers exposed for 180 min to 10 μM of mannitol in HBSS-HEPES 
(pH 7.4) did not show significant changes in TEER values (Fig. 2.2). In contrast, 
TEER decreased non-linearly with increasing concentrations of lime and lemon juices   
(Fig. 2.2a and b), the fall in TEER being steeper over the concentration range of 10- 
30%. Addition of 30% of lime juice into the B chamber reduced the TEER value to 
that obtained in blank wells, suggesting a total breach of the intercellular tight 
junctions. When added to the A chamber, the same concentration of lime juice 
exhibited a smaller effect on TEER, which remained at 40 ± 8% of control value. 
Similar phenomena were observed with 30% lemon juice. In contrast, grapefruit and 
orange juices, at up to 50% in either A or B chambers, had little effect on the cellular 
TEER (Fig. 2.2c and e). TEER was also not modified by the presence of up to 30% of 
pummelo juice, but was significantly raised to 126% and 146% of control values by 
the addition of 50% of pummelo juice in the A and B chambers, respectively (Fig. 
2.2d).  
 
AB and BA Papp values for [14C]-mannitol transport over 180 min were 0.98 (± 0.22) 
x 10-6 and 1.01 (± 0.19) x 10-6 cm/s, respectively, giving a net efflux ratio of 1.03 
(Table 2.2). Lime and lemon juices facilitated mannitol transport in both the AB and 
BA directions, but the BA flux was increased to a greater extent, such that the 
mannitol transport became increasingly polarized at higher juice concentrations 
(Table 2.2). At 30%, lime juice significantly increased the AB and BA Papp values by  
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Figure 2.2. Effects of citrus fruit juices on the transepithelial electrical resistance 
(TEER, % of control, mean ± SD, n = 4) of Caco-2 cell monolayers after AB () and 
BA () mannitol transport experiments conducted over 180 min at 37oC in the 
presence of (a) lime juice; (b) lemon juice; (c) grapefruit juice; (d) pummelo juice; 
and (e) orange juice. * p < 0.05 when mean 100(TEERfinal/TEERinitial) value was 
compared with control.  
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6- and 12-folds, while 30% of lemon juice raised the AB and BA Papp values by 8- 
and 14-folds, respectively. Net efflux values were correspondingly adjusted to 2.15 
and 1.85 by the lime and lemon juices (Table 2.2). 
 
Table 2.2.  Effects of citrus fruit juices on the apparent permeability coefficient (Papp) 
and net efflux ratio of [14C]-mannitol transport across Caco-2 cell monolayers.  
 




% (v/v)         AB          BA 
Net Efflux 
Ratioc 
Control 0  0.98 ± 0.22   1.01 ± 0.19 1.03 
5  1.36 ± 0.85   1.38 ± 0.72 1.01 
10  2.06 ± 0.57   2.44 ± 0.73 1.19 
Lime juice 
30  5.53 ± 1.40* 11.89 ± 1.18* 2.15 
5  0.78 ± 0.30   0.91 ± 0.42 1.17 
10  2.25 ± 0.46   2.91 ± 0.67 1.30 
Lemon juice 
30  7.72 ± 1.66* 14.31 ± 3.69* 1.85 
5  0.93 ± 0.42   1.10 ± 0.26 1.19 
10  0.93 ± 0.55   1.02 ± 0.55 1.10 
30  1.41 ± 0.42   1.26 ± 0.37 0.89 
Grapefruit juice 
50  2.11 ± 1.01   1.95 ± 1.08 0.93 
5  1.22 ± 0.34   1.60 ± 1.07 1.31 
10  1.33 ± 0.75   1.69 ± 0.19 1.27 
30  2.20 ± 0.96   1.58 ± 0.69 0.72 
Pummelo juice 
50  2.58 ± 0.76*   2.08 ± 0.22 0.81 
5  2.11 ± 0.48   2.17 ± 0.11* 1.03 
10  2.92 ± 0.86*   1.37 ± 0.13 0.47 
30  4.36 ± 1.07*   2.52 ± 0.23* 0.58 
Orange juice 
50  5.99 ± 0.94*   2.65 ± 0.49* 0.44 
a Donor compartment contained 10 μM of [14C]-mannitol. All solutions were 
adjusted to pH 7.4. 
b Data represent mean ± SD, n = 4. 
c Net efflux ratio = Papp (BA) / Papp (AB). 
* p < 0.05 compared with control.  
 
In comparison, grapefruit and pummelo juices at up to 50% concentration were found 
to induce smaller changes to the AB and BA [14C]-mannitol fluxes. Papp values 
obtained in the presence of grapefruit juice were not significantly different from  
control values (Table 2.2), although the juice caused greater variations in mannitol 
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fluxes. This phenomenon was also observed with the other fruit juices. Pummelo juice 
at 50% did not produce a statistically different BA Papp value, but its effect on the AB 
Papp value was less clear, the statistical analysis yielding a p value of 0.03 indicating a 
small increase in the AB Papp value (2.6-fold). Grapefruit and pummelo juices did not 
polarize the mannitol transport profile. Net mannitol efflux remained within the 
narrow range of 0.89 to 1.19 for solutions containing up to 50% of grapefruit juice, 
and within 0.81 to 1.31 for solutions containing up to 50% of pummelo juice (Table 
2.2). 
 
Orange juice produced a more complex mannitol transport profile. It behaved like the 
lime and lemon juices in enhancing the AB and BA [14C]-mannitol fluxes, raising the 
Papp values to significantly higher levels at ≥ 30% concentration (Table 2.2). 
However, while the AB Papp value obtained with 30% orange juice was comparable 
with that obtained with 30% lime juice, orange juice exerted a smaller effect on the 
BA flux. Consequently, orange juice was the odd juice that lowered the net mannitol 
efflux ratio to 50% of control value (Table 2.2).  
 
Further experiments were conducted to determine whether the detrimental effects of 
the lime and lemon juices on the cell monolayer integrity were reversible. To avoid 
overt cytotoxicity (Section 2.3.4), the lime and lemon juices were applied at a low 
concentration of 10%. Application of the two juices at concentrations higher than 
10% would induce a certain degree of cytotoxicity, which could compound any 
reversibility effects on the drug transport pathway. The results, tabulated in Table 2.3, 
suggest that the Caco-2 cell monolayers, exposed to 10% of lime and lemon juices for 
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3 h, were able to recover monolayer integrity after 24 h of incubation in culture 
medium following juice removal. The cellular TEER was observed to revert to near 
baseline levels, and this was accompanied by smaller mannitol Papp values in both the 
AB and BA directions (Table 2.3). In general, the AB mannitol transport profile 
showed a faster recovery compared to mannitol transport in the BA direction for cell 
monolayers exposed to the juices.  
 
Table 2.3. Reversibility of juice-mediated effects on the tight junctions of Caco-2 cell 
monolayers.  
 
TEER (% control) b,c  Mannitol Papp ( x 10-6 cm/s) c,d 







































90.6 ± 4.3 68.5 ± 
38.2 









1.54 ± 0.24 2.61 ± 0.16* 1.69 
a Adjusted to pH 7.4. 
b Change in TEER expressed as a percent of that obtained for control sample.  
c Data represent mean ± SD, n = 4, except for # , where n = 1.  
dDonor compartment contained 10 μM of [14C]-mannitol. 
e Net efflux ratio = Papp (BA) / Papp (AB). 
f HBSS-HEPES (pH 7.4) 
g Experiments conducted on cells immediately after 3 h of exposure to sample. 
h Experiments conducted on cells after 24 h incubation in culture medium following 
exposure to sample for 3 h 
* p < 0.05 compared with control at 3 h.  
 
 
Chapter 2.   Effects of citrus fruit juices on cytotoxicity and drug transport 




2.3.2. [3H]-propranolol Transport  
[3H]-propranolol did not exhibit polarized transcellular flux rates over 180 min, and 
the AB and BA Papp values were, respectively, 24.07 (± 0.63) x 10-6 and 26.18 (± 
1.57) x 10-6 cm/s, giving a net efflux ratio of 1.09 (Table 2.4). All 5 citrus juices 
reduced the BA propranolol flux in a concentration-dependent manner, but had 
negligible effects on the AB propranolol flux (Table 2.4). A comparison of the juices 
at 30% suggests that the ranking order of their effects on the BA Papp values was lime 
(50%) ≥ lemon (48%) >  pummelo (37%) ≥ grapefruit (35%) > orange (30%). Net 
propranolol efflux ratio was observed to fall by 13% to 48% upon the addition of the 
fruit juices (Table 2.4).   
 
Table 2.4.  Effects of citrus fruit juices on the apparent permeability coefficient (Papp) 
and net efflux ratio of [3H]-propranolol transport across Caco-2 cell monolayers.  
 
Papp ( x 10-6 cm/s) b 





Control 0 24.07 ± 0.63 26.35 ± 1.57 1.09 
10 22.05 ± 0.81* 16.39 ± 0.88* 0.74 Lime juice 
30 21.31 ± 0.42* 13.15 ± 0.65* 0.62 
10 25.09 ± 0.72 16.64 ± 2.13* 0.66 Lemon juice 
30 23.96 ± 0.25 13.71 ± 0.93* 0.57 
10 22.39 ± 0.54* 19.21 ± 1.31* 0.86 Grapefruit juice 
30 23.57 ± 0.16 17.08 ± 0.97* 0.72 
10 21.11 ± 0.19* 20.04 ± 0.88* 0.95 Pummelo juice 
30 21.93 ± 0.93* 16.69 ± 0.64* 0.76 
10 26.74 ± 0.81* 21.87 ± 1.90* 0.82 Orange juice 
30 26.96 ± 0.77* 18.55 ± 0.70* 0.69 
a Donor compartment contained 10 μM of [3H]-propranolol. All solutions were 
adjusted to pH 7.4. 
b Data represents mean ± SD, n = 4. 
c Net Efflux = Papp (BA) / Papp (AB). 
* p < 0.05 compared with control.  
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2.3.3. R-123 efflux and cellular accumulation 
The AB and BA Papp obtained for R-123 transport across the Caco-2 cell monolayers 
were 0.56 (± 0.13) x 10-6 and 2.29 (± 0.04) x 10-6 cm/s, respectively, giving a net 
efflux of 4.06. These values were consistent with those reported by Yumoto et al.  
(1999). Addition of 100 µM of verapamil, an established P-gp inhibitor, elevated the 
AB Papp to 1.08 (± 0.36) x 10-6 cm/s and lowered the BA Papp to 1.64 (± 0.46) x 10-6 
cm/s, giving a net efflux of 1.51. Verapamil also increased the cellular accumulation 
of R-123 by 1.4-fold (Fig. 2.3b), suggesting that the R-123 translocation profile was 
significantly driven by P-gp-mediated transport activity. Grapefruit, pummelo and 
orange juices at 50% concentration inhibited the secretory flux of R-123, and 
increased its cellular accumulation to levels comparable to those produced by 100 µM 
of verapamil (Fig. 2.3). Lime and lemon juices at 50% concentration, on the other 
hand, elevated R-123 efflux by at least 2-fold. Cellular accumulation of R-123 in the 
presence of lime and lemon juices was also higher than control, but the levels of 
accumulation were lower than those seen in the presence of grapefruit, pummelo and 
orange juices.    
 
2.3.4. Cytotoxicity Studies 
Of the 5 fruit juices, lime juice exhibited the greatest cytotoxicity against the Caco-2 
cells in that it significantly reduced the cell viability even at a diluted concentration of 
5% (Fig. 2.4). However, the cytotoxicity of lime juice did not show a strong 
correlation to concentration (R2 = 0.7423). Lemon juice was comparatively less 
cytotoxic, decreasing the cell viability only at concentrations of 30% or higher. Unlike
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Figure 2.3.  (a) BA permeability (Papp) of R-123 across Caco-2 cell monolayers and 
(b) cellular accumulation of R-123 by basal membrane of Caco-2 cells exposed to: 
transport medium (TM), 100 µM of verapamil (V), and 10% and 50% of grapefruit 
(1G,5G), pummelo (1P,5P), orange (1O,5O), lime (1I,5I) and lemon juices (1L,5L)  
over 180 min. Data represents mean ± SD, n = 3. * p < 0.05 compared with TM.  
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the lime and lemon juices, the pummelo and grapefruit juices enhanced the viability 
of the Caco-2 cells at increasing concentrations. Significantly increased mitochondrial 
enzyme activity was noted for cells exposed to 50% of grapefruit juice and ≥ 30% of 
pummelo juice. Orange juice showed anomalous behaviour. While it enhanced cell 
viability at low concentrations of 5–30%, cell viability appeared to revert to control 












Figure 2.4. In vitro cytotoxicity profile of citrus fruit juices against the Caco-2 cell 
monolayers after 4 h of exposure. Cytotoxicity was measured by the MTT assay and 
is expressed as percent cell viability relative to the viability of cells exposed to HBSS-
HEPES. Cells were exposed to: lime (I), lemon (L), grapefruit (G), pummelo (P) and 
orange (O) juices at concentrations of 10% (denoted by the number 1), 30% (denoted 
by 3) and 50% (denoted by 5). Negative (-) control was 0.1% dextran, and positive (+) 
control was 0.1% SDS, both dissolved in HBSS-HEPES. Data represent mean ± SD, n 
= 5. * significantly different from  negative control (p < 0.05).  
 
 
Despite their dissimilar pH, the unadjusted fruit juices had comparable osmotic 
pressures at equivalent concentrations (Table 2.5). Adjustment to pH 7.4, however, 
introduced significant variation in osmotic pressure to the fruit juices. The changes in 
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osmotic pressure were related to the acidity of the juices; the more acidic the fruit 
juice, the greater the amount of base required to neutralize it, and therefore the greater 
the change in osmotic pressure after pH adjustment.   
 
Table 2.5. Osmotic pressure and pH of citrus fruit juices measured before and after 
pH adjustment to 7.4. 
% Juice 
(v/v) 













5  2.3 ± 0.6 278.3 ± 20.0 325.5 ± 53.0  
10  2.2 ± 0.5 284.7 ± 18.2 337.7 ± 42.1  
30  1.9 ± 0.5 311.3 ± 24.0 441.7 ± 36.2  
50  1.9 ± 0.4 336.7 ± 26.7 546.3 ± 49.1  
Lemon juice 
5  2.5 ± 0.3 286.7 ± 15.0 315.3 ± 59.5  
10  2.1 ± 0.4 293.0 ± 20.8 337.3 ± 49.7  
30  1.9 ± 0.4 323.7 ± 36.2 467.0 ± 65.0  
50  1.8 ± 0.3 377.7 ± 33.5 605.7 ± 70.9  
Orange juice 
5  5.2 ± 0.3 256.5 ± 72.8 298.5 ± 50.2  
10  4.1 ± 0.4 287.5 ± 46.0 316.5 ± 43.1  
30  3.3 ± 0.5 330.0 ± 55.2 360.0 ± 58.0  
50  3.1 ± 0.2 375.5 ± 64.3 418.0 ± 77.8  
Grapefruit juice 
5  5.9 ± 0.5 274.0 ± 26.1 294.7 ± 31.0  
10  4.3 ± 0.3 279.7 ± 28.0 320.3 ± 28.4  
30  3.5 ± 0.3 293.3 ± 30.9 355.0 ± 18.3  
50  3.4 ± 0.3 316.0 ± 27.6 357.0 ± 57.1  
Pummelo juice 
5  7.3 ± 0.2 277.0 ± 27.1 287.0 ± 32.2  
10  7.3 ± 0.2 283.7 ± 30.5 288.3 ± 29.5  
30  7.0 ± 0.3 306.3 ± 31.0 317.0 ± 35.0  
50  6.8 ± 0.2 339.0 ± 32.0 347.7 ± 41.7  
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Hypertonic HBSS-HEPES-NaCl (350-550 mosm/kg) did not affect the intracellular 
dehydrogenase activity of the Caco-2 cells (Fig. 2.5). However, when the osmotic 
pressure of the same medium was raised to 650 mosm/kg, the viability of the Caco-2 























Figure 2.5. In vitro cytotoxicity of hypertonic HBSS-HEPES-NaCl media on Caco-2 
cell monolayers as expressed by percent cell viability relative to the viability of cells 
exposed to HBSS-HEPES only. Negative and positive control cells were treated with 
0.1% dextran (-) and 0.1% SDS (+) respectively. Cells were exposed to 350, 450, 550 
and 650 mosm/kg HBSS-HEPES adjusted with NaCl. Data represents mean ± SD, n = 
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There are several reasons for employing the concentration range of 5-50% fruit juices 
for the various experiments. Firstly, the juice concentrations used in the study 
correspond to the intestinal concentration following the consumption of a normal 
(250-500 ml) or excessive (900-1200 ml) amount of juices, on the basis that the 
volume of the gastrointestinal fluid is about 3-5 L (Egashira et al., 2004). Perhaps of 
this reason, studies from many other laboratories have also employed fruit juice or 
juice extracts at up to 50% concentration in in vitro cell-based experiments (Egashira 
et al., 2004; Honda et al., 2004; Takanaga et al., 1998; Tian et al., 2002; Xu et al., 
2003).  We were, however, concerned about using a juice concentration that could 
induce overt cytotoxicity, as the damage to the cell could obscure any efforts to study 
the modulating effects of the juice on a specified drug transport or metabolic pathway. 
For this reason, we also carried out in vitro cytotoxicity studies to delineate the non-
cytotoxic doses of each fruit juice against the cell lines used. In most cases, it was 
found that a juice concentration range of 5-30% could be satisfactorily applied for the 
drug transport or metabolic studies.  
 
[14C]-Mannitol is a radiolabeled hydrophilic marker widely used to evaluate the 
paracellular transport pathway and the integrity of confluent cell monolayers 
(Balimane et al., 2004; Markowska et al., 2001; Pade and Stavchansky, 1997; Yee, 
1997). It is not known to be taken up by absorptive cells in significant amounts but is 
highly permeable through the tight junctions of cell monolayers. The control AB 
mannitol Papp value was comparable to literature values (Markowska et al., 2001), 
which affirmed the integrity of the Caco-2 cell monolayers used in this study. The 
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threshold TEER value adopted for screening the Caco-2 cell monolayers for mannitol 
transport experiments was therefore appropriate.  
 
Diluted lime juice at 10% or lower did not affect cell monolayer TEER or [14C]-
mannitol fluxes. Increasing the juice to 30% caused a reduction in TEER concomitant 
with an increase in mannitol flux, suggesting that lime juice facilitated mannitol 
transport by opening up the paracellular pathway. The larger increase in BA Papp 
relative to the AB Papp was correlated with a steeper fall in TEER, and this might be 
attributed to the larger area of the basolateral cell membrane exposed to the juice in 
the basal chamber. It was a phenomenon universally observed with the other fruit 
juices used in the study. 
 
Lemon juice produced comparable mannitol transport profiles as the lime juice. The 
AB and BA mannitol Papp values as a function of lemon juice concentration was also 
inversely correlated to the cellular TEER, implying a similar action of lemon juice on 
the intercellular tight junction. However, compared to the lime juice, lemon juice 
mediated larger increases in the mannitol Papp value despite causing smaller changes 
to the TEER. This discrepancy might be attributed to the inherent difficulties in 
obtaining Caco-2 cell monolayers of comparable TEER values for different transport 
experiments. In addition, the method for measuring TEER was highly sensitive to the 
positioning of the chopstick electrodes in the culture wells. Thus, TEER values, 
although commonly cited in the literature to reflect intercellular tight junction 
integrity, should best be regarded as a qualitative assessment of epithelial integrity. 
The higher mannitol Papp values induced by the lemon juice could not be attributed to 
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cell death because lemon juice was less toxic to the Caco-2 cells compared to the lime 
juice at 30% concentration.  
 
The adverse effects on cell monolayer integrity that lime and lemon juices exhibited 
at 10% concentration were reversible 24 h after juice removal. Final TEER and 
mannitol Papp values measured 24 h after juice removal had reverted to near baseline 
levels. The mannitol Papp data also suggest that the recovery of tight junction integrity 
was faster for the apical membrane than for the basal membrane of the cell 
monolayers. This is probably because the apical membrane generally re-constructs 
faster than the basal membrane (Hirashima et al., 1985; Mammen and Matthews, 
2003). 
 
   Unlike the lime and lemon juices, grapefruit juice at up to 50% did not exert 
significant effects on the cell monolayer TEER or [14C]-mannitol fluxes in the AB and 
BA directions. Similarly, pummelo juice at 30% had no effects on the mannitol fluxes 
or monolayer TEER, but it significantly raised the cell monolayer TEER when present 
in the A or B chambers at 50%. Despite apparently restricting the paracellular 
transport pathway, pummelo juice at 50% in the A chamber appeared to slightly 
enhance mannitol transport in the AB direction. The mechanism underlying this 
anomaly is not known, since pummelo juice did not reduce cell viability at these 
concentrations. Another anomaly was observed with the orange juice, which increased 
mannitol transport in both AB and BA directions without bringing about significant 
changes in the monolayer TEER. In this case, however, the enhanced mannitol 
transport could not be associated with the cytoxicity of the orange juice.  
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Based on the effects of the juices on the mannitol transport data, lime and lemon 
juices could be grouped together as juices that significantly modulate the intercellular 
tight junction to increase mannitol transport at concentrations of 30% or greater. 
Grapefruit and pummelo juices, characterized by negligible effects on mannitol 
transport in both the AB and BA directions at 30%, might be classified as a separate 
group. Orange juice was more like the lime and lemon juices in increasing mannitol 
fluxes, but resembled grapefruit and pummelo juices in increasing cellular TEER. It 
might therefore be considered as a species connecting the two groups. This 
categorization of the fruit juices is consistent with the groupings of the fruit juices 
according to their major flavonoid pattern and/or taxonomy (Xu et al., 2003). 
 
[3H]-propranolol is a highly lipophilic marker used widely to document passive 
transcellular transport due to its high permeability across epithelial cells (Violini et 
al., 2002). As expected (Adson et al., 1995), bidirectional propranolol fluxes across 
the Caco-2 cell monolayers in the AB and BA directions were comparable. Citrus 
fruit juices contain flavonoids, including flavone, which are lipophilic and are 
reported to be transported by passive diffusion across intestinal cells and to 
accumulate extensively in the cells (Kuo, 1998). Our data indicated that the citrus 
fruit juices affected the AB and BA propranolol fluxes to different extents. While all 
juices at up to 30% had negligible effects on the AB Papp, the BA Papp value was 
significantly reduced. The more pronounced effect of the fruit juices on the BA 
propranolol flux might again be attributed to the larger area of access of the 
basolateral cell membrane. Aggravation of the basolateral plasma protein binding 
might also reduce the efflux of propranolol (Walgren and Walle, 1999).  Based on the 
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rank order of their effects on BA propranolol flux, lime and lemon juice could again 
be categorized into a group that showed greater effects than grapefruit and pummelo 
juices. The modulating activity of orange juice on BA propranolol flux was the least 
of these two groups. 
 
R-123 is a typical P-gp substrate and a model compound for studying P-gp-mediated 
transport due to its excellent fluorescent properties and transport characteristics 
(Masereeuw et al., 1997). Troutman and Thakker (2003a,b) have recently shown that 
R-123 absorptive transport occurs primarily by paracellular route, whereas its 
secretory transport involves influx across the basal membrane mediated solely by a 
saturable process, followed by apically directed efflux via the P-gp. As such, the P-gp 
inhibitor, GW918, did not affect the absorptive AB Papp of R-123 but enhanced that of 
the BA direction. For these reasons, P-gp-mediated R-123 transport may best be 
studied in the BA transepithelial transport direction only (van der Sandt et al., 2000) 
or in terms of R-123 intracellular accumulation from the basal membrane (Zastre et 
al., 2002).  
 
The modulating effects of citrus fruit juices on R-123 efflux in a cellular model have 
not been studied, although Tian et al. have demonstrated that the serosal-to-mucosal 
flux of R-123 from the rat small intestine was inhibited by 50% of grapefruit and 
orange juice extracts (Tian et al., 2002). This is concordant with our results. Besides 
grapefruit and orange juices, the pummelo juice also modulated R-123 efflux and 
cellular accumulation in a manner reminiscent of a typical P-gp inhibitor. Of the 3, 
pummelo and grapefruit juices showed comparable modulating activities, while 
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orange juice showed lowest inhibitory action on R-123 efflux but greatest 
enhancement of R-123 cellular accumulation. In contrast, while the lime and lemon 
juices also modulated R-123 efflux and cellular accumulation, the enhancement of 
both efflux and cellular accumulation suggests that these effects might be related to 
juice-mediated cytotoxicity and opening of the intercellular tight junctions.   
 
The data obtained for R-123 efflux across the Caco-2 cell monolayers mirrored those 
observed for digoxin, another P-gp substrate, in previous work performed in our 
laboratory (Xu et al., 2003). In the previous study, which excluded orange juice, 
grapefruit and pummelo juices at 10% also did not modulate the BA transport of 
digoxin, but they inhibited digoxin efflux significantly at the higher concentration of 
50%. Likewise, lime and lemon juices at 50% concentration enhanced the BA 
transport of digoxin. It is interesting that the citrus juices had similar modulating 
effects on the efflux of R-123 and digoxin despite the different initial uptake 
mechanisms of the two substrates across the basal membrane. R-123 is a cationic 
hydrophilic compound whose BA transport involves apically-directed uptake by a 
transporter localized on the basal membrane, followed by P-gp-mediated efflux from 
the intracellular space across the apical membrane (Troutman and Thakker, 2003a). 
Digoxin, on the other hand, is a neutral lipophilic compound whose transport across 
the basal membrane is likely to involve both diffusional uptake and Na+-K+ pump-
mediated endocytosis, followed by active P-gp-mediated extrusion at the apical 
membrane (Cavet et al., 1996). The collective data suggest that P-gp-mediated efflux 
is an important determinant of the net efflux of both substrates, and that citrus juices 
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can influence the net efflux of R-123 and digoxin according to their dominant 
flavonoid pattern and taxonomy. 
 
The cytotoxic profiles of the lime, lemon, grapefruit and pummelo juices obtained in 
this study correlated with results obtained previously in our laboratory (Xu et al., 
2003). In the previous studies, unadjusted grapefruit and pummelo juices were shown 
not to reduce cell viability while the highly acidic lime and lemon juices reduced cell 
viability to about 26% and 38%, respectively, of control at low concentrations of 5%. 
The cytotoxicity of lime and lemon juices could not, however, be attributed solely to 
the acidic components in these juices. This is because the neutralization of the two 
juices to pH 7.4 did not eliminate their adverse effect on intracellular dehydrogenase 
activity although it did lower the toxicity of the juices significantly. Moreover, the 
acidic grapefruit juice did not exhibit a similar cytotoxic profile as the lime and lemon 
juices (Table 2.5).   
 
Neither could the cytotoxic profile of the fruit juices be directly correlated with 
osmotic pressure. Hypertonicity could not, however, be the sole factor contributing to 
the cytotoxicity of the lime and lemon juices. This is because the hypertonic 
pummelo, grapefruit and orange juices (up to 550 mosm/kg) were found to enhance 
the intracellular dehydrogenase activity of the Caco-2 cells. Moreover, a comparison 
of the cytotoxicity of lime and lemon juices against equivalently hypertonic HBSS-
HEPES-NaCl media also found the two fruit juices to significantly reduce the 
intracellular enzyme activity. 
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In a numerical taxonomic study of affinity relationships, Barret and Rhodes (1976) 
recognized two main groups in cultivated Citrus. In the C1 group, the sweet orange is 
related to pummelo via the intermediary of grapefruit, while lime and lemon belong to 
C2 (Fig. 2.6). The connection between the C1 and C2 groups is proposed to be lemon 
with either grapefruit or sweet orange. More recent studies on the predominant 
flavonoid pattern of Citrus cultivars suggest that the sweet orange is closer in 
characteristics with the lemon, and had in fact been categorized with lime and lemon 
in the same botanical subclass of rutinosyl species. Grapefruit and pummelo were 
grouped together in the Citrus subclass of neohesperidosyl species based on their 
flavonoid pattern. Collectively, the data suggest that the sweet orange is related to the 
pummelo via the grapefruit (C1) and to the lime via the lemon (C2) (Fig. 2.6).   
 
 
  Sour orange           Mandarin 
 
 
C1  Sweet orange     Grapefruit             Pummelo 
 
 
C2  Citron     Lemon    Lime 
 
Figure 2.6. Diagram of affinity relationships among the Citrus species (Ref. Barret 
and Rhodes, 1976). 
 
The acidity and cytotoxicity results from our experiments support this inter-
relationship of the fruits according to their taxonomy and flavonoid pattern. While 
lime and lemon juices were highly acidic and the pummelo juice was near neutral, the 
grapefruit and orange juices exhibited moderate acidity. Cytotoxicity data indicated 
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that lime and lemon juices reduced, while grapefruit, pummelo and orange juices 
promoted the intracellular dehydrogenase activity of the Caco-2 cells. Between lime 
and lemon, the former exhibited greater cytotoxicty. Among the grapefruit, pummelo 
and orange juices, the enhancement of enzyme activity was highest with the pummelo 
juice, while orange juice showed mixed effects at increasing concentration.  
 
2.5. CONCLUSION 
On the basis of their effects on the TEER, cell viability, mannitol, propranolol and R-
123 transport profiles in the Caco-2 cell model, the 5 fruit juices may be broadly 
categorized into two groups, with lime and lemon juices in one group, grapefruit and 
pummelo juices in another, and orange juice being the unique species that has certain 
characteristics in common with the two groups. The grouping is consistent with the 
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3.1. INTRODUCTION  
This section of the project set out to further validate the hypothesis that the 
modulating activity of citrus fruit juices on P-gp-mediated efflux activity was 
dependent on the dominant flavonoid pattern and taxonomy of the citrus fruits. Of the 
five citrus fruit juices, grapefruit juice was the first to be evaluated for P-gp activity. 
In the late 1990s, when grapefruit juice had been established to have CYP3A4 
inhibitory action, it was proposed that the juice might also modulate intestinal P-gp 
activity due to the co-localization and overlapping substrate and inhibitor specificities 
of the P-gp and CYP3A4. This led to several studies involving grapefruit juice and P-
gp or P-gp/CYP3A4 substrates, including digoxin (Xu et al., 2003), vinblastine 
(Takanaga et al., 1998), saquinavir (Eagling et al., 1999), and talinolol (Schwarz et 
al., 2005), that firmly established grapefruit juice to be a P-gp inhibitor.  
 
Sawada et al. subsequently found that the ethyl acetate extract and polymethoxylated 
flavones of orange juice were also potent inhibitors of the P-gp (Honda et al., 2004; 
Ikegawa et al., 2000; Takanaga et al., 2000b). Unlike grapefruit juice, these 
components of orange juice did not inhibit CYP3A4 activity (Takanaga et al., 2000b). 
More recently, our laboratory observed that the pummelo juice was comparable in 
potency to the grapefruit juice in inhibiting P-gp-mediated efflux of digoxin across the 
Caco-2 cell monolayers (Xu et al., 2003). This finding was disputed by Sawada’s 
group, who argued that pummelo juice had negligible effects on the P-gp function 
(Egashira et al., 2004). Such disparity in results might have been caused by 
differences in juice processing methods. While our laboratory used juices that had 
been freshly hand-squeezed from the pummelo fruit, Sawada’s group has applied the 
ethyl acetate extract of pummelo juice to the cells. In addition, Sawada’s group 




studied P-gp-mediated tacrolimus and digoxin transport across a different cell model, 
the LLC-GA5-COL150 cells, which are LLC-PK1 cells transfected with the human 
MDR1 cDNA.  
   
The objective of the present study was to provide further evidence for the modulating 
effects of grapefruit, pummelo, orange, lime and lemon juices on the P-gp at both the 
functional and expression levels. Both cell- and animal-based assays were performed. 
For cellular experiments, the P-gp efflux activity was evaluated by comparing bi-
directional digoxin transport profiles across the L-MDR1 and LLC-PK1 cells. P-gp 
protein level was determined in the L-MDR1 cells. For the animal-based experiments, 
the P-gp protein and associated mdr1a mRNA expression levels were analyzed by 
Western blot analysis and reverse transcription-polymerase chain reaction (RT-PCR), 
respectively, following juice dosing in the rat model.      
 
The LLC-PK1 cells are porcine kidney epithelial cells (Hull et al., 1976), while the L-
MDR1 cells are LLC-PK1 cells stably transfected with the human MDR1 cDNA 
(Schinkel et al., 1995). Like the Caco-2 cells, the L-MDR1 cells are polarized when 
cultured as a monolayer on microporous membrane filters, and they express the P-gp 
protein on the apical membrane, which allows for the study of vectorial transcellular 
transport (Fromm et al., 1999; Kim et al., 1998). Although our laboratory had 
previously studied the effects of citrus fruit juices on digoxin transport across the 
Caco-2 cell monolayers, the orange juice was not included in the previous study. 
Furthermore, an additional MK-571-sensitive secretory pathway was reportedly 
involved, along with the P-gp, in mediating digoxin secretion across the Caco-2 cells 
(Lowes et al., 2003). Thus, a cell line like the L-MDR1, which over-expresses the P-




gp protein, could serve as a better model for evaluating P-gp-related transport activity. 
The parental LLC-PK1 cell line, which expresses low levels of constitutive P-gp, 
served as a control to determine the effects of the juices on the passive transcellular 
transport of digoxin (Tanigawara et al., 1992; Wandel et al., 2002). To delineate the 
general toxicity of the fruit juices from their specific effects on the drug transport 
pathways and P-gp expression level, in vitro cytotoxicity and anti-cell proliferation 
studies were performed using the MTT assay (Scudiero et al., 1988).  
 
Animal experiments were conducted for those citrus fruit juices that inhibited the P-
gp-mediated efflux of digoxin in the cell-based experiments. The effects of these 
juices on the P-gp protein and associated mdr1a mRNA levels in various rat tissues 
were determined using the Western blot analysis and RT-PCR, respectively. The 
animal experiments allowed (1) the chronic effects of the citrus fruit juices and (2) the 
juice-mediated changes in mdrla mRNA levels to be evaluated. It was not feasible to 
determine the modulating effects of the juices on the mRNA levels in the L-MDR1 
cells because these cells were transfected with the human MDR1 cDNA. mRNA-
transfected cells are often employed for functional (Kim and Benet, 2004; Schinkel et 
al., 1995) and protein expression studies (Maitra et al., 2001), but they are 
inappropriate models for studies that require the monitoring of mRNA expression 
(Kim and Benet, 2004; Taipalensuu et al., 2004). The cell model, however, 
complemented the animal model in providing an isolated system, free from the 
influence of variables normally encountered in vivo, to allow mechanistic data to be 
generated on P-gp-mediated transport activity.   
 
 




3.2. METHODS AND MATERIALS 
3.2.1. Materials 
[3H]-digoxin (37.0 Ci/mmol) was purchased from PerkinElmer LifeSciences; M199 
and Opti-MEM media were from Gibco BRL Life Technologies; TRIzol® was from 
Invitrogen Corporation (Carlsbad, CA, U.S.A.); digoxin, verapamil HCl, Protease 
Inhibitor Cocktail, mouse monoclonal β-actin antibody, and diethyl pyrocarbonate 
(DEPC) were from the Sigma-Aldrich, Inc.; complete mini protease inhibitor cocktail 
tablets were obtained from Roche Diagnostics GmbH (Mannhelm, Germany); protein 
assay dye reagent concentrate, 40% Acrylamide/Bis gel solution 37.5:1 (2.6% C), 
bromophenol blue, Precision Plus Protein™ All Blue Standards (Molecular weight 
markers, 10-250 kDa), polyvinylidenedifluoride (PVDF) membrane, dithiothreitol 
(DTT), sucrose and ethidium bromide were from Bio-Rad Laboratories, Inc.; β-
mercaptoethanol was from Merck; Tris(hydroxymetyl)aminomethane (Tris (Base)) 
was from J.T.Baker (Phillipsburg, NJ, U.S.A.); Tween-20 was from Spectrum 
Chemical Mfg. Corp. (San Pedro St., Gardena, CA, U.S.A.); SDS/Glycine 
Electrophoresis Buffer 5 X and Tris acetic acid EDTA (TAE) Buffer 1 X were from 
the NUMI Media Preparation facility (National University of Singapore, Singapore); 
C219 concentrated mouse monoclonal antibody for the detection of cellular P-gp was 
obtained from Signet, Research Biolabs (Dedham, MA, U.S.A.); the secondary 
antibody, ECL™ Anti-mouse IgG, Horseradish Peroxidase linked F(ab’)2 fragment 
(from sheep), was purchased from Amersham Biosciences UK Limited; agarose was 
from BioWhittaker Molecular Applications (Rockland, ME, U.S.A.); 100 base pair 
(bp) DNA ladder marker was from Promega Corporation (Madison WI, U.S.A.); 
methanol, isopropanol, absolute ethanol and chloroform were from Fisher Scientific 
(Fair Lawn, NJ, U.S.A.); SuperSignal® West Pico Chemiluminescent Substrate and 




Supersignal® West Femto Maximum Sensitivity Substrate were from Pierce, Inc. 
(Rockford, IL, U.S.A.); phenylmethylsulfonylfluoride (PMSF) was from BDH 
Chemicals Ltd; skim milk was purchased from a local supermarket; Transwell™ 
polycarbonate cell culture inserts (12 mm diameter, 3.0 μm pore size) were from 
Corning Costar Corp. L-MDR1 and LLC-PK1 cells were kindly provided by Dr. A. 
H. Schinkel (Netherlands Cancer Institute, Amsterdam, the Netherlands). Buffers 
were prepared with Milli-Q water (Milli-Q® Ultrapure Water Purification Systems, 
Millipore Corporate, Billerica, MA, U.S.A.). All reagents used were of analytical 
grade, and all other materials were similar to those listed in Section 2.2.1.  
 
3.2.2.   Digoxin Transport 
L-MDR1 and LLC-PK1 cells (passage 232-240 and 246-251, respectively) were 
cultured using methods similar to those reported in the literature (Fromm et al., 1999; 
Huisman et al., 1995; Wandel et al., 2002). The cells were seeded onto Transwell™ 
cell culture inserts at a density of 5 x 105 cells/insert and cultured at 37oC in 5% CO2 / 
95% humidified air in the CO2 incubator in M199 medium supplemented with 10% of 
FBS, 50 μg/ml of penicillin and 50 μg/ml of streptomycin. Medium was replaced 
every 2-3 days and the cells were used for the transport studies on day 5-7 post-
seeding.  
 
Just before the start of the transport experiments, the culture medium was aspirated 
from both the apical (A) and basal (B) chambers, and the cells were washed once with 
the prewarmed serum-free transport medium, Opti-MEM (37oC, pH 7.4), before they 
were equilibrated with fresh Opti-MEM (A, 0.5 ml; B, 1.5 ml) at 37oC for 30 min. 
The integrity of the cell monolayers was confirmed qualitatively by TEER 




measurements. Confluent cell monolayers with TEER values greater than 200 Ω.cm2, 
after correction for resistance in control blank wells, were used in the transport 
experiments. 
 
Transport experiments were initiated by adding 700 μl of Opti-MEM dosed with [3H]-
digoxin (5 μM, 0.54 μCi/ml) in the donor chamber and an equal volume of Opti-
MEM in the receiver chamber. Drug transport was conducted at 37oC in 5% CO2 / 
95% air. The amount of drug appearing in the receiver chamber after 1, 2, 3 and 4 h 
was measured in 50 μl-aliquots and the samples withdrawn were immediately 
replenished with an equal volume of prewarmed Opti-MEM. At the end of the 
experiment, the cell monolayers were re-incubated with Opti-MEM (A, 0.5 ml; B, 1.5 
ml) for 30 min at 37°C before the measurement of TEER. Each 50 μl-aliquot sample 
was incubated overnight with 3 ml of scintillation fluid and its radioactivity was 
measured using the liquid scintillation counter. Change in monolayer TEER and 
digoxin Papp values were calculated as previously described in Section 2.2.4. 
 
3.2.3. Modulation of digoxin transport  
Digoxin transport experiments across the L-MDR1 and LLC-PK1 cells were also 
performed in the presence of each of the citrus fruit juices using protocols similar to 
those described in Section 3.2.2. The juices were squeezed from the respective fruits 
using methods described in Section 2.2.3, and added to the transport media in both the 
donor and receiver chambers (10 to 50% v/v, adjusted to pH 7.4 with 5 N NaOH). 
Verapamil (100 µM), a well-established competitive P-gp inhibitor (Cavet et al., 
1996; Pauli-Magnus et al., 2000), was used as a positive control. An inhibition of P-
gp-mediated transport would result in a reduction or abolishment of net secretion of 




[3H]-digoxin due to elevated AB Papp and reduced BA Papp (Cavet et al., 1996; Xu et 
al., 2003).  
 
The integrity of the cell monolayers in the presence of the citrus fruit juices was also 
monitored by determining the bi-directional transport of the paracellular marker, 
[14C]-mannitol (10 μM, 0.54 μCi/ml) (Markowska et al., 2001; Pade and Stavchansky, 
1997). The AB and BA mannitol fluxes (n = 1) were determined for cell monolayers 
cultured on the same Transwell plates as cell monolayers used for the [3H]-digoxin 
transport experiments. Mannitol flux was expressed as a percent of the amount of 
mannitol originally added to the donor chamber; flux values higher than 5%/h were 
taken to be indicative of a leaky cellular tight junction (Cavet et al., 1996; Woodland 
et al., 1997).  
 
3.2.4. Cytotoxicity and Anti-proliferative Studies 
Citrus fruit juices were mixed at 10 to 50% with Opti-MEM and adjusted to pH 7.4 
with 5 N NaOH. The osmotic pressures of the solutions before and after pH 
adjustment were measured. Control samples included Opti-MEM (no treatment) and 
0.1% dextran and 0.1% SDS in Opti-MEM (negative and positive controls, 
respectively).  
 
L-MDR1 and LLC-PK1 cells were seeded onto 96-well plates at 1x104 cells per well, 
and incubated with 100 μl of culture medium in 5% CO2 / 95% air at 37°C for 48 h. 
The spent medium was replaced with 150 μl of control or juice samples (n = 8), and 
the cells were incubated for a further 4 h at 37oC. The MTT assay was performed in 
accordance to the method described in Section 2.2.7. Cell viability was calculated as a 




percent based on the absorbance measured relative to the absorbance obtained from 
cells exposed only to the Opti-MEM.  
 
Anti-cell proliferative activity of juices that inhibited the P-gp function was evaluated 
with verapamil (100 µM) as control sample. The experimental protocols were similar 
to those for the evaluation of juice cytotoxicity. However, cell proliferation was 
evaluated by prolonging to 24 h the period of co-incubation of the cells with the juices 
(or controls) before commencing with the MTT assay. In addition, the juice and 
control samples were sterilely diluted with the culture medium (M199) instead of 
using Opti-MEM as diluent. As the replacement of the culture medium with up to 
50% v/v of fruit juices could result in a significant reduction of nutrients for cell 
growth, parallel experiments, in which the culture medium was diluted with 50% of 
PBS, were conducted to delineate the effects of nutrient deficiency on cell 
proliferation.  
 
3.2.5. Semi-quantitative Determination of P-gp expression in L-MDR1 cells by 
Western Blot Analysis 
L-MDR1 cells (passage 230) were cultured in T-25 cm2 flasks for 5 days before they 
were co-incubated for 24 h with 10, 30 and 50% of grapefruit, pummelo or orange 
juices in M199 medium. Control cells were replenished with blank M199 medium or 
50% of PBS in M199 or 100 μM of verapamil in M199. Cells were then washed with 
ice-cold PBS, harvested by scraping, and centrifuged at 2000 rpm for 3 min at 4 oC. 
The supernatant was decanted and the cell pellets were homogenised on ice for 1 h 
with 70 μl of 1 X complete mini protease inhibitor solution containing 1% of Triton-
X, before centrifuging at 10,000 x g for 20 min at 4oC. The supernatant was then 




collected and the total protein content was determined using the Bio-Rad protein 
assay and BSA as the calibration standard.  
 
The cell proteins (50 μg), along with 4 µl of molecular weight markers (10-250 kDa), 
were separated by electrophoresis on 7.5% SDS-polyacrylamide gels and transferred 
to PVDF membranes. The membranes were blocked in Tris-buffered saline 
containing 0.1 % of Tween 20 (TBST) and 5% of skim milk for 2 h, then incubated 
with C219 (1:1000), a P-gp antibody, or with the β-actin antibody (1:4000) overnight. 
This was followed by incubation with the horseradish peroxidase-conjugated sheep 
anti-mouse IgG secondary antibody (1:3000) for 1 h. To minimize the non-specific 
binding of antibodies with the proteins, the membranes were washed with the TBST 
buffer for 5-10 min, repeated 4 times, between the incubation steps. Proteins were 
visualised by the SuperSignal® enhanced chemiluminescence detection reagent (West 
Femto Substrate for P-gp detection; West Pico Substrate for β-actin detection), and 
quantified using a scanning densitometer installed with the Quantity One® software 
(Bio-Rad Laboratories, Inc., Hercules, CA, U.S.A.).  
 
3.2.6. Animal Treatment and Tissue Collection 
Animal handling and experimentation were performed in accordance with the NUS 
institutional guidelines for the care and use of laboratory animals 
(http://www.nus.edu.sg/lac/html/intl_guide.htm). Male Sprague–Dawley rats 
(Laboratory Animals Center, National University of Singapore, Singapore) weighing 
200–250 g were dosed by intragastric gavage (16-gauge, Kent Scientific, Torrington, 
CT, U.S.A.) with 10 ml/kg of water, grapefruit, pummelo or orange juices twice daily 
(at 9 am and 6 pm) for 10 days. Fruit juices were hand squeezed from the respective 




fruits and administered immediately as neat solutions. Rats were randomly assigned to 
the juice and control groups, with 4 rats per group, and all rats had free access to rat 
chow and water. Rats were fasted overnight on Day 10, immediately after the last 
dose was administered. On day 11, the rats were euthanized by intraperitoneal 
injection of 3 ml/kg of pentobarbital sodium. A laparotomy was performed, and 0.5-
cm segments of the liver and kidney (with fat tissues trimmed off), together with 2.0-
cm segments of the duodenum (20 cm from the gastric pylorus), ileum (20 cm before 
the caecum) and jejunum (the length in between), each amounting to approximately 
100 mg of tissue samples, were harvested. Tissue specimens for Western blot analysis 
were washed rapidly with ice-cold saline (0.9% NaCl) and transferred into eppendorf 
tubes (Axygen Scientific Inc., CA, U.S.A.). Tissue specimens for RT-PCR analysis 
were immersed in 1 ml of TRIzol® reagent to limit RNA degradation, and quenched 
in liquid nitrogen before storing at -80oC until use.  
 
3.2.6.1. Semi-quantitative Determination of P-gp expression in Rat Tissues by 
Western Blot Analysis 
Tissue specimens were weighed at 100 mg, minced with scissors and homogenized 
(Sigma-Aldrich, Inc.) in 500 µl of freshly prepared homogenizing buffer (pH 7.4) 
containing 250 mM of sucrose, 5 mM of HEPES, 2.5 % (v/v) of protease inhibitor 
cocktail, 1 mM of PMSF and 0.5 mM of DTT. After approximately 10 strokes, 
another 500 µl of homogenizing buffer was added. The crude homogenates were 
centrifuged at 3,000 x g for 10 min at 4oC to pellet the cell debris, nuclei and 
mitochondria, and the supernatant was collected and centrifuged at 15,000 x g for 30 
min at 4oC to pellet the crude membrane fractions. The pellets containing the crude 
membranes were resuspended in 25 μl of freshly prepared resuspending buffer (pH 




7.5) containing 50 mM of mannitol, 20 mM of HEPES, 2.5 % (v/v) of protease 
inhibitor cocktail, 1 mM of PMSF and 0.5 mM of DTT. The total protein 
concentration was determined, and the Western blotting analysis was performed on 80 
μg of total protein in accordance to the methods listed in Section 3.2.5.   
 
3.2.6.2. Semi-quantitative Determination of mdr1a mRNA levels in Rat Tissues 
by Reverse Transcription-Polymerase Chain Reaction (RT-PCR) 
Total RNA was extracted from the rodent tissue specimens according to the product 
protocol. Briefly, 50 mg of tissue specimens were homogenized in 1 ml of TRIzol® 
and 400 μl of chloroform was added to precipitate the proteins and DNA. The mixture 
was vortexed, incubated at room temperature for 2-3 min, and centrifuged at 12,000 x 
g for 10 min at 4oC. The supernatant was collected and 1 ml of isopropanol was added 
with vortexing to precipitate the RNA. The mixture was incubated at room 
temperature for 10 min before it was centrifuged at 12,000 x g for 10 min at 4oC. 
After discarding the supernatant, the pellet was washed with 1 ml of solvent 
comprising 75:25 (v/v) of ethanol and aqueous DEPC (0.1% in water), and the 
mixture was centrifuged again at 12,000 x g at room temperature for 5 min. The 
ethanol was removed and the RNA pellet was dried under vacuum for 1-2 min, mixed 
with 100 μl of aqueous DEPC and stored at -80oC until use. To confirm the quality of 
RNA extracted, the RNA solution was diluted 100-fold with aqueous DEPC, and its 
absorbance at 260 nm (λmax for RNA) and 280 nm (λmax for proteins) were 
determined. An OD260/OD280 ratio of 1.6-1.8 was assumed to be indicative of 
substantial RNA purity (Kim and Benet, 2004). RNA concentration (μg/ml) was 
calculated by multiplying the OD260 by 40 (Kim and Benet, 2004). 




The mRNA levels of mdrla and the housekeeping gene, actin, were semi-
quantitatively analyzed by RT-PCR using the Access RT-PCR system (Promega 
Corporation, Madison WI, U.S.A.) and specific primers (Table 3.1) from Proligo 
Singapore Pte Ltd (Singapore). Reactions were conducted according to the 
manufacturer’s protocol with slight modifications. Briefly, the RNA sample (0.2 
µg/µl, 1 µl), together with 0.025 μl each of forward and reverse primers solutions 
(100 μM) (Table 3.1), were mixed with the enzymes and reagents of the Access RT-
PCR system to give a total volume of 12.5 μl. The enzymes and reagents were the 
Avian Myelobastosis Virus (AMV) reverse transcriptase (5 U/μl), Thermus flavus 
(Tfl) DNA polymerase (5 U/μl), dinucleotide triphosphate mix (dNTP; 10 mM), 
magnesium sulfate (25 mM) and AMV/Tfl reaction buffer (5 X). RT reaction was 
initiated by incubating the mixture for 45 min at 45°C (1 cycle) for cDNA synthesis, 
and 2 min at 94°C (1 cycle) for AMV RT inactivation and cDNA denaturation in a 
thermal cycler (Techne Flexigene, Krackeler Scientific, Inc., Albany, NY, U.S.A.). 
PCR amplification of cDNA was performed in 25 sequential cycles (except for the 
mdr1a gene in the rat liver, which was performed in 33 cycles) comprising of 
denaturation at 94°C for 30 s, annealing of primers at 60oC for 1 min, and DNA 
synthesis and extension at 68oC for 2 min. Final extension was carried out for 7 min at 
68oC (1 cycle), and the PCR products were cooled and stored at 4°C prior to analysis.   
 
Table 3.1.  Gene-specific oligonucleotide PCR primer sequence 
 
 Gene Direction Sequence 
forward 5'GATGGAATTGATAATGTGGACA3' mdr1a 
reverse 5'AAGGATCAGGAACAATAAA 3' 
forward 5' GACGAGGCCCAGAGCAAGAGA 3' actin 
reverse 5' CCAGAGGCATACAGGGACAACACA 3' 
 




PCR products were separated, along with a 100-bp DNA ladder marker, on a 2% 
agarose gel stained with 0.3 μg/ml of ethidium bromide. The mRNA levels were 
scanned and photographed under ultraviolet illumination at 312 nm using a Bio-Rad 
camera. Band densities were measured using the computer program, Quantity One® 
version 4.5, and the ratio of band densities of mdrla to actin was calculated. 
 
3.2.7. Statistical Analyses 
Experimental data are expressed as mean ± SD or mean ± SEM. Differences between 
mean values were analysed by One-way ANOVA with the Tukey’s test applied for 
paired comparisons (SPSS 10.0, SPSS Inc., Chicago, IL). Cytotoxicity data on the L-
MDR1 and LLC-PK1 cells were analysed by Two-Way ANOVA with the Tukey’s 
test applied for multiple comparison of means. A p value of less than or equal to 0.05 
was considered statistically significant. 
 
3.3.      RESULTS 
3.3.1. [3H]-Digoxin transport across L-MDR1 and LLC-PK1 cell monolayers 
The AB and BA apparent permeability coefficients (Papp) of [3H]-digoxin across the 
P-gp-expressing L-MDR1 cell monolayers were 0.68 (± 0.10) x 10-6 and 4.51 (± 0.40) 
x 10-6 cm/s, respectively, giving a high net efflux ratio of 6.63 (Table 3.2). This 
polarized transport was confirmed to be mediated by P-gp because it was abolished in 
the presence of 100 μM of verapamil (Fig 3.1). Addition of verapamil elevated the 
AB Papp to 1.92 (± 0.29) x 10-6 cm/s and lowered the BA Papp to 2.13 (± 0.14) x 10-6 
cm/s, giving a net efflux ratio of 1.11 (Table 3.2). These Papp values were comparable 
 
 




























Table 3.2.  Effects of verapamil and citrus fruit juices on the apparent permeability 
coefficient (Papp) and net efflux ratio of [3H]-digoxin transport across polarized L-
MDR1 cell monolayers. 
 




% (v/v)         AB          BA 
Net Efflux 
Ratioc 
Control 0 0.68 ± 0.10 4.51 ± 0.40 6.63 
Verapamil (100 μM) -  1.92 ± 0.29*  2.13 ± 0.14* 1.11 
10 0.96 ± 0.15 4.23 ± 0.29 4.41 
30   1.20 ± 0.12*   3.26 ± 0.24* 2.72 
Grapefruit juice 
50   1.57 ± 0.43*   2.66 ± 0.18* 1.69 
10 0.99 ± 0.13 4.35 ± 0.44 4.39 
30 1.05 ± 0.26   3.14 ± 0.10* 2.99 
Pummelo juice 
50   1.52 ± 0.37*   3.13 ± 0.40* 2.06 
10 1.06 ± 0.28 4.63 ± 0.22 4.37 
30   1.41 ± 0.54 4.59 ± 0.38 3.26 
Orange juice 
50  1.83 ± 0.64* 4.45 ± 0.47 2.43 
10  9.27 ± 1.16*   9.31 ± 0.75* 1.00 Lime juice 
30  6.15 ± 0.69*   7.26 ± 0.62* 1.18 
10  7.84 ± 0.99*   8.67 ± 0.75* 1.11 Lemon juice 
30 6.55 ± 0.33*   7.45 ± 0.58* 1.14 
a Donor compartment contained 5 μM of [3H]-digoxin. All solutions were adjusted 
to pH 7.4. 
b Data represent mean ± SD, n = 4. 
c Net efflux ratio = Papp (BA) / Papp (AB). 











Figure 3.1.  [3H]-digoxin (loading concentration 5 μM) flux in the AB () and BA 
() direction across polarized L-MDR1 (⎯) and LLC-PK1 (---) cell monolayers at 
37oC. Addition of verapamil (100 μM) abolished the polarized transport of digoxin 
across the L-MDR1 cell monolayers (.....). Data represent mean ± SD, n = 4.  




to those obtained for digoxin transport across the P-gp-deficient LLC-PK1 cells. [3H]-
digoxin did not exhibit polarized transport across the LLC-PK1 cell monolayers (Fig. 
3.1), the  AB and BA digoxin Papp across the LLC-PK1 cell monolayers being 2.02 (± 
0.70) and 2.24 (± 0.54) x 10-6 cm/s, respectively (Table 3.3). These Papp values were 
in agreement with literature values (Pauli-Magnus et al., 2001). 
 
Table 3.3.  Effects of citrus fruit juices on the apparent permeability coefficient (Papp) 
and net efflux ratio of [3H]-digoxin transport across polarized LLC-PK1 cell 
monolayers. 
 




% (v/v)         AB          BA 
Net Efflux 
Ratioc 
Control 0 2.02 ± 0.70 2.24 ± 0.54 1.11 
10 2.21 ± 0.27 2.26 ± 0.22 1.02 
30 2.33 ± 0.29 2.25 ± 0.09 0.97 
Grapefruit juice 
50 2.34 ± 0.53 2.39 ± 0.12 1.02 
10 1.85 ± 0.22 2.31 ± 0.04 1.25 
30 1.93 ± 0.32 2.43 ± 0.35 1.26 
Pummelo juice 
50 2.10 ± 0.35 2.49 ± 0.15 1.19 
10 2.09 ± 0.34 2.08 ± 0.31 1.00 
30   2.21 ± 0.27 2.30 ± 0.14 1.04 
Orange juice 
50 1.53 ± 0.32 1.89 ± 0.11 1.24 
10   3.51 ± 0.68*   4.49 ± 0.15* 1.28 Lime juice 
30 2.64 ± 0.48 2.86 ± 0.24 1.08 
10   4.41 ± 0.67*   5.71 ± 0.45* 1.29 Lemon juice 
30 2.35 ± 0.16   3.33 ± 0.15* 1.42 
a Donor compartment contained 5 μM of [3H]-digoxin. All solutions were adjusted 
to pH 7.4. 
b Data represent mean ± SD, n = 4. 
c Net efflux ratio = Papp (BA) / Papp (AB). 
* p < 0.05 compared with control.  
 
[14C]-mannitol fluxes across the L-MDR1 and LLC-PK1 cell monolayers were well 
below 5%/h in both the AB and BA directions when Opti-MEM was used as the 
transport medium (Tables 3.4 and 3.5). The L-MDR1 and LLC-PK1 cell monolayers 
exposed for 4 h to 5 μΜ of [3H]-digoxin in Opti-MEM (pH 7.4) also did not show  
significant changes in TEER values (Tables 3.4 and 3.5). It may be inferred from the 




collective data that the paracellular transport pathways in the polarized L-MDR1 and 
LLC-PK1 cell monolayers were not compromised by the presence of Opti-MEM or 
by 5 μΜ of [3H]-digoxin for up to 4 h.  
 
Like verapamil, grapefruit and pummelo juices (at concentrations of 30% and above), 
as well as orange juice (at 50%), significantly diminished the polarized transport of 
digoxin across the L-MDR1 cell monolayers (Table 3.2). Grapefruit and pummelo 
juices at 50% elevated the AB digoxin Papp by 131 and 124% of control value, 
respectively, while the digoxin Papp in the BA direction was reduced by 41 and 31%, 
respectively. Orange juice at the same concentration elevated the AB digoxin Papp to a 
relatively higher extent, by 169%, but did not modulate the BA digoxin Papp 
significantly. The ranking order of the juices (50%) in reducing the net efflux ratio of 
digoxin transport across the L-MDR1 cells was orange juice (63% reduction) < 
pummelo juice (69%) < grapefruit juice (75%). None of the juices at the 
concentrations studied was as strong as verapamil in inhibiting the P-gp function in 
the L-MDR1 cells (Table 3.2). Verapamil at 100 µM increased the AB digoxin Papp by 
182%, and reduced the BA digoxin Papp by 53%.  
 
Grapefruit, pummelo and orange juices, applied at up to 50% in either the apical or 
basal chamber of the Transwell inserts, did not cause significant changes to the TEER 
nor the mannitol fluxes in the polarized L-MDR1 cell monolayers (Table 3.4). These 
results suggest a lack of detrimental effects on the tight junction integrity of the L-
MDR1 cell monolayers. In the case of the LLC-PK1 cells, only grapefruit juice at 
 




Table 3.4. Effects of citrus fruit juices on (1) the transepithelial electrical resistance 
(TEER) across L-MDR1 cell monolayers after Apical-to-Basal (AB) or Basal-to-
Apical (BA) digoxin transport experiments conducted over 4 h at 37oC, and (2) the bi-
directional [14C]-mannitol transport across the L-MDR1 cell monolayers. 
 
TEER (% control) b  
Mannitol Transport 
(%/h)c Samples a 
Conc 
% (v/v) AB BA AB BA 
Control - 100.0 100.0 0.22 0.40 
Verapamil (100 μM) -   99.1 ± 12.4 130.3 ± 5.8* 0.28 0.37 
10 96.1 ± 3.2 104.7 ± 7.7 0.24 0.50 
30 84.1 ± 2.7   90.0 ± 3.6 0.50 0.42 
Grapefruit juice 
50 82.5 ± 5.3   94.8 ± 4.7 0.74 0.77 
10 90.8 ± 6.7   90.7 ± 5.8 0.57 0.59 
30 86.8 ± 7.2   91.3 ± 7.6 0.35 0.67 
Pummelo juice 
50 88.0 ± 2.2   96.9 ± 5.1 0.74 0.98 
10 100.5 ± 10.0 113.4 ± 6.5 0.49 0.61 
30 110.1 ± 13.2   113.6 ± 10.9 0.47 0.60 
Orange juice 
50   87.5 ± 10.1 100.1 ± 7.5 0.96 1.62 
10 32.3 ± 3.4*   34.2 ± 3.8* 5.86 6.52 Lime juice 
30 25.0 ± 3.8*   32.7 ± 5.0* 7.50 6.79 
10 37.2 ± 4.4*   41.6 ± 6.4* 6.02 7.11 Lemon juice 
30 32.2 ± 3.2*   35.3 ± 2.0* 6.60 6.57 
a For digoxin transport experiments, donor compartment contained 5 μM of [3H]-
digoxin; for mannitol transport experiments, donor compartment contained 10 μM 
of [14C]-mannitol. All samples had been adjusted to pH 7.4.  
b Data represent TEER change expressed as a percent of TEER change in control 
sample, and are expressed as mean ± SD, n = 4. 
c Data represent mannitol flux as a percent of initial mannitol load, n = 1.  
* p < 0.05 when mean 100(TEERfinal/TEERinitial) value was compared with control.  
 
50% elevated the mannitol flux to slightly above 5%/h in both the AB and BA 
directions (Table 3.5). Orange and pummelo juices at up to 50% did not increase 
mannitol fluxes to beyond 5%/h.  However, the TEER of the LLC-PK1 cell 
monolayers was more sensitive to the juices, with significant TEER reduction  
observed in 50% of pummelo or grapefruit juices. Nonetheless, the 3 juices at 
concentrations of up to 50% did not affect the bi-directional digoxin fluxes across the 
LLC-PK1 cell monolayers (Table 3.3).  
 




Table 3.5.  Effects of citrus fruit juices on (1) the transepithelial electrical resistance 
(TEER) across LLC-PK1 cell monolayers after Apical-to-Basal (AB) or Basal-to-
Apical (BA) digoxin transport experiments conducted over 4 h at 37oC, and (2) the bi-
directional [14C]-mannitol transport across the LLC-PK1 cell monolayers.  
 
TEER (% control) b  
Mannitol Transport 
(%/h)c Samples a 
Conc 
% (v/v) AB BA AB BA 
Control - 100.0  100.0 0.61 0.74 
10 107.4 ± 3.5 121.4 ± 9.1* 1.28 1.67 
30   94.0 ± 2.1   95.8 ± 6.9 3.42 3.78 
Grapefruit juice 
50   72.7 ± 6.5*   89.6 ± 2.0 5.56 5.70 
10    101.7 ± 7.6    122.5 ± 5.7* 0.65 0.77 
30  100.9 ± 15.2    111.5 ± 6.7 0.45 0.91 
Pummelo juice 
50      65.1 ± 1.0*    95.1 ± 14.7 0.84 1.16 
10  114.7 ± 14.3  114.6 ± 10.1 0.76 0.94 
30  88.0 ± 4.0    102.0 ± 2.1  1.13 0.96 
Orange juice 
50  94.8 ± 6.9    108.5 ± 7.3 1.57 1.58 
10  29.0 ± 3.0*  30.1 ± 1.7* 4.93 5.75 Lime juice 
30  34.4 ± 2.8*    48.9 ± 12.2* 2.03 2.58 
10  28.7 ± 2.5*  30.2 ± 1.3* 6.34 7.21 Lemon juice 
30  39.2 ± 2.4*  47.6 ± 8.4* 4.26 3.31 
a For digoxin transport experiments, donor compartment contained 5 μM of [3H]-
digoxin; for mannitol transport experiments, donor compartment contained 10 μM 
of [14C]-mannitol. All samples had been adjusted to pH 7.4. 
b Data represent TEER change expressed as a percent of TEER change in control 
sample, and are expressed as mean ± SD, n = 4. 
c Data represent mannitol flux as a percent of initial mannitol load, n = 1.  
* p < 0.05 when mean 100(TEERfinal/TEERinitial) value was compared with control.  
 
Lime and lemon juices elevated both the AB and BA digoxin fluxes across the L-
MDR1 cells to the extent of abolishing the polarized transport profile and reducing 
the net efflux ratios to near unity values (Table 3.2). The two juices appeared to exert 
a greater influence on digoxin transport when applied at 10% than at the higher 
concentration of 30% (Table 3.2). In the presence of 10% lime or lemon juice, the AB 
digoxin Papp was increased by 12-14 fold, while the 30% juice samples increased the 
Papp by 9-10 fold. These values were much higher than those obtained with grapefruit, 
pummelo and orange juices at equivalent concentrations. It was likely that the lime 
and lemon juices facilitated the digoxin transport in the L-MDR1 cells by opening up 




the intercellular tight junctions. Both juices, whether added at 10 or 30% to the L-
MDR1 cells, were observed to reduce the cellular TEER by more than 50% (Table 
3.4), and to elevate the mannitol transport rate to more than 5%/h across the cell 
monolayers (Table 3.4). This breaching of the monolayer integrity was also observed 
when the lime and lemon juices were co-incubated with the LLC-PK1 cells (Table 
3.5). There were, however, differences in response between the two cell types with 
respect to the juice concentration. In the LLC-PK1 cells, smaller changes in TEER 
and mannitol transport were seen at 30% than at 10% juice concentration (Table 3.5). 
In contrast, the modulations of TEER and mannitol transport in the L-MDR1 cells 
were observed to increase with increasing juice concentration (Table 3.4).  
 
3.3.2. Cytotoxicity and Anti-proliferative Studies  
In vitro cytotoxicity profiles of the fruit juices against the L-MDR1 and LLC-PK1 
cells were assessed at pH 7.4 to give a measure of cell viability over the course of the 
4 h-digoxin transport experiments. Orange, lemon and lime juices were significantly 
more cytotoxic against the L-MDR1 cells compared to the negative control (Fig. 
3.2a). All 3 juices, in particular orange juice, were found to reduce the cell viability to 
a greater extent at 10% than at higher concentrations. The L-MDR1 cell viability was 
unaffected by orange juice at 30 and 50%, but was reduced to 76% when the orange 
juice was diluted to 10%. Grapefruit and pummelo juices, on the other hand, enhanced 
the mitochondrial activity of the L-MDR1 cells (Fig. 3.2a). Of the two, grapefruit 
juice showed a more pronounced effect, raising the measured cell viability to 138% at 
a concentration of 30%. In comparison, pummelo juice at 50% increased the cell 
viability only marginally to 108%.  
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Figure 3.2.  In vitro cytotoxicity profile of citrus fruit juices against the (a) L-MDR1 
and (b) LLC-PK1 cell monolayers after 4 h of exposure. Cytotoxicity was measured 
by the MTT assay and is expressed as percent cell viability relative to the viability of 
cells exposed to Opti-MEM. Cells were exposed to: grapefruit (G), pummelo (P), 
orange (O), lime (I) and lemon (L) juices at concentrations of 10% (denoted by the 
number 1), 30% (denoted by 3) and 50% (denoted by 5). Negative (-) control was 
0.1% dextran, and positive (+) control was 0.1% SDS, both dissolved in Opti-MEM. 




The viability of the L-MDR1 cells was also measured upon prolonged incubation with 
juice-supplemented culture medium in order to determine whether the juices inhibited 
cell proliferation during the P-gp expression experiments. Only the grapefruit, pummelo 
and orange juices were evaluated because lime and lemon juices were not used for the 
P-gp expression experiments. Enhanced cell viability was observed of the L-MDR1  













































viability seen at 30% of fruit juices (Fig. 3.3). Orange juice, surprisingly, also increased 
cell viability when it was incubated for 24 h with the L-MDR1 cells. It did not, 
however, increase cell viability in a concentration-dependent manner. Pummelo, orange 
and grapefruit juices were comparable promoters of cell proliferation as they produced 
cell viability in the range of 128-159%, 137-155%, and 121-144%, respectively. 
Control experiments were performed by culturing the cells in PBS-supplemented M199 
medium to determine the effects of nutrient depletion on cell growth over 24 h. Cells 
cultured in 50% of PBS showed reduced cell viability (78%). On the other hand, the P-
gp inhibitor, verapamil, did not modulate L-MDR1 cell viability after 24 h co-






























Figure 3.3.  Anti-cell proliferative activity of citrus fruit juices against the L-MDR1 
cell monolayers after 24 h of exposure. Cell viability was measured by the MTT assay 
and is expressed as percent cell viability relative to the viability of cells exposed to 
M199 culture medium. Cells were exposed to grapefruit (G), pummelo (P) and orange 
(O) juices at concentrations of 10% (denoted by the number 1), 30% (denoted by 3) 
and 50% (denoted by 5). Negative (-) control was 0.1% dextran, and positive (+) 
control was 0.1% SDS, both dissolved in M199 medium. Other controls included 50% 
of PBS in M199 (PBS) and 100 μM of verapamil in M199 (V). Data represent mean ± 
SD, n = 8. * significantly different from negative control (p < 0.05). 
 




Relative to the L-MDR1 cells, the LLC-PK1 cells were more sensitive to the citrus 
fruit juices. Poorer cell viability was observed when the LLC-PK1 cells were exposed 
for 4 h to any one of the 5 juices, even at concentrations as low as 10% (Fig. 3.2b). 
For all 5 juices, their cytotoxic effects against the LLC-PK1 cells were comparable 
within the concentration range of 10–50% (p > 0.05, Two-way ANOVA). Cell 
viability was, nevertheless, affected by the type of juice applied, with the grapefruit 
juice showing significantly different cytotoxicity against the LLC-PK1 cells from the 
pummelo (p = 0.029) and lime (p = 0.027) juices. Orange juice was less cytotoxic 
compared with the lemon (p = 0.002), pummelo (p = 0.000) and lime (p = 0.000) 
juices. The latter three juices had comparable cytotoxicity against the LLC-PK1 cells 
(p > 0.05).  
 
As cell viability could also be adversely affected by pH and osmotic pressure, the 
osmolality of the samples administered to the cells was measured. pH was not 
considered to play a role because the samples were adjusted to pH 7.4 just prior to 
administration to the cells. Tables 3.6 and 3.7 are the respective records of the 
osmolality of Opti-MEM and M199 media containing fruit juice, PBS or verapamil. 
The osmotic pressure of the media increased with increasing juice concentrations. Of 
the 5 juices, pummelo juice contributed the least (< 1.3-fold at 50% concentration) to 
osmotic pressure changes, while lime and lemon juices almost doubled the osmotic 
pressure of the media when added at 50% concentration. Dilution of the M199 
medium with 50% v/v of PBS also increased the osmotic pressure by 1.2-fold due to 
the salt content in PBS. On the other hand, verapamil at 100 μΜ  did not increase the 
osmotic pressure of either the transport or culture media. The sample osmotic 
pressure, however, correlated poorly with the cell viability data for the L-MDR1 (R2 = 




0.0608) and LLC-PK1 (R2 = 0.0027) cells. There was also poor correlation between 
sample osmotic pressure and anti-cell proliferative activity against the L-MDR1 cells 
(R2 = 0.1456). These suggest that osmotic pressure was not the dominating factor in 
determining the cytotoxicity of the fruit juices. 
 
Table 3.6. Osmotic pressure of Opti-
MEM to which has been added 
verapamil or fruit juices at various 
concentrations. All samples were 
adjusted to pH 7.4 with 5 N NaOH.   
 
 Table 3.7. Osmotic pressure of M199 
medium to which has been added 
verapamil, PBS or fruit juices at various 
concentrations. All samples were adjusted 











Control - 287  Control - 296 
Verapamil 100 μM 296 Verapamil 100 μM 288  PBS 50% 343 
10 % 304 10 % 323 
30 % 343 30 % 373 
Grapefruit 
juice 
50 % 397 
Grapefruit 
juice 
50 % 414 
10 % 291 10 % 315 
30 % 318 30 % 345 
Pummelo 
juice 
50 % 329 
Pummelo 
juice 
50 % 376 
10 % 322 10 % 320 
30 % 397 30 % 364 
Orange 
juice 
50 % 488 
Orange 
juice 
50 % 406 
10 % 338 10 % 365 
30 % 458 30 % 462 
Lime  
juice 
 50 % 586 
Lime  
juice 
 50 % 527 
10 % 326 10 % 361 
30 % 438 30 % 448 
Lemon 
juice 
50 % 558 
Lemon 
juice 




3.3.3. Modulation of P-gp expression in L-MDR1 cells 
To determine whether those juices that modulate the P-gp function in the L-MDR1 
cells were also capable of regulating the P-gp protein expression in the cells, Western 
blotting experiments were conducted using the C219 primary antibody. The cellular 
P-gp protein level was measured after 24 h incubation with juice-supplemented 































culture medium. Grapefruit and orange juices at up to 50% were found not to 
modulate the P-gp expression level significantly, although they appeared to induce, 
respectively, lower and higher P-gp band intensities compared to control (Fig. 3.4). 
 Pummelo juice also did not affect the P-gp expression level until its concentration 
was increased to 50%, whereupon the P-gp level dropped to 68% of control. Co- 
culturing the L-MDR1 cells with medium supplemented with 50% of PBS 
significantly enhanced the P-gp level to 127% (Fig. 3.4). The increased P-gp level  
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                                                                  (b) 
Figure 3.4. P-gp expression in L-MDR1 cells cultured in T-flasks for 5 days before 
they were exposed for 24 h to culture medium (control sample denoted as 0), 50% of 
PBS (PBS), 100 μM of verapamil (V) and grapefruit (G), pummelo (P) and orange 
(O) juices at 10, 30 and 50%, respectively, where 1, 3 and 5 denote the respective 
juice concentrations. (a) Western blot analysis of P-gp using C219 as primary 
antibody. Upper bands, P-gp; lower bands, β-actin. β-actin was used to confirm equal 
protein loading. The result of one typical experiment out of three is shown. (b) Optical 
density of P-gp/β-actin bands as quantified by densitometric analyses. Data represent 
mean ± SEM, n = 3. * p < 0.05 compared with control cells.  
 
 

















was consistent with the phenomenon of protein induction commonly executed by cells 
under serum deprivation (Muller et al., 1995). On the other hand, verapamil at 100 
µM did not modulate the P-gp level of the L-MDR1 cells. 
 
3.3.4. Modulation of P-gp expression in vivo 
Different levels of P-gp protein were detected in tissues harvested from the control 
rats, which were gavaged daily with water for 10 days (Fig. 3.5). The duodenum and 
jejunum of some of the rats did not have detectable levels of P-gp, making it difficult 
to derive conclusive data from these tissues, since n was less than 4. It is not unusual 
to find very low levels of P-gp in the duodenum and jejunum because the P-gp level is 
known to increase progressively along the length of the small intestine of the rodent 
(Ayrton and Morgan, 2001; Ho et al., 2003; Wagner et al., 2001). The P-gp protein 
was more consistently expressed in the rodent ileum, liver and kidney, with detectable 










Figure 3.5. P-gp () and actin () levels in control rat tissues after the rats were fed 
for 10 days with water by twice daily intragastric gavage. Western blot analysis of P-
gp and actin were performed using the C219 and β-actin antibody, respectively. β-
actin was analysed to confirm equal protein loading. Optical density of P-gp and β-
actin were quantified by densitometric analyses. Data represent mean ± SEM (n = 4), 
except for duodenum and jejunum where n = 2.  



























































































Twice daily gavage of the rats with 10 ml/kg of grapefruit, orange or pummelo juices 
did not produce any significant difference in P-gp levels in the ileum after 10 days 
(Fig. 3.6c). The hepatic and renal P-gp levels were, however, significantly up-
regulated by pummelo juice to 1.8- and 3.4-folds, respectively, of control levels (Fig. 
3.6d and e). Although grapefruit and orange juices also increased the P-gp levels in 
these two organs, the increases, by 1.2- and 2.0-folds, respectively, were not 
statistically significant (p > 0.05).  
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Figure 3.6. P-gp levels in rat tissues after the rats were fed for 10 days with water 
(control, C) or 10 ml/kg of grapefruit juice (GFJ), orange juice (OJ) or pummelo juice 
(PJ) by twice daily intragastric gavage. Western blot analysis of P-gp in the rodent (a) 
duodenum, (b) jejunum, (c) ileum, (d) liver and (e) kidney was performed using the 
C219 antibody. Upper bands, P-gp; lower bands, β-actin. β-actin was used to confirm 
equal protein loading. The result of one typical experiment out of four is shown. 
Optical density of P-gp/β-actin was quantified by densitometric analyses. Data 
represent mean ± SEM (n = 4), except for (a) and (b), where n = 1 (#) or 2 (+) due to 





3.3.5. Modulation of mdr1a mRNA in vivo 
The mdr1a mRNA level in the tissues of rats dosed twice daily with 10 ml/kg of 
grapefruit, pummelo or orange juice (neat juices) was evaluated. This dosage was 
adopted from various studies (Kamath et al., 2005; Mangano et al., 2001; Mohri et al., 
2000), which used similar dosages to demonstrate the modulating effects of fruit 
juices on the oral bioavailability of nifedipine, cyclosporin A and fexofenadine in rats. 
RT-PCR analysis of tissues obtained from the control rats detected low levels of 
































































mdr1a mRNA in the rodent liver and kidney (Fig. 3.7d and e; left panel). This is in 
agreement with the data reported by Brady et al. (2002), who found the hepatic and 
renal mdr1a mRNA levels to be less than one-tenth of that in the ileum. However, 
when the band density of the mdr1a mRNA was expressed as a function of the actin 
mRNA band density (Fig 3.7; right panel), the differences between the liver and ileum 
became insignificant because of the low actin content in the liver. The mdr1a mRNA 
level was also not uniformly distributed along the rodent small intestine, as lower 
levels were detected in the duodenum and jejunum compared to the ileum (Fig. 3.7a-
c; left panel). These results again resonate with those reported by Brady et al. (2002) 
and Takara et al. (2003).  
 
Chronic treatment of the rats with 10 ml/kg of grapefruit, pummelo and orange juices 
twice daily for 10 days did not produce significant changes to the mdr1a mRNA 
  
        mdr1a mRNA             
 
500 bp -                            
400 bp -                                          
300 bp - 
 
         β-actin mRNA                                
500 bp -                            
 
 
300 bp -                                          
200 bp -                            
 
 
          M          C         GFJ              OJ               PJ 
                                                                       
          (a) 
          mdr1a mRNA             
 
500 bp -                            
400 bp -                                         
300 bp - 
 
         β-actin mRNA                                
500 bp -                            
 
300 bp -                                          
200 bp -                            
 
 
          M          C         GFJ              OJ               PJ 
                                                                       
          (b) 































































































          mdr1a mRNA             
 
500 bp -                            
400 bp -                                          
300 bp - 
 
         β-actin mRNA                                
500 bp -                            
 
300 bp -                                          
200 bp -                            
 
 
          M          C         GFJ              OJ               PJ 
                                                                       
          (c) 
 
 
          mdr1a mRNA             
 
500 bp -                            
400 bp -                                          
300 bp - 
 
         β-actin mRNA                                
500 bp -                            
 
 
300 bp -                                          
200 bp -                            
 
 
          M          C         GFJ              OJ               PJ 
                                                                       




          mdr1a mRNA             
 
500 bp -                            
400 bp -                                          
300 bp - 
 
         β-actin mRNA                                
500 bp -                            
 
 
300 bp -                                          
200 bp -                            
 
 
          M          C*         GFJ              OJ               PJ 
                                                                       
          (e) 
 
Figure 3.7. mdr1a mRNA level in various rat tissues. Semi-quantitative RT-PCR 
analysis of mdr1a and actin mRNA of rodent (a) duodenum, (b) jejunum, (c) ileum, 
(d) liver and (e) kidney of rats were performed after the rats were fed for 10 days with 
water (control, C) or 10 ml/kg of grapefruit juice (GFJ), orange juice (OJ) or 
pummelo juice (PJ) by twice daily intragastric gavage. M represents the 100 bp DNA 
ladder loaded as a size marker. Band density of mdrla/β-actin mRNA was quantified 
by densitometric analysis. Data represents mean ± SEM, n = 4, except for *, where n 
= 2 because the mdr1a mRNA could only be detected in 2 out of 4 samples.  
 




levels in all the tissues studied (Fig. 3.7). Although there was a trend of the 3 fruit 
juices increasing the relative mdr1a mRNA level in the rat duodenum, liver and 
kidney, the changes were not statistically significant when compared to the control 
levels (p > 0.05) (Fig. 3.7a, d and e; right panel). 
 
 
3.4. DISCUSSION   
Citrus fruit juices are normally consumed neat or diluted with water following the 
extraction of the juices from the respective fruits by mechanical means. Yet, data on 
the effects of hand-squeezed citrus fruit juices on the transepithelial transport of a P-
gp substrate are scarce. Besides data published by our laboratory (Xu et al., 2003), 
most researchers employed the ethyl acetate extracts of fruit juices for studies relating 
to the P-gp (Egashira et al., 2004; Honda et al., 2004; Takanaga et al., 1998, 2000b). 
This difference in fruit juice preparation method might well account for the 
differences in P-gp inhibition data obtained by Sawada’s group (Egashira et al., 2004) 
and our laboratory (Xu et al., 2003) with respect to the pummelo juice. In addition, 
most data on fruit juice-mediated P-gp activity were obtained from uptake studies 
rather than transport studies (Romiti et al., 2004; Takanaga et al., 1998, 2000b), which 
more closely simulate drug transport across the GIT mucosa.  
 
This study set out to use another cell-line, the L-MDR1 cells which specifically over-
expressed the P-gp, to confirm the previous findings of our laboratory. Using a 
specific P-gp-expressing cell line is advantageous in eliminating the contribution of 
other transport pathways, in particular those involving unknown transporters or 
systems, in mediating the transport of the substrate (Chan et al., 2004; Lowes et al., 




2003). Orange juice was also added to the list of citrus fruit juices studied in this 
project because of its unique position in the citrus fruit taxonomy. The comparative 
effects of all 5 citrus fruit juices on the expression of P-gp at protein and mRNA 
levels were also evaluated, for the first time, in both the in vitro cellular and in vivo 
rat models.   
 
P-gp function was evaluated by measuring the bi-directional digoxin fluxes across the 
chosen cell monolayers. Digoxin (Fig. 3.8), which is used therapeutically as a cardiac 
glycoside, is a well established marker for the study of P-gp-mediated efflux in 
intestinal cells and tissues (Pauli-Magnus et al., 2001; Taipalensuu et al., 2004; 
Takara et al., 2002). It is routinely used to identify compounds that have the potential 






Figure 3.8. Structure of digoxin (Mw = 780.94). 
(Source from http://www.sigmaaldrich.com).  
 
P-gp activity (Balimane et al., 2004). Reasons for its popularity as a P-gp functional 
marker include it being a neutral compound (Cavet et al., 1996) of low cytotoxicity 
(Kakumoto et al., 2003) that undergoes minimal metabolism (Balimane et al., 2004; 
Fromm et al., 1999). In this project, the digoxin transport profiles across the polarized 
L-MDR1 cell monolayers bore the typical characteristics of P-gp-mediated efflux 
activity (Pauli-Magnus et al., 2000; Tanigawara et al., 1992; Wandel et al., 2002). 




Digoxin not only showed polarized transport across the cell monolayers but the 
polarized transport was abolished by verapamil, an established P-gp inhibitor 
(Balimane et al., 2004; Cavet et al., 1996; Takara et al., 2002). In addition, when 
digoxin was transported across the control P-gp-deficient LLC-PK1 cell monolayers, 
comparable fluxes were observed in the AB and BA directions, suggesting a 
predominant passive transport mechanism. The highly lipophilic (Molin et al., 1983) 
digoxin would be transported via the passive transcellular pathway across monolayers 
with intact tight junctions (Pauli-Magnus et al., 2000; Tanigawara et al., 1992). The 
TEER and mannitol transport data have collectively ruled out the paracellular 
pathway as the dominant route of transport for digoxin across the L-MDR1 and LLC-
PK1 cell monolayers.  
 
Verapamil was used as the positive control for the P-gp functional studies. Verapamil 
at 100 µM was shown to inhibit P-gp efflux activity, causing the AB digoxin Papp 
across the L-MDR1 cell monolayers to increase by 182% and digoxin efflux to reduce 
by 53%. These results are in agreement with those reported by Nakamura et al. 
(2002). Of the 5 citrus fruit juices studied, 3 of them, grapefruit, pummelo and orange 
juices, produced similar trends in digoxin transport profiles as verapamil. At 50% 
concentration, these fruit juices increased the AB digoxin Papp across the L-MDR1 cell 
monolayers in the ranking order of orange juice (169%) > grapefruit juice (131%) > 
pummelo juice (124%). The capacity of the juices to reduce the BA digoxin Papp was, 
however, in a different order of grapefruit juice (41%) > pummelo juice (31%) >> 
orange juice (1%). If potency as a P-gp inhibitor was based on the net efflux of 
digoxin, calculated as the ratio of mean BA Papp to AB Papp, orange juice would be 
regarded as the weakest inhibitor of the 3 juices. The ability of the fruit juices to 




suppress the net efflux of digoxin ranked in the order of grapefruit juice (75%) > 
pummelo juice (69%) > orange juice (63%). All 3 juices would be considered to be 
less potent P-gp inhibitors compared to verapamil, which suppressed the net digoxin 
efflux by 83%. Not surprisingly, the fruit juices did not influence the bi-directional 
digoxin fluxes across the P-gp-deficient LLC-PK1 cells. The inference is that the 
grapefruit, pummelo and orange juices did not affect the passive transcellular 
transport of digoxin across the LLC-PK1 cell monolayers.  
 
Bi-directional digoxin fluxes across the L-MDR1 cell monolayers were also modified 
by the lime and lemon juices. However, in enhancing the digoxin fluxes in the AB as 
well as the BA directions, both juices would not be considered to modulate the 
digoxin transport profiles in a manner that was characteristic of a P-gp inhibitor. The 
TEER and mannitol transport data supported our previous hypothesis (Xu et al., 2003) 
that these two juices facilitated digoxin transport across the cell monolayers by 
opening up the paracellular transport pathway. The same phenomena were also 
observed when the experiments were repeated in the LLC-PK1 cells. 
 
Despite the employment of different cell systems and digoxin concentrations, digoxin 
transport data obtained in the present study for grapefruit, pummelo, lime and lemon 
juices correlated well with those obtained in the previous study by our laboratory (Xu 
et al., 2003). The digoxin transport data obtained for the hand-squeezed orange juice 
were, however, novel. Although there have been several reports on orange juice-
mediated P-gp activity, the majority of these utilized the ethyl acetate extracts of 
orange juice to study the cellular uptake of P-gp substrates (Honda et al., 2004; 
Ikegawa et al., 2000; Takanaga et al., 2000b). Only Sawada’s group had applied 




commercial orange juice, but they too, employed uptake studies rather than transport 
experiments to demonstrate P-gp activity (Takanaga et al., 2000b). Despite the 
experimental differences, our data generally corroborated the uptake data reported in 
these studies to establish the orange juice as possessing P-gp inhibitory activity. The 
potency of orange juice as a P-gp inhibitor was, however, weaker than those of the 
grapefruit and pummelo juices prepared in a similar manner. A recent report (Honda 
et al., 2004), which evaluated the transepithelial transport of vinblastine and 
saquinavir in the Caco-2 cell monolayers, has also concluded that the ethyl acetate 
extract of orange juice was a weaker P-gp inhibitor compared to the ethyl acetate 
extract of grapefruit juice.  
 
Except for the 50% pummelo juice sample, which down-regulated the P-gp 
expression in the cells, the grapefruit, pummelo and orange juices did not modulate 
the P-gp protein level in the L-MDR1 cells after 24 h of co-incubation. Grapefruit and 
orange juices also had little effects on the rodent P-gp and mdr1a mRNA levels, with 
twice daily gavage for 10 days with 10 ml/kg of the juices producing no significant 
changes in the P-gp protein and mRNA levels in the ileum, liver and kidney of the rat 
model. Pummelo juice at the same dose, however, was able to up-regulate the P-gp 
levels in the rat liver and kidney following twice daily dosing for 10 days. It did not 
affect the P-gp level in the ileum, nor the mdr1a mRNA levels in all the organs tested. 
Given the variation in results obtained with the pummelo juice on different systems 
and rat tissues, more experiments will have to be conducted on this juice with respect 
to the factors governing its modulating activity on the cellular P-gp level, and the 
associated clinical significance.  
 




More experimentation might also be required for the grapefruit and orange juices, 
despite their lack of modulation of P-gp expression in the present study. This is 
because our data on grapefruit juice contradicted those reported by Romiti et al. 
(2004), who observed lower P-gp and associated mRNA levels in the human proximal 
tubular cells (HK-2) exposed for 3-4 days to grapefruit juice at low concentrations of 
0.05-5%. Our data were, however, consistent with a clinical study (Schwarz et al., 
2005), which showed no changes in duodenal P-gp and MDR1 mRNA levels in 
human volunteers who had ingested up to 900 ml of grapefruit juice for up to 6 days. 
Apart from cell type being an influencing factor for the different results, the duration 
of juice exposure could also play a role, although Kioka et al. (1992) had claimed that 
the P-gp level in human renal adenocarcinoma cells were modified following 
exposure to quercetin and sodium arsenite for as short as 4 h. 
 
The cytotoxicity data generated for grapefruit, pummelo, lime and lemon juices were 
in agreement with those obtained in the previous study conducted by our laboratory 
(Xu et al., 2003). Orange juice, whose cytotoxicity was not evaluated in the previous 
study, showed anomalous behavior when compared to the other juices. It behaved like 
the lime and lemon juices in reducing cell viability upon acute exposure to the cells. 
However, it was more cytotoxic at lower than at higher concentrations. Moreover, 
orange juice produced opposing effects by promoting cell viability upon prolonged 
co-incubation with the cells, a phenomenon associated with the grapefruit and 
pummelo juices. Clearly, further experiments are required to understand the 
mechanisms underlying the juice-mediated effects on cell viability. The present study 
has, however, showed that the effects of the grapefruit, pummelo and orange juices on 




P-gp function and expression in the L-MDR1 cells could not be correlated to their 
influence on cell viability.   
 
Lime and lemon juices exhibited stronger effects on digoxin transport in the L-MDR1 
cells, and induced greater changes in TEER and mannitol transport in the LLC-PK1 
cells when applied at 10% than at 30% concentration. The data obtained in this 
project were inadequate to explain such anomalous behaviour, but the phenomena 
could be related to the cytotoxicity of the juices. The MTT assay had shown both 
juices to be more potent at reducing the viability of L-MDR1 and LLC-PK1 cells at 
10% than at 30% concentration. Since the orange juice also induced higher 
cytotoxicity against the L-MDR1 cells at 10% concentration than at higher 
concentrations, these phenomena might be attributed to certain rutinosyl constituents 
present in all 3 juices. 
 
All 5 juices exhibited more pronounced cytotoxic effects on the LLC-PK1 cells than 
on the L-MDR1 cells, which could be attributed to the inherent resistant character of 
the L-MDR1 cells due to the transfected MDR1 gene (Mealey et al., 2003). The LLC-
PK1 cells are also known to have innate leakier monolayers than the L-MDR1 cells 
(Ward et al., 2000). This was confirmed in the present study, as the LLC-PK1 cell 
monolayers presented with greater variations in the TEER values and mannitol fluxes. 
Nevertheless, the grapefruit, pummelo and orange juices did not seem to affect the bi-
directional digoxin fluxes across the polarized LLC-PK1 cell monolayers, suggesting 
that the integrity of the cell monolayers were intact, at least for digoxin transcellular 
transport in the presence of the three fruit juices.  
 





On the basis of their effects on the TEER, cell viability and digoxin transport profiles 
in the L-MDR1 and LLC-PK1 cell models, the 5 fruit juices may be broadly 
categorized into two groups, with lime and lemon juices in one group, and grapefruit, 
pummelo and orange juices in another. The groupings are consistent with the 
categorization of the citrus fruits according to their dominant flavonoid pattern and 
taxonomy, suggesting that the modulating activities of the fruit juices on P-gp activity 
may be predicted based on the dominant flavonoid pattern and/or taxonomy of the 
fruit. Although the grapefruit, pummelo and orange juices have been established to 
inhibitors of the P-gp function, they had limited modulating effects on the P-gp level 
in the L-MDR1 cells. When consumed at 10 ml/kg daily over 10 days, the 3 juices did 
not modulate the intestinal P-gp level, nor the mdr1a mRNA levels in the small 
intestine, liver and kidney of the rat. Chronic consumption of pummelo juice 
enhanced the P-gp level in the rat liver and kidney. 
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This section of the project set out to evaluate the hypothesis that the modulating 
activity of citrus fruit juices on the organic cation transporter 2 (OCT2) was 
dependent on the dominant flavonoid pattern and taxonomy of the citrus fruits. OCT2 
is one of the three isoforms of OCT (OCT1, 2, and 3), which mediate the absorption 
and secretion of approximately 50% of clinical drugs classified as organic cations 
(OC) (Jonker and Schinkel, 2004). These OC are mainly small (60-350 Da) 
hydrophilic compounds with at least one positively charged amine moiety at 
physiological pH. In humans, the hOCT2 is predominantly expressed in the 
basolateral membrane of the proximal renal tubule and it plays an important role in 
the renal clearance of endogenous and exogenous OCs, including drugs and their 
metabolites (Masereeuw and Russel, 2001; Ullrich and Rumrich, 1996; Wright, 
2005). For the great number of drugs that are eliminated from the body by urinary 
excretion, co-administration of an OCT2 inhibitor could result in renal tubular 
accumulation (Nierenberg, 1987; van Crugten et al., 1986). This has clinical 
implications, particularly when the drug has a narrow therapeutic index. Fatal 
interactions have been reported between OCT2 substrates, e.g. methotrexate and non-
steroidal anti-inflammatory drugs (King et al., 1987; Kremer and Hamilton, 1995; 
Maiche, 1986; Singh et al., 1986).  
 
To date, no study has been reported on fruit juice and OCT2 interactions, although 
Ofer et al. (2005) have shown that selected flavonoids of citrus fruits, e.g. hesperetin, 
quercetin, kaemferol and naringin, could inhibit OCT2-mediated tetraethylammonium 
bromide (TEA) uptake into LLC-PK1 cells. The objective of the present study was to 
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evaluate the effects of grapefruit, pummelo, orange, lime and lemon juices on the 
OCT2 at both the functional and expression levels. LLC-PK1 cells were used as the 
cell model for the OCT2 transport experiments, with the porcine OCT2 (pOCT2) 
level in the cells determined by Western blot analysis. To delineate the general 
toxicity of the fruit juices from their specific effects on the drug transport pathways 
and pOCT2 expression level, in vitro cytotoxicity and anti-cell proliferation studies 
were performed using the MTT assay.  
 
LLC-PK1 cells are derived from a normal Hampshire pig kidney (Hull et al., 1976) 
and they have been extensively used as a model to characterize cationic drug transport 
in kidney epithelial cells (Fouda et al., 1990; Li et al., 2004; Smit et al., 1998b). The 
LLC-PK1 cells express pOCT2 in the apical membrane (Dudley et al., 2000; 
Gründemann et al., 1997; Schömig et al., 1993), and they form a polarized monolayer 
with epithelial characteristics, such as tight junctions and apical microvilli, when 
grown on a microporous support (Gstraunthaler et al., 1990; Pfaller et al., 1990). For 
these reasons, confluent LLC-PK1 cell monolayers cultured on Transwells™ culture 
inserts are often used as a cell model to study OCT2-mediated transport across 
epithelial cells.  
 
The substrate chosen was R-123 (Fig. 4.1), a fluorescent dye of 380 Da which 
exhibits a positive charge at physiological pH (Hirsch-Ernst et al., 2001), and is 
classified as a Type I OC. Because it is readily quantified by fluorimetry in cell 
extracts and intact cells (Hirsch-Ernst et al., 2001), R-123 is often used as a probe to 
elucidate cellular mechanisms (Singh, 1989; Skowronek et al., 1992; Troutman and 
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Thakker, 2003a). The selection of R-123 as the probe for the OCT2-mediated uptake 
study was based on several features. R-123 has been demonstrated (Masereeuw et al., 
1997) to accumulate extensively in the isolated perfused rat kidney. It exhibits higher 
affinity for the apical renal OCT system compared to the basolateral OCT (Pietruck 
and Ullrich,1995), and its transport in the intact rat kidney and LLC-PK1 cells is 
predominantly mediated by the OCT than by the P-gp (Ando et al., 2001; Masereeuw 
et al., 1997; van der Sandt et al., 2000). Positive control for the present study was 
TEA, a putative substrate and inhibitor of OCT (Wright and Dantzler, 2004). As R-
123 is also a substrate of the P-gp transporter, verapamil was applied as a control to 










Figure 4.1. Structure of the hydrophilic cationic substrate, rhodamine 123 (R-123). 
Calculated pKa for rhodamine 123 is 6.12 ± 0.40 (amine), log D values at pH 7.4 is 




4.2. METHODS AND MATERIALS 
4.2.1. Materials 
Tetraethylammonium bromide (TEA) was from the Sigma-Aldrich, Inc.; PT2 mouse 
monoclonal antibody for the detection of OCT2 was obtained from Novus 
Biologicals, Inc. (Littleton, CO, U.S.A). All reagents used were of analytical grade, 
and all other materials were similar to those listed in Sections 2.2.1 and 3.2.1. 
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4.2.2.   R-123 transepithelial transport and cellular accumulation 
LLC-PK1 cells (passage 245-254) were seeded onto Transwell™ cell culture inserts 
(12 mm diameter, 3.0 μm pore size) at a density of 5 x 105 cells/insert and cultured in 
M199 medium as described in Section 3.2.2. On day 6-7 post-seeding, the culture 
medium was replaced with Opti-MEM (37oC, pH 7.4; A, 0.5 ml; B, 1.5 ml) and the 
cells were equilibrated in the transport medium for 30 min. Confluent cell monolayers 
with TEER values greater than 200 Ω.cm2, after correction for resistance in control 
blank wells, were used. The transport experiments were initiated by adding 700 μl of 
Opti-MEM dosed with R-123 (5-200 μM) in the donor chamber and an equal volume 
of Opti-MEM in the receiver chamber. Transport was conducted at 37oC in 5% CO2 / 
95% air. The amount of R-123 appearing in the receiver chamber after 1, 2, 3 and 4 h 
was measured in 50 μl-aliquots and the samples withdrawn were immediately 
replenished with an equal volume of prewarmed Opti-MEM. At the end of the 
experiment, the cell monolayers were re-incubated with Opti-MEM (A, 0.5 ml; B, 1.5 
ml) for 30 min at 37°C before the measurement of TEER. Each 50 μl-aliquot sample 
was measured for R-123 content by fluorimetry, according to the method described in 
Section 2.2.6. To determine the amount of R-123 accumulated in the cells, the LLC-
PK1 cells were washed rapidly with ice-cold PBS at the end of the transport 
experiment at 4 h, and the quantity of R-123 in the cells was determined according to 
the methods described in Section 2.2.6.  
 
Parallel R-123 transport experiments were performed in the presence of each of the 
citrus fruit juices. The juices were squeezed from the respective fruits using methods 
described in Section 2.2.3 and added to the media in both the donor and receiver 
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chambers (5 to 50% v/v, pH 7.4). Control experiments were carried out using TEA 
(0.1-100 μM), verapamil (100 μM) or a combination of TEA and verapamil (100 μM 
of each) instead of the fruit juices.  
 
4.2.3. Cytotoxicity and Anti-proliferative Studies 
Cytotoxicity profiles of the fruit juices against the LLC-PK1 cells have been 
discussed in Section 3.2.4. for the juice concentration range of 10 to 50% v/v. All 
juices, except for orange juice, were shown to modulate the LLC-PK1 cell viability at 
a concentration of 10%. In this section, the cytotoxicity profile of the fruit juices 
against the LLC-PK1 cells was extended to include a lower juice concentration of 5%. 
Anti-proliferative activity of the fruit juices against the LLC-PK1 cells was also 
evaluated over the concentration range of 5 to 50% v/v. The experimental protocols 
for both studies were similar to those described in Section 3.2.4. Parallel experiments 
were conducted with TEA (1, 10 and 100 μM), verapamil (100 μM) or a combination 
of TEA and verapamil (100 μM of each) to delineate the effects of the OCT2 and P-
gp inhibitors on cell viability and proliferation.  
 
4.2.4. Semi-quantitative Determination of pOCT2 expression in LLC-PK1 cells 
by Western Blot Analysis 
LLC-PK1 cells (passage 249-252) were cultured in T-25cm2 flasks for 6 days, then 
co-incubated for 24 h with the citrus fruit juices. Grapefruit, pummelo and orange 
juices were applied as 5, 10, 30 and 50% solutions, while lime and lemon juices were 
applied as 5 and 10% solutions. In all cases, complete M199 medium served as the 
diluent. Control cells were co-incubated with the M199 medium or M199 containing 
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PBS (50%), verapamil (100 μM), TEA (1, 10 and 100 µM) or a combination of TEA 
and verapamil (100 μM of each).  At the end of 24 h, the cells were harvested for 
Western blot analysis as previously described in Section 3.2.5. Cellular pOCT2 
protein was detected using the OCT2 antibody, PT2 (1:1000).  
 
4.2.5. Statistical Analyses 
Experiments were repeated at least three times and the data expressed as mean ± SD 
or mean ± SEM. Differences between mean values were analysed by One-way 
ANOVA with the Tukey’s test applied for paired comparisons (SPSS 10.0, SPSS Inc., 




4.3.1. R-123 transepithelial transport and cellular accumulation 
There were no significant differences in the TEER of the LLC-PK1 cell monolayers 
exposed for 4 h to R-123 at 5 to 200 µM in Opti-MEM (pH 7.4) (Table 4.1). Cellular 
TEER was, however, affected by the addition of TEA (0.1 to 100 µM), verapamil 
(100 µM) or a combination of verapamil and TEA (100 µM of each) to the 5 µM R-
123 dosing solution. Significantly higher TEER values were observed when TEA or 
verapamil was present, although the two agents in combination produced a more 
muted effect on the TEER value. Likewise, the addition of 10-50% of pummelo or 
orange juices to the 5 µM R-123 dosing solution also enhanced the cellular TEER 
significantly (Table 4.1). Grapefruit juice, on the other hand, showed dual effects; 
cellular TEER was enhanced in the presence of 10% grapefruit juice, but higher juice  
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Table 4.1. Effects of R-123, TEA, verapamil and citrus fruit juices on the 
transepithelial electrical resistance (TEER) across LLC-PK1 cell monolayers after 
Apical-to-Basal (AB) and Basal-to-Apical (BA) R-123 transport experiments 
conducted over 4 h at 37oC. 
TEER (% control) c Sample Amount AB BA 
5 100.0 100.0 
50 103.4 ± 1.7   94.2 ± 9.6 
100   97.6 ± 3.7   84.7 ± 5.1 
R-123 (µM) a 
200 103.3 ± 2.5   93.2 ± 11.3 
Verapamil (µM) b  100 169.9 ± 11.8* 148.4 ± 3.7* 
0.1 127.8 ± 5.6*   99.9 ± 7.5 
1 115.8 ± 2.9     91.8 ± 14.4 
10 128.4 ± 3.2* 112.2 ± 4.8 
TEA (µM) b  
100 163.6 ± 13.2* 138.3 ± 7.3* 
TEA + Verapamil  (µM)b 100 of each 119.4 ± 9.1*   96.8 ± 3.1 
5 102.7 ± 6.2   86.6 ± 7.4 
10 125.2 ± 9.8* 102.5 ± 3.1 
30   74.9 ± 5.5*   65.9 ± 5.8* 
Grapefruit juice b  
(% v/v)  
50   55.1 ± 1.3*   47.0 ± 4.3* 
5 113.8 ± 3.1   98.7 ± 3.1 
10 134.2 ± 2.6* 118.5 ± 4.8* 
30 132.7 ± 4.4* 117.0 ± 7.9 
Pummelo juice b 
(% v/v)  
50 159.7 ± 8.6* 125.7 ± 7.9* 
5 108.3 ± 7.7 112.9 ± 3.5 
10 163.7 ± 12.6* 149.3 ± 3.5* 
30 154.4 ± 4.3* 137.0 ± 4.5* 
Orange juice b 
(% v/v)  
50 144.7 ± 3.5* 128.8 ± 5.9* 
5   76.7 ± 0.7*   65.5 ± 1.4* 
10   81.6 ± 2.8*   74.6 ± 5.9* 
30   54.9 ± 2.6*   46.3 ± 3.2* 
Lime juice b 
(% v/v)  
50   41.5 ± 3.7*   35.4 ± 2.1* 
5   74.4 ± 2.4*   57.9 ± 6.3* 
10   42.4 ± 7.4*   37.8 ± 5.6* 
30   27.1 ± 1.6*   24.3 ± 5.9* 
Lemon juice b 
(% v/v)  
50   17.5 ± 3.3*   16.8 ± 4.8* 
a Added to the donor compartment only. Receiver compartment contained Opti-MEM. 
b Added to both donor and receiver compartments, with donor compartment 
containing 5 μM of R-123. All solutions were adjusted to pH 7.4. 
c Data represent TEER change expressed as a percent of TEER change in control 
sample, and are expressed as mean ± SD, n = 4. 
* p < 0.05 when mean 100(TEERfinal/TEERinitial) value was compared with control. 
 
concentrations of 30 and 50% produced lower TEER values (Table 4.1). In contrast, 
decreasing TEER values were observed with increasing concentrations of lime and 
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lemon juices. At 50% concentration, these two juices reduced the cellular TEER to 40 
and 20% of control values, respectively. 
 
R-123 transport across the confluent LLC-PK1 cell monolayers was polarized, with 
transport in the AB direction favored over that in the BA direction (Fig. 4.2a). At a 
loading concentration of 5 µM, the AB transport rate and cellular accumulation for R-
123 were, respectively, 10.6- and 1.2-folds higher than those in the BA direction (Fig. 
4.2a and b). Increasing the R-123 loading concentration from 5 to 200 µM led to 
proportionately higher AB transport rate (linear R2 = 0.845). In contrast, the BA 
transport rate remained relatively unchanged over the loading concentration range of 
5 to 100 µM, increasing in value only when the loading concentration was increased 
to 200 µM (Fig. 4.2a). Cellular accumulation of R-123 transported in the AB direction 
was independent of the loading concentrations, while cellular accumulation of R-123 
transported in the BA direction was observed to increase with increasing loading 
concentrations (Fig. 4.2b). 
 
 
          
 
             












                   (a)                     (b)    
 
Figure 4.2. Effects of R-123 loading concentration on the (a) AB () and BA () 
transport of R-123 across, and (b) cellular accumulation of R-123 in the LLC-PK1 
cell monolayers over 4 h. Data are expressed as mean ± SD, n = 4. * p < 0.05 
compared with R-123 at 5 µM. 
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To confirm the involvement of the pOCT2 in mediating R-123 transport across the 
LLC-PK1 cell monolayers, the putative OCT2 substrate and inhibitor, TEA, was 
applied at 0.1-100 µM. The R-123 loading concentration of 5 µM was used to avoid 
carrier saturation. TEA at concentrations as low as 1 µM was observed to inhibit the 
AB transport of R-123, while BA transport of R-123 was facilitated by TEA at 10 µM 
or higher (Fig. 4.3a). This confirms the presence of a functional pOCT2 that aided in 
the transport of R-123 across the apical membrane of the LLC-PK1 cells.  At the 
highest TEA concentration of 100 µM, comparable transport rates of R-123 were seen 
in the AB and BA directions, suggesting an effective inhibition of the pOCT2 
transport activity. This was accompanied by a reduction in the cellular accumulation 
of R-123 applied in the apical chamber, and an enhanced cellular accumulation of R-
123 applied in the basal chamber (Fig. 4.3b).   
   
 
 













(a) (b)  
 
Figure 4.3. Effects of TEA on the (a) AB () and BA () transport of R-123 across, 
and (b) cellular accumulation of R-123 in the LLC-PK1 cell monolayers after 4 h 
exposure to R-123 applied at a loading concentration of 5 µM. Data are expressed as 
mean ± SD, n = 4. * p < 0.05 compared with 0 µM of TEA.  
 
Unlike TEA, verapamil at 100 µM did not modulate the R-123 transport and cellular 
accumulation profiles in the LLC-PK1 cells in either the AB or BA directions (Fig. 
4.4a and 4.5a). This verifies that the P-gp efflux pump was not involved in mediating 
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the transport of R-123 across the LLC-PK1 cells. Interestingly, the combination of 
TEA and verapamil, at 100 µM of each, was observed to give rise to AB and BA R-
123 transport profiles that were comparable with those obtained with verapamil alone 
(Fig. 4.4a), yet the corresponding R-123 accumulation profiles were different from 
those obtained with either agent (Fig. 4.5a). The data suggest that verapamil had 
attenuated the capacity of TEA to inhibit the pOCT2-mediated transport of R-123 and 
the capacity of TEA to enhance the cellular accumulation of R-123 applied in the 
basal chamber. When TEA was used in combination with verapamil, the AB and BA 
accumulations of R-123 were both reduced, by 37 and 45%, respectively, when 
compared to the control (Fig. 4.5a). In contrast, TEA when used alone was found to 
lower the AB accumulation of R-123 by 47%, but it increased the BA accumulation 
of R-123 by 42% (Fig. 4.5a).  
 
Of the 5 citrus fruit juices evaluated, grapefruit, pummelo and orange juices appeared 
to possess inhibitory activity against the pOCT2 transporter in that they attenuated the 
AB transport of R-123 but facilitated the BA transport of R-123 (Fig. 4.4b, c and d). 
In particular, pummelo and orange juices at 10 to 50% produced AB and BA R-123 
transport profiles that were comparable to those observed in the presence of 100 μM 
of TEA. Grapefruit juice at 10% also produced similar R-123 transport profiles, but 
there were significant increases in the amount of R-123 transported in both the AB 
and BA directions when the grapefruit juice concentration was increased to 30% and 
beyond (Fig. 4.4b). This bi-directional increase in R-123 transport might be associated 
with the opening of the intercellular tight junctions, as reflected by the lower TEER of 
the LLC-PK1 cell monolayers (Table 4.1). Bi-directional increases in R-123 transport  
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Figure 4.4. AB () and BA () transepithelial transport of R-123 (% initial) across 
the LLC-PK1 cell monolayers over 4 h in the presence of (a) transport medium (TM), 
100 µM of verapamil (Ver), 100 µM of TEA (TEA), and 100 µM each of TEA and 
Ver (TEA + Ver), (b) grapefruit, (c) pummelo, (d) orange, (e) lime, and (f) lemon 
juices at 5, 10, 30 and 50% (v/v). R-123 loading concentration was 5 μM.  Data 
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Figure 4.5. Cellular accumulation of R-123 from the AB () and BA () directions 
in the LLC-PK1 cell monolayers after 4 h exposure to R-123 at a loading 
concentration of 5 μM in the presence of (a) transport medium (TM), 100 µM 
verapamil (Ver), 100 µM TEA (TEA), and 100 µM each of TEA and Ver (TEA + 
Ver), (b) grapefruit, (c) pummelo, (d) orange, (e) lime, and (f) lemon juices at 5, 10, 
30 and 50% (v/v). Data represent mean ± SD, n = 4. * p < 0.05 compared with TM 
(ie. 0% juice). 
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were also seen in cell monolayers exposed to the lime and lemon juices (Fig. 4.4e and 
f). In these cases, the increases in R-123 transport were more substantial, which was 
congruous with the much lower cellular TEER induced by the lime and lemon juices 
(Table 4.1).  
 
Cellular accumulation profile of R-123 in the presence of the citrus fruit juices was 
more complex. While grapefruit, pummelo and orange juices at 10 to 50% induced 
relatively higher BA to AB accumulation of R-123 (Fig. 4.5b, c and d), accumulation 
profiles comparable to those produced with 100 µM of TEA were seen only for 
grapefruit juice at 30%, and pummelo juice at 10 and 30% (Fig. 4.5b and c). 
Increasing the grapefruit juice concentration to 50% caused both the AB and BA 
accumulation of R-123 to be attenuated, and the ratio of BA to AB accumulation to 
fall (Fig. 4.5b). On the other hand, increasing the pummelo juice concentration to 
50% increased both the AB and BA accumulation of R-123 in a proportionate manner 
(Fig. 4.5c). Orange juice at 10 to 50% produced higher bi-directional accumulation of 
R-123 compared with TEA, although the ratio of BA to AB R-123 accumulation was 
comparable for both agents (Fig. 4.5a and d).  
 
Lime and lemon juices produced different cellular R-123 accumulation profiles from 
TEA (Fig. 4.5e and f). At low concentration of 5%, both juices promoted the BA 
accumulation of R-123 relative to the AB accumulation, a phenomenon observed only 
at higher concentrations of TEA, or the other citrus fruit juices (Fig. 4.5). For lime 
and lemon juices, however, this effect was abolished when the juice concentration 
was increased to 10%, and the reduced BA accumulation was accompanied by lower 
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AB accumulation of R-123 (Fig. 4.5e and f). Further increase in juice concentration 
from 10 to 50% did not produce substantial changes to the R-123 accumulation 
profiles for lemon juice (Fig. 4.5f), but higher lime juice concentrations increased 
slightly both the AB and BA accumulation of R-123 (Fig. 4.5e). The ratio of BA to 
AB accumulation of R-123 was observed to approach unity at higher concentrations 
of the lime and lemon juices.  
 
4.3.2. Cytotoxicity and Anti-proliferative Studies 
The cytotoxicity profiles of the fruit juices against the LLC-PK1 cells over the 
concentration range of 10-50% have been discussed in Section 3.3.2. Except for 
orange juice, all the citrus fruit juices examined in this project reduced the cell 
viability when compared to the negative control. In this section, the in vitro 
cytotoxicity profiles of the fruit juices at 5%, together with the cytotoxicity profiles of 
TEA and verapamil, applied alone or in combination at 100 μM, were examined 
against the LLC-PK1 cells. TEA and verapamil did not modulate the viability of 
LLC-PK1 cells after 4 h exposure (Fig. 4.6).  However, cells exposed to a 
combination of both agents showed significantly higher viability compared to the 
negative control (Fig. 4.6). Likewise, all the citrus fruit juices at 5% significantly 
enhanced the cell viability, with lime juice showing the highest potency, followed by 
the lemon, orange, grapefruit and pummelo juices (Fig. 4.6). 
 
The anti-proliferative activity of the citrus fruit juices against the LLC-PK1 cells was 
also assessed by incubating the cells for 24 h with the respective juice-supplemented 
culture medium. TEA and verapamil were also included in the study. Of the 5 juices,  
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Figure 4.6. In vitro cytotoxicity profile of 100 μM of TEA (TEA), 100 μM of 
verapamil (Ver), 100 μM each of TEA and verapamil (TEA + Ver) and 5% (v/v) of 
grapefruit (5G), pummelo (5P), orange (5O), lime (5I), and lemon (5L) juices against 
the LLC-PK1 cells after 4 h of exposure. Cytotoxicity was measured by the MTT 
assay and expressed as percent cell viability relative to the viability of cells exposed 
to Opti-MEM. Negative (-) control was 0.1% dextran, and positive (+) control was 
0.1% SDS, both dissolved in Opti-MEM. Data represent mean ± SD, n = 6-8. * 
significantly different from negative control (p < 0.05). 
 
 
orange juice produced the smallest effect on cell proliferation, with cell viability 
varying within the narrow range of 89 to 110% for this juice (Fig. 4.7d). Three of the 
juices, grapefruit, lime and lemon, exhibited anti-proliferative activity against the 
LLC-PK1 cells over the concentration range evaluated (Fig. 4.7b, e and f). However, 
while grapefruit juice showed concentration-independent activity, producing cell 
viability within the range of 55 to 61% for the concentration range tested (Fig. 4.7b), 
lime and lemon juices exhibited concentration-dependent anti-proliferation activity 
(Fig. 4.7e and f). At high concentrations, the latter two juices severely attenuated the 
proliferation of the LLC-PK1 cells, causing the cell viability to fall below 50%. 
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Figure 4.7. Anti-proliferation activity of (a) PBS at 50% (PBS), TEA at 1, 10, 100 
μM (1, 10, 100 TEA), verapamil at 100 μM (Ver), and TEA and verapamil at 100 μM 
of each (TEA + Ver), (b) grapefruit, (c) pummelo, (d) orange, (e) lime, and (f) lemon 
juices at concentrations of 5, 10, 30 and 50% (v/v) against the LLC-PK1 cells after 24 
h of exposure. Cell viability was measured by the MTT assay and expressed as 
percent cell viability relative to the viability of cells exposed to M199 culture 
medium. Negative (-) control was 0.1% dextran, and positive (+) control was 0.1% 
SDS, both dissolved in M199 medium. Data represent mean ± SD, n = 8. * 
significantly different from negative control (p < 0.05). 
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up to 10%, but promoted cell proliferation at higher concentrations of 30 and 50% 
(Fig. 4.7c). TEA applied at up to 100 μM was not shown to modulate the proliferation 
of the LLC-PK1 cells, but PBS (50%), verapamil (100 μM), and TEA and verapamil 
used in combination (100 μM of each) reduced the cell proliferation significantly 
(Fig. 4.7a). Mean cell viability did not, however, fall below 81 % in the presence of 
these agents.  
 
Tables 4.2 and 4.3 record the osmolality of Opti-MEM and M199 media to which 
specified concentrations of the citrus fruit juices, TEA or verapamil had been added. 
All samples were adjusted to pH 7.4 with 5N NaOH prior to osmotic pressure 
measurements. TEA and verapamil, alone or in combination at 100 μΜ, were found 
not to increase the osmotic pressure of the transport and culture media significantly 
(Table 4.2 and 4.3). The citrus fruit juices, on the other hand, increased the osmotic 
pressures of both media in a concentration-dependent manner. In particular, the 
addition of lime and lemon juices to the media, followed by pH adjustment to 7.4, 
resulted in the most hypertonic samples. By comparison, pummelo juice gave rise to 
the smallest increases in osmotic pressure. Nevertheless, there was poor correlation 
between the osmotic pressure and the cytotoxicity of samples against the LLC-PK1 
cells (R2 = 0.1546). Neither was the osmotic pressure well correlated with the anti-
proliferation activity of the samples against the LLC-PK1 cells (R2 = 0.3335). These 
suggest that sample hypertonicity was not the dominating factor in determining the 
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Table 4.2. Osmotic pressure of Opti-
MEM to which has been added TEA and 
verapamil (Ver), alone or in combination, 
or fruit juices at various concentrations. 
All samples were adjusted to pH 7.4 with 
5 N NaOH. 
 
 Table 4.3. Osmotic pressure of M199 
medium to which has been added PBS, 
TEA and verapamil (Ver), alone or in 
combination, or fruit juices at various 
concentrations. All samples were 












Control - 287 Control - 296 
Ver  100 μM 288 PBS 50% 343 
TEA  100 μM 287 Ver  100 μM 296 
TEA+Ver  100 μM each 289 1 μM 294 
5 % 300 10 μM 299 
10 % 304 
TEA  
100 μM 301 
30 % 343 TEA+Ver 100 μM each 297 
Grapefruit 
juice 
50 % 397 5 % 311 
5 % 293 10 % 323 
10 % 291 30 % 373 
30 % 318 
Grapefruit 
juice 
50 % 414 
Pummelo 
juice 
50 % 329 5 % 304 
5 % 298 10 % 315 
10 % 322 30 % 345 
30 % 397 
Pummelo 
juice 
50 % 376 
Orange 
juice 
50 % 488 5 % 308 
5 % 315 10 % 320 
10 % 338 30 % 364 
30 % 458 
Orange 
juice 




50 % 586 5 % 333 
5 % 316 10 % 365 
10 % 326 30 % 462 




50 % 527 
Lemon 
juice 
50 % 558 5 % 334 
10 % 361 





50 % 554 
 
4.3.3. Modulation of pOCT2 expression in LLC-PK1 cells 
Cellular pOCT2 protein level in the LLC-PK1 cells was measured after 24 h 
incubation with juice-supplemented culture medium by Western blot analysis using 
the PT2 antibody. Grapefruit, pummelo and orange juices were assessed over the 
concentration range of 5 to 50%, while lime and lemon juices were applied at up to 
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10% because of their detrimental effects on cell proliferation at higher concentrations 
(Fig. 4.7 e and f). At these concentrations, grapefruit and lemon juices did not 
modulate the pOCT2 level significantly (Fig. 4.8). Pummelo, orange and lime juices 
upregulated the pOCT2 level in the LLC-PK1 cells in a concentration-dependent 
manner (Fig. 4.8). However, while increasing concentrations of orange and lime  
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Figure 4.8. pOCT2 expression in LLC-PK1 cells cultured in T-flasks for 6 days 
before they were exposed for 24 h to culture medium (C), 100 μM of verapamil (V), 
50% of PBS (PBS), 1, 10, 100 μM of TEA (T), 100 μM each of TEA and verapamil 
(TV), or different concentrations of fruit juices: grapefruit (G), pummelo (P) and 
orange (OJ) juices at concentrations of 5, 10, 30 and 50%, and lime (I) and lemon (L) 
juices at 5 and 10%. (a) Western blot analysis of pOCT2 using [PT2]. Upper bands, 
OCT2; lower bands, β-actin. β-actin was used to confirm equal protein loading. (b) 
Optical density of OCT2/β-actin bands as quantified by densitometric analyses. Data 
represent mean ± SEM, n = 3. * p < 0.05 compared with control cells (C). 
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juices produced higher pOCT2 protein levels, pummelo juice was most effective in 
enhancing the pOCT2 protein level at lower concentrations (Fig. 4.8). Cellular 
pOCT2 level was increased by 1.9-fold when incubated with 5% of pummelo juice, 
but the protein level decreased progressively with higher concentrations of pummelo 
juice to reach only 1.2-fold of the control level at 50% of pummelo juice. In contrast, 
50% of orange or lime juice was observed to increase the cellular pOCT2 level by 
more than 2-fold (Fig. 4.8). Cells cultured with 50% of PBS also had 2-fold higher 
pOCT2 level compared with control cells (Fig. 4.8), whereas TEA and verapamil, 
whether applied alone or in combination, had no effect on the cellular pOCT2 level 
(Fig. 4.8).  
 
4.4. DISCUSSION   
The role of pOCT2 in mediating the transepithelial transport of R-123 across the 
LLC-PK1 cell monolayers was evaluated for the first time in this study. LLC-PK1 
cells express pOCT2 in the apical membrane, and this has been shown to support the 
apical uptake of TEA (Gründemann et al., 1997). R-123 is positively charged at pH 
7.4, and has been classified as a type I OC. Its polarized transport across the LLC-
PK1 cell monolayers, where the AB transport rate was up to 15.8-fold higher than the 
BA transport rate, underpinned a carrier-mediated transport mechanism. The 
attenuation of the AB transport rate, with concomitant abolishment of the polarized R-
123 transport profile, by TEA confirmed a pOCT2-mediated influx of R-123 across 
the apical membrane. Since transepithelial transport of R-123 was demonstrated, the 
intracellular R-123 must necessarily exit across the basolateral membrane of the cells. 
The exit mechanism has not been established in this project, but could involve the 
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following pathways. OC exit across the luminal membrane of kidney cells has been 
reported to involve a carrier-mediated antiport of OC for H+, the exchange of one OC 
for one H+ permitting the development of a luminal concentration as large as or larger 
(depending on the size of the transluminal H+ gradient) than that in the cytoplasm, 
resulting in net transepithelial secretion (Wright and Dantzler, 2004). There is, 
however, no report to date on the existence of such an OC/H+ exchanger in the 
basolateral membrane of the LLC-PK1 cells. More likely, the exit of intracellular R-
123 from the LLC-PK1 cells involved the diffusion of uncharged R-123 across the 
plasma membrane. Dudley et al. (2000) has shown that the apical uptake of 
metoprolol across LLC-PK1 cell monolayers was contributed by a combination of 
non-ionic passive diffusion of the uncharged metoprolol and pOCT2-mediated uptake 
of the cationic metoprolol. In contrast, the basolateral flux was consistent with the 
non-ionic diffusion of uncharged metoprolol. R-123 transport across the LLC-PK1 
cells was not expected to differ significantly from this model. The exit of protonated 
R-123 by passive diffusion across the cell membrane would not be energetically 
favored in view of the inside-negative membrane potential (PD) of the cells. But the 
negative PD, combined with OCT2-mediated uptake, would build up a substantial 
accumulation of R-123 in the cells (Wright and Dantzler, 2004), and in turn provide 
the concentration gradient that drove the diffusion of uncharged R-123 across the 
basolateral membrane. 
 
For BA transport, the R-123 flux would be predominantly governed by passive 
diffusion of the uncharged species across the basolateral membrane, followed by exit 
across the apical membrane. Given that R-123 was largely protonated at pH 7.4, its 
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translocation by passive diffusion would not be favorable. In addition, the uncharged 
R-123 could become protonated upon internalization (Dudley et al., 2000), and its 
consequent attraction to the protein anions in the cells would counter the tendency of 
R-123 to exit from the cells. Collectively, these would lead to low transepithelial 
transport rate, but could cause a substantial cellular accumulation of R-123 in the BA 
direction. The pOCT2 in the LLC-PK1 cells has been shown, however, to mediate 
trans-apical fluxes in response to the prevailing electrochemical gradient of the 
substrate (Wright and Dantzler, 2004). Thus, R-123 efflux across the apical 
membrane could occur under a favorable outwardly directed electrochemical gradient, 
and this in turn would decrease cellular accumulation.  
 
P-gp-mediated efflux did not play a major role in the translocation of R-123 across the 
LLC-PK1 cells, since R-123 transport and cellular accumulation data obtained in the 
presence of verapamil were no different from those of the control samples. The 
absence of P-gp function in the cells was consistent with the findings established in 
Chapter 3 for digoxin transport across the LLC-PK1 cells. Passive diffusion of R-123 
along the paracellular route was also not expected to play a major role in its 
translocation across the LLC-PK1 cell monolayers unless the intercellular tight 
junctions had been compromised.  
 
Addition of increasing concentrations of TEA progressively inhibited the AB 
transport of R-123, finally reducing the AB transport flux to the same level as the BA 
transport flux at a concentration of 100 µM. TEA is classified as a type I OC, like R-
123, and would competitively inhibit the pOCT2-mediated uptake of R-123 across the 
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apical membrane. The addition of 100 µM of TEA into the 5 µM R-123 sample would 
cause the AB flux of R-123 to be driven mainly by passive diffusion, the same 
mechanism as that proposed for the BA direction. Thus, comparable transepithelial 
transport fluxes for R-123 were observed in the AB and BA directions under the 
influence of TEA. However, AB cellular accumulation of R-123 was observed to 
decrease by 47% while the BA accumulation was enhanced by 42% in the presence of 
100 µM of TEA. This suggests that, in the absence of the competitive inhibitor, the 
AB and BA cellular accumulation of R-123 were substantially manipulated by 
pOCT2-mediated uptake and trans-apical fluxes of R-123. Transepithelial transport of 
R-123 via the paracellular route was again not considered to be a major pathway 
because TEA caused a tightening of the intercellular tight junctions. 
 
In the presence of verapamil, TEA appeared to have lost its capacity to inhibit the 
pOCT2 function in the LLC-PK1 cells, the R-123 transport profiles obtained with 
verapamil and TEA being comparable to those obtained for control cells and cells 
exposed to verapamil alone. Yet the resultant cellular accumulation profiles of R-123 
in the presence of verapamil and TEA were different from those obtained with the 
control cells, or with cells exposed to TEA or verapamil alone. These results were 
unexpected. In retrospect, the combination of verapamil and TEA as inhibitors to 
probe, respectively, the P-gp- and pOCT2-mediated transport of R-123 in the LLC-
PK1 cells is perhaps not appropriate. Although it is more widely known to be a P-gp 
inhibitor, verapamil is also an organic cation at physiological pH, like TEA and R-
123, and it is a proven OCT inhibitor (Martel et al., 2000; Shu et al., 2001). In fact, 
verapamil has been found to not only interfere with OC transport by the OCT family 
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of transporters, but it can also inhibit OC transport mediated by other transporters, e.g. 
the plasma membrane monoamine transporter (PMAT) (Engel and Wang, 2005). 
Therefore, the incorporation of verapamil would complicate the interactions between 
TEA and R-123. 
 
Of the 5 citrus fruit juices examined, grapefruit, pummelo and orange juices produced 
R-123 transport and cellular accumulation profiles that were comparable to those 
observed for 100 µM of TEA. The implication is that these 3 fruit juices possessed 
inhibitory action against the pOCT2 function. For pummelo and orange juices, 
complete inhibition of the pOCT2 function was seen at juice concentrations ranging 
from 10 to 50%. Grapefruit juice at 10% effectively inhibited the pOCT2 function, 
but its adverse effects on the intercellular tight junctions at higher concentrations 
implicate the growing influence of the paracellular pathway in determining the bi-
directional transport of R-123 across the cell monolayers. Consequently, the AB and 
BA transport fluxes of R-123 obtained at 30 and 50% of grapefruit juice were higher 
than those expected from transcellular passive diffusion alone. Our results are 
consistent with the data reported by Ofer et al. (2005). The latter have demonstrated 
that the following flavonoids: quercetin, hesperetin, naringin and naringenin inhibited 
pOCT2-mediated uptake of TEA into the LLC-PK1 cell monolayers. Quercetin and 
hesperetin are flavonoids found in orange juice (Radtke, 2001), while naringin and 
naringenin are major flavonoids of grapefruit juice (Kuhnau, 1976). A comparison of 
the IC50 values obtained by Ofer et al. (2005) and the relevant concentrations of 
flavonoids in the juices also implicate the orange juice to be a more potent inhibitor of 
pOCT2 activity than the grapefruit juice. 
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Higher AB and BA cellular accumulations of R-123 were observed with grapefruit, 
pummelo and orange juices at increasing concentrations from 10 to 50%, with the 
exception of 50% of grapefruit juice. While the reason for the enhanced accumulation 
is not clear at this juncture, the high osmotic pressures of the concentrated juice 
samples could play a role in raising the intracellular solute concentration by causing 
water outflow from the cells (crenation in response to hypertonic solutions). Indeed, 
the changes in intracellular concentration of R-123, whether accumulated from the 
AB or BA direction, mirrored the osmotic pressures of the juice samples applied in 
both the apical and basal chambers. Of the 3 juices, orange juice produced the most 
hypertonic samples on a concentration basis, and it resulted in the highest intracellular 
concentration of R-123.     
 
The effects of lime and lemon juices on the apical pOCT2 function are difficult to 
assess in view of the significant opening of the intercellular tight junctions induced by 
the juices even at a low concentration of 5%. R-123 transport across the LLC-PK1 
cell monolayers may therefore be presumed to occur predominantly by passive 
diffusion along the paracellular pathway in the presence of either of these two juices. 
Thus, there was no difference in R-123 transport flux between the AB and BA 
directions at the same concentration gradient of R-123 applied. In addition, the R-123 
transport fluxes correlated with the cellular TEER values observed at different juice 
concentrations, reflecting the extent of tight junction damage caused by the juices. 
The higher R-123 transport fluxes obtained with the lemon juice are also in agreement 
with the TEER changes induced by this juice compared to equivalent concentrations 
of lime juice.  
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At a low concentration of 5%, lime and lemon juices promoted the BA cellular 
accumulation of R-123, which again could be associated with the high osmotic 
pressure of the juice samples. As shown in Table 4.2, the lime and lemon juice 
samples were the most hypertonic compared to samples spiked with grapefruit, 
pummelo or orange juices. The enhanced R-123 cellular accumulation was, however, 
absent at stronger lime and lemon juice concentrations, probably because of the 
extensive damage inflicted by the juices on the LLC-PK1 cell monolayer integrity. 
This phenomenon was consistent with that observed for the 50% grapefruit juice 
sample.  
   
The effects of the fruit juices on the R-123 transport and accumulation profiles are not 
likely to be related to their cytotoxicity against the LLC-PK1 cells. Although all 5 
juices reduced the cell viability when applied at concentrations of 10% or higher, the 
reduction in cell viability was not substantial, and did not go beyond 26% relative to 
the negative control. Moreover, higher cell viability was associated with low 
concentration (5%) of the citrus fruit juices, yet this did not produce a definitive trend 
in R-123 transport and accumulation profiles. 
 
Pummelo, orange and lime juices were shown to modulate the pOCT2 expression in 
the LLC-PK1 cells by up-regulating the cellular pOCT2 protein level following 24 h 
incubation. While the modulating effects of orange and lime juices increased with 
increasing juice concentration, the modulating effect of pummelo juice was inversely 
proportional to the juice concentration. Whether the latter was associated with the 
capacity of the pummelo juice to promote LLC-PK1 cell proliferation at these 
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concentrations is not firmly established, but rapidly dividing cells might not be able to 
express the pOCT2 transporter (Kaplan, 1978). By comparison, the LLC-PK1 cell 
proliferation rate was not substantially changed by the orange and lime juices at the 
concentration ranges used. The finding that lime juice at 5 and 10% could modify 
pOCT2 protein level in the LLC-PK1 cells suggests that this juice might have a role 
in modulating pOCT2 function. This needs to be verified at juice concentrations that 
do not compromise the intercellular tight junctions. Unlike the lime juice, grapefruit 
juice did not modulate pOCT2 protein level despite showing inhibitory activity 
against the pOCT2 function at concentrations of 10 and 30%. Again, it is not clear if 
the expression data stemmed from the strong anti-proliferation activity of grapefruit 
juice at these concentrations. Repeating the experiments at lower concentrations of 
grapefruit juice will be useful to delineate the cytotoxic effects of the juice from its 
modulating action on the cellular pOCT2 protein level. 
 
4.5. CONCLUSION 
On the basis of their effects on TEER, cell viability and R-123 transport and 
accumulation profiles in the LLC-PK1 cells, the 5 fruit juices may be broadly 
categorized into two groups, with lime and lemon juices in one group, and grapefruit, 
pummelo and orange juices in another. The groupings are again consistent with the 
categorization of the citrus fruits according to their dominant flavonoid pattern and 
taxonomy, suggesting that the modulating activities of the fruit juices on OCT2-
activity may be predicted based on the dominant flavonoid pattern and taxonomy of 
the fruit. On the other hand, the effects of the dominant flavonoid pattern and 
taxonomy of the citrus fruits in determining their action on the pOCT2 protein level in 
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the LLC-PK1 cells are less certain. Grapefruit juice showed anomalous behaviour 
from orange and pummelo juices in not inducing an up-regulation of the cellular 
pOCT2 protein level at the concentration ranges studied. Lime juice also differed 
from lemon juice in promoting the expression of the pOCT2 protein level in the LLC-
PK1 cells.  
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5.1.  INTRODUCTION 
This section of the project set out to evaluate the hypothesis that the modulating 
activity of citrus fruit juices on CYP3A4-mediated metabolism was dependent on the 
dominant flavonoid pattern and taxonomy of the citrus fruits.  For more than a decade, 
grapefruit juice has been well documented to markedly increase the oral 
bioavailability of a variety of commonly used medications, including felodipine, 
nifedipine, terfenadine, midazolam, cyclosporine A, ethinylestradiol, lovastatin, and 
simvastatin (Bailey et al., 1991; Benton et al., 1996; Ducharme et al., 1995; Edgar et 
al., 1992; Kantola et al., 1998; Kupferschmidt et al., 1995; Lilja et al., 1998; Weber et 
al., 1996). These drugs share a common characteristic in that they undergo extensive 
presystemic metabolism mediated by CYP3A4 (Di Marco et al., 2002; Edwards et al., 
1996; Kane and Lipsky, 2000; Lown et al., 1997a). Grapefruit juice taken in the usual 
volumes (up to 3 glasses a day at normal strength) has been shown to increase the 
drug bioavailability by selectively inhibiting the intestinal CYP3A4 catalytic activity 
(Di Marco et al., 2002; Kolars et al., 1991; Lown et al., 1997a; Uno et al., 2000; Wu 
et al., 1995). The mechanisms of inhibition include both reversible, competitive 
(Bailey et al., 2000; Greenblatt et al., 2003; Guo et al., 2000) and noncompetitive 
(Greenblatt et al., 2003; Paine et al., 2004), and irreversible (mechanism-based) 
inhibition (Bailey et al., 2000, 2003; Greenblatt et al., 2003; Guo et al., 2000; Lown et 
al., 1997a; Schmiedlin-Ren et al., 1997). Grapefruit juice was also shown to reduce 
the intestinal CYP3A4 protein level (Lown et al., 1997a; Schmiedlin-Ren et al., 
1997), but it did not affect the mRNA level (Lown et al., 1997a).  
 
Besides grapefruit juice, the ethyl acetate extracts of pummelo juice and commercial 
lime juice have been reported to inhibit the CYP3A4-mediated metabolism of 




tacrolimus (Egashira et al., 2004) and testosterone (Bailey et al., 2003), respectively. 
The in vitro data were, however, not matched by clear inhibitory potency in vivo 
(Bailey et al., 2003; Egashira et al., 2003). Orange juice, on the other hand, has been 
documented to be incapable of inhibiting the catalytic activity of CYP3A4 (Bailey et 
al., 1991; Takanaga et al., 2000b), and was often used as a negative control for the 
study of CYP3A4 inhibition by grapefruit juice (Edwards et al, 1996; Kakar et al., 
2004; Malhotra et al., 2001). 
 
We aim to test the validity of our hypothesis by measuring the effects of grapefruit, 
pummelo, orange, lime and lemon juices on the CYP3A4-mediated metabolism of 
midazolam (MDZ) in the human intestinal microsomes (HIM). In vitro microsomal 
metabolism of MDZ to its major metabolite, 1’- or alpha-hydroxymidazolam (1’-OH 
MDZ) (Ghosal et al., 1996; Gorski et al., 1994; Heizmann and Ziegler, 1981; Hoen et 
al., 2001; Kronbach et al., 1989) is a well-established method to measure CYP3A4 
enzyme activity (Gibbs et al., 1999; Yuan et al., 2002). However, most laboratories 
employed microsomes from the human liver, due to the relative ease in extracting 
liver microsomes and the abundance of CYP3A4 enzyme per mg of total liver 
microsomal protein (de Waziers et al., 1990). We have chosen to use the HIM system 
because the metabolism of MDZ to its major metabolite occurs more extensively in 
the intestine than in the liver (Paine et al., 1996; Thummel et al., 1996). Paine et al. 
(1996) have demonstrated the role of the small intestine in limiting the oral 
bioavailability of MDZ. By analyzing the disposition of MDZ and 1’-OH MDZ in 10 
liver transplant recipients, immediately following the surgical removal of the diseased 
liver, they were able to show that the fraction of peroral MDZ metabolized during 
transit through the enterocytes was 0.43. Under the same circumstances, MDZ 




administered intravenously had a significantly lower extraction ratio of 0.08. The 
extraction ratios of MDZ in the intestine and liver were then estimated to be 0.43 and 
0.47, respectively, on the basis that the oral bioavailability of MDZ in healthy human 
volunteers was 0.30 (Thummel et al., 1996). This suggests that the small intestine 
(Doherty and Charman, 2002), along with the liver, plays an important role in 
reducing the bioavailability of orally administered MDZ. The use of the HIM system 
for the in vitro study of CYP3A4-mediated metabolism of MDZ was therefore 
justified. A more important reason for choosing the HIM for the current study was 
that grapefruit juice selectively inhibited the intestinal CYP3A4 when consumed at 
usual volumes (Di Marco et al., 2002; Kolars et al., 1991; Lown et al., 1997a; Uno et 
al., 2000; Wu et al., 1995). Grapefruit juice was shown to affect the pharmacokinetic 
parameters of peroral MDZ by increasing the Cmax (by 56%), tmax (79%) and 
bioavailability (35%), yet did not significantly alter the area under the curve (AUC) of 
intravenously administered MDZ (Kupferschmidt et. al., 1995). Thus, the evaluation 
of the modulating effects of the grapefruit and other citrus fruit juices on HIM was 
appropriate.  
 
To date, no one has compared the CYP3A4 activity of citrus fruit juices in the HIM 
system. The closest attempt was reported by Arimori’s group, which investigated the 
CYP3A4-inhibitory effects of grapefruit, pummelo and orange juices using the human 
liver microsomes (Fujita et al., 2003; Hidaka et al., 2004). However, lime and lemon 
juices were excluded from the study. Watkins’s group had employed the HIM system, 
but they used it to evaluate the CYP3A4 effects of bergamottin and 6’,7’-
dihydroxybergamottin (DHB), two of the major components in grapefruit juice (Paine 
et al., 2004, 2005).  




MDZ is a short-acting benzodiazepine that is administered intravenously or 
intramuscularly for the induction and maintenance of anesthesia. It is also taken orally 
as a sedative or hypnotic (Crevoisier et al., 1983; Heizmann et al., 1983; Kanto and 
Allonen, 1983; Reves et al., 1985; Smith et al., 1981). The United States Food and 
Drug Administration (Yuan et al., 2002) had reviewed that MDZ is the most common 
substrate after testosterone to be used by the pharmaceutical industry to investigate in 
vitro drug interaction studies. Under optimal experimental conditions and low 
substrate concentrations, MDZ 1’-hydroxylation was proposed to be a good in vitro 
probe reaction of CYP3A4 activity. MDZ has to be applied at concentrations less than 
10 μM in order to avoid substrate-inhibition kinetics for the 1’-OH MDZ formation 
(Kronbach et al., 1989). 
 
For the present study, ketoconazole was incorporated as a positive control. 
Ketoconazole, used therapeutically as an antifungal agent, is well known to be a 
potent CYP3A4 inhibitor (Greenblatt et al., 1998; Tsunoda et al., 1999; 
Venkatakrishnan et al., 2000; von Moltke et al,. 1996a,b; Wrighton and Ring, 1994). 
It yields comparable mean Ki of 17.0 ± 7.7 nM and 14.9 ± 6.7 nM for CYP3A4 
activity in the intestinal and liver microsomes, respectively (Gibbs et al., 1999). 
Ketoconazole has been reported to impair the clearance of several benzodiazepines 
metabolized by CYP3A isoforms, including midazolam, triazolam and alprazolam 
(Greenblatt et al., 1998; Tsunoda et al., 1999; Venkatakrishnan et al., 2000; von 
Moltke et al., 1996b; Yuan et al., 1999).  The capacity of ketoconazole to impair the 
biotransformation of these and other CYP3A substrates in vitro is also well-
established (Thummel and Wilkinson, 1998; Venkatakrishnan et al., 2000; von 
Moltke et al., 1996a,b).  




5.2. METHODS AND MATERIALS 
5.2.1. Materials 
NADPH regenerating system, pooled human intestinal microsomes (HIM) and 1’-
hydroxymidazolam (1’-OH MDZ) were purchased from BD Gentest (Woburn, MA, 
U.S.A.); midazolam (MDZ) was from Hoffmann-La Roche, Inc. (Nutley, NJ, U.S.A.); 
norclomipramine HCl, ketoconazole, potassium phosphate, monobasic, and potassium 
phosphate, dibasic, were from the Sigma-Aldrich, Inc.; HPLC-grade acetonitrile and 
methanol were purchased from Fisher Scientific (Santa Clara, CA, U.S.A.). All other 
materials were similar to those listed in Sections 2.2.1 and 3.2.1. 
 
5.2.2. Assay of Human Intestinal CYP3A4-mediated Midazolam 1’-
Hydroxylation  
The assay of human intestinal CYP3A4 activity was performed according to the 
manufacturer’s recommendations for HIM, with minor modifications. An incubation 
mixture consisting of the NADPH regenerating system (1.3 mM NADP+, 3.3 mM 
glucose-6-phosphate, 0.4 U/ml glucose-6-phosphate dehydrogenase, and 3.3 mM 
magnesium chloride), 0.1 M potassium phosphate buffer (pH 7.4) and 0.8 mg/ml of 
HIM were equilibrated in a shaking water bath at 37oC. Reactions were initiated 5 
min later by the addition of 8 μM of MDZ to a final volume of 0.2 ml (Fujita et al., 
2003; Gibbs et al., 1999; Hidaka et al., 2004). After incubation for 10 min, 394 μl of 
ice-cold methanol was added to terminate the reaction, and norclomipramine HCl as 
internal standard (IS) was added to a final concentration of 10 μM (ter Horst et al., 
2003). The microsomal protein was precipitated by vigorous shaking for 30 s on a 
vortex mixer, and the mixture was centrifuged at 10,000 x g for 10 min at 4oC  




(Ghosal et al., 1996). MDZ and 1’-OH MDZ in the supernatant (30 μl) was quantified 
by HPLC analysis.  
                    
Control experiments, in which HIM or MDZ were excluded, were performed in 
parallel to validate CYP3A4-dependent metabolism (Patki et al., 2003). Experiments 
to determine the effects of the citrus fruit juices on CYP3A4 activity were conducted 
by introducing 10 μl of hand-squeezed grapefruit, pummelo, orange, lime or lemon 
juice to the incubation mixture 5 min before the addition of midazolam. The final 
concentration of fruit juice in the system was 5 or 12.5 % v/v.  Ketoconazole (10 μM) 
was applied in place of the fruit juices as a positive control (Patki et al., 2003).  
 
Experiments involving the citrus fruit juices at 5% v/v were conducted in two separate 
pooled HIM systems ordered from BD Gentest. These HIM systems were also used to 
optimize and validate the HPLC assays. Additional evaluation of the juices at 12.5% 
v/v could not be duplicated due to the depletion of HIM stock at BD Gentest, and the 
long turnover time required for pooling HIM from suitable donors. For these reasons, 
it is a norm for researchers working with human liver and intestinal microsomes 
systems to present their results as mean values obtained from duplicate experiments 
(Cotreau et al., 2000; Fujita et al., 2003; Gibbs et al., 1999; Patki et al., 2003; Tran et 
al., 2002). We have chosen to also present the data obtained with the 12.5% juice 
samples despite the lack of replicates.  
 
Enzyme activity was determined based on the formation of 1’-OH MDZ 
(pmol/min/mg HIM protein) or the loss of MDZ (nmol/min/mg HIM protein) over an 




incubation period of 10 min. All assays were performed in duplicates (Cotreau et al., 
2000; Fujita et al., 2003; Gibbs et al., 1999; Tran et al., 2002).  
 
5.2.3. HPLC analyses of midazolam and 1’-hydroxymidazolam  
MDZ and 1’-OH MDZ were quantified in a HPLC system (Shimadzu model 
LC2010A series, Kyoto, Japan) equipped with a XTerra™ RP18 analytical column (4.6 
X 250 mm, pore size 5 μm; Waters, Ireland) and a XTerra® RP18 guard column (3.9 X 
20 mm, pore size 5 μm; Waters, Ireland) maintained at 37oC. Elution was conducted 
over 30 min at a rate of 1 ml/min using an isocratic mobile phase comprising 45% of 
10 mM phosphate buffer (pH 7.4), 20% of acetonitrile and 35% of methanol. The 
identities of MDZ and 1’-OH MDZ were verified by comparing the retention time 
(Rt) with authenticated standards. Peak area ratio was determined by comparing the 
peak areas of MDZ and 1’-OH MDZ, monitored at 242 nm, with that of the IS (Fujita 
et al., 2003; Hidaka et al., 2004). Quantitation was performed by comparing the peak 
area ratios with those of the standard curve. 
 
To prepare standard solutions of 1’-OH MDZ and MDZ for calibration, incubation 
mixtures similar in composition to that described in Section 5.2.2 were used, but the 
HIM was heat-inactivated by boiling at 100oC for 5 minutes (Tran et al., 2002). Upon 
cooling to 37oC, the inactivated HIM mixtures were spiked with 1’-OH MDZ (50-250 
nM) or MDZ (2-10 μM), and processed as described for the enzyme assay in section 
5.2.2. The supernatants collected after centrifugation of the mixtures served as 
standard solutions of 1’-OH MDZ and MDZ for constructing the calibration curve.  
 




The HPLC method of analysis was validated according to the U.S.A. standard 
guidelines (Guidance for Industry: Bioanalytical Method Validation 2001, issued 
jointly by the U.S. Department of Health and Human Services, Food and Drug 
Administration, Center for Drug Evaluation and Research, and Center for Veterinary 
Medicine). Intraday and interday coefficient of variation (COV), and the mean 
accuracy were determined by analysis of standard solutions of 1’-OH MDZ at 50, 150 
and 250 nM, and MDZ at 2, 6 and 10 μM (QC samples). Intraday and interday COV 
were obtained by analyzing the solutions in triplicates within a single day and on three 
consecutive days, respectively. Recovery studies were not conducted as there was no 
extraction procedure involved in the preparation of samples for analysis (Patki et al., 
2003).  
 
5.2.4. Statistical Analyses 
Experiments using HIM were repeated at least two times and the data are expressed as 
mean ± SEM. Differences between mean values were analysed by One-way ANOVA 
with the Tukey’s test applied for paired comparisons of means (SPSS 10.0, SPSS Inc., 




5.3.1. HPLC assay of MDZ and 1’-OH MDZ and validation of CYP3A4 activity 
in HIM 
Figures 5.1a and b show the HPLC chromatograms for standard solutions of MDZ 
and 1’-OH MDZ prepared in heat-inactivated HIM systems. Under the experimental 
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Figure 5.1.  HPLC chromatograms of (a) midazolam (MDZ; Rt = 10.63 min) and (b) 
1’-hydroxymidazolam (1’-OH MDZ; Rt = 7.93 min) in heat-inactivated HIM systems.  
 
conditions employed, 1’-OH MDZ exhibited a peak at the retention time (Rt) of 7.93 
while MDZ had a Rt of 10.63 min. The peak assigned to 1’-OH MDZ was observed 
when incubation mixtures of MDZ and HIM were analyzed (Fig. 5.2a), but it was not 
seen in the chromatograms of mixtures in which either the HIM or MDZ was 
excluded (Fig. 5.2b and c). 1’-OH MDZ was also absent when MDZ was incubated 
with HIM in the presence of ketoconazole, the CYP3A4 inhibitor (Fig. 5.2d). In 
contrast, the peak assigned to MDZ (Fig. 5.1b) was not seen in chromatograms of 
incubation mixtures in which MDZ was excluded (Fig. 5.2c). Ketoconazole was 
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observed to elute at 23.78 min (Fig. 5.2d), while norclomipramine HCl, the IS, gave a 



























Figure 5.2.  HPLC chromatograms of incubation mixtures containing (a) human 
intestinal microsomes (HIM) with 8 μM of MDZ, (b) MDZ alone, (c) HIM alone, and 
(d) HIM with 8 μM of MDZ and 10 μM of ketaconazole. HPLC analysis was 
performed after 10 min of incubation at 37oC.  Peaks were assigned to the following 
compounds: 1’-hydroxymidazolam (1’-OH MDZ; Rt = 7.93 min), midazolam (MDZ; 
Rt = 10.63 min), norclomipramine HCl as internal standard (IS; Rt = 16.53 min) and 
ketaconazole (Keto; Rt = 23.78 min). 
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The appearance of 1’-OH MDZ in the incubation mixtures of MDZ and HIM was 
indicative of the presence of functional CYP3A4 enzymes in the microsomes. The 
attenuation of this transformation by ketoconazole suggests that ketoconazole was an 
effective inhibitor of the CYP3A4-mediated hydroxylation of MDZ. The lack of 
formation of 1’-OH MDZ in incubation mixtures that excluded HIM (Fig. 5.2b) or 
MDZ (Fig. 5.2c) further validated the CYP3A4-dependent metabolism in the system 
employed. 
 
Calibration of the HPLC was performed with standard solutions containing known 
concentrations of MDZ and 1’-OH MDZ in deactivated HIM systems. The HPLC 
peak area ratio of MDZ was observed to increase linearly with concentration (y = 
0.2006x + 0.1251; R2 = 0.989) in the concentration range of 2 and 10 μM (Appendix, 
Fig. 9.1a). A linear calibration graph (y = 0.0011x + 0.0028; R2 = 0.9962) was also 
obtained for the 1’-OH MDZ standard solutions in the concentration range of 50 and 
250 nM (Appendix, Fig. 9.1b). 
 
The intraday COV was ≤ 9.9% while the interday COV was ≤ 14.2% (Table 5.1) for 
all the QC samples of 1’-OH MDZ and MDZ. The intraday and interday mean 
accuracies were in the range of 85.0-104.7% and 90.7-105.9%, respectively, for both 
analytes (Table 5.1). Since the COV values and the differences between the true and 
measured concentrations were less than 15% at any QC sample concentration and 
time of analysis, the employed HPLC methods were validated to withhold accuracy 
and precision in the analytical runs. 
 
 




Table 5.1.  Intraday and interday precision and mean accuracy of the HPLC methods 
employed for the determination of MDZ and 1’-OH MDZ in deactivated HIM 
systems. 
 
 Intradaya Interdayb 
QC samples COV(%)c Accuracy(%)d COV(%)c Accuracy(%)d 
1’-OH MDZ (nM)                                
50 0.8 102.5 7.7 104.2 
150 3.3 104.7 1.8 105.9 
250 3.1 85.0 13.7 92.4 
MDZ (μM) 
2 9.9 89.0 14.2 95.7 
6 2.4 86.7 1.7 90.7 
10 1.8 97.4 2.1 101.8 
a Triplicate analysis on a single day. 
b Triplicate analysis on three consecutive days.  
c Precision calculated by % standard deviation of each value relative to the mean 
value; upper limit of 15%*.  
d  Mean accuracy calculated by % accuracy of the mean value relative to the true value 
(concentration) of the analyte; acceptable deviation within 15% of the true value*. 
* Guidance for Industry: Bioanalytical Method Validation 2001 by the U.S. 
Department of Health and Human Services, Food and Drug Administration, Center 
for Drug Evaluation and Research, and Center for Veterinary Medicine.  
 
 
5.3.2.   Inhibition of Human Intestinal CYP3A4 activity 
The incubation of 8 μM of MDZ with HIM for 10 min resulted in the metabolism of 
42% of the initial MDZ load and the production of 209 nM of 1’-OH MDZ (Fig. 5.3). 
The putative CYP3A4 inhibitor, ketoconazole, significantly inhibited the metabolism 
of MDZ to 88 % of the initial load (Fig. 5.3b), and 1’-OH MDZ formation was only at 
4% of the control level (Fig. 5.3a). These data suggest that CYP3A4 was functionally 
active, and ketoconazole at 10 µM was a potent inhibitor of the CYP3A4-mediated 



































































































   (b) 
Figure 5.3.   Effects of citrus fruit juices on the amount of (a) 1’-OH MDZ formed 
and (b) MDZ remaining after 8 μM of MDZ was incubated for 10 min in human 
intestinal microsome (HIM) system. From left to right: HIM without inhibitor 
(Control), HIM with ketoconazole (Keto; 10 μM), grapefruit (GFJ), pummelo (PJ), 
orange (OJ), lime (LiJ) or lemon juices (LJ). Citrus fruit juices were applied at 5 
(n=2) or 12.5% v/v (n=1). Data are presented as mean ± SEM, except data for juices 
at 12.5% v/v.  
 




The citrus fruit juices were applied at 5% (n=2) and 12.5% (n=1) to evaluate their 
effects on the CYP3A4-mediated MDZ metabolism. At 5% concentration, grapefruit, 
pummelo and lemon juices reduced the production of 1’-OH MDZ to 18, 17 and 13% 
of control level, respectively (Fig. 5.3a). These juices, however, did not result in an 
increase in the level of MDZ conserved (Fig. 5.3b). Lemon juice at the higher 
concentration of 12.5% further inhibited the formation of 1’-OH MDZ to 3% of 
control, while the 1’-OH MDZ levels in the presence of 12.5% of grapefruit and 
pummelo juices were 16 and 13% of control, respectively (Fig. 5.3a). At the higher 
concentration of grapefruit and pummelo juices, the amount of MDZ conserved was 
raised to 84 and 74% of the initial load, respectively (Fig. 5.3b). By comparison, 
lemon juice at 12.5% conserved only 56% of the initial MDZ load (Fig. 5.3b).  
 
Orange juice did not inhibit the metabolism of MDZ, as the amounts of MDZ 
conserved at both juice concentrations were comparable to the control sample (Fig 
5.3b). However, the amount of 1’-OH MDZ produced was reduced to 80 and 48% of 
control level, respectively, in the presence of 5 and 12.5% of orange juice (Fig. 5.3a). 
The concentration-dependent inhibitory effect of orange juice on 1’-OH MDZ 
formation has also been observed by the Arimori’s group using the human liver 
microsomes (Fujita et al., 2003; Hidaka et al., 2004).  
 
Lime juice had a different modulating profile on the CYP3A4-mediated metabolism 
of MDZ. Applied at 5% concentration, it did not modulate the amount of 1’-OH MDZ 
formed or the amount of MDZ conserved (Fig. 5.3a and b). At the higher 
concentration of 12.5%, however, the juice appeared to promote the metabolism of 
MDZ because the amount of 1’-OH MDZ produced was 3-fold higher than control 




(Fig. 5.3a), while the amount of MDZ conserved was reduced by 13-fold (Fig. 5.3b). 
The data for the 12.5% juice should, however, be interpreted with caution since it was 
based on only one sample. The supplier was unable to procure more HIM to allow us 
to conduct replicate experiments to validate the observations.  
 
5.4. DISCUSSION 
In order to validate our hypothesis, we performed a preliminary screening of 
grapefruit, pummelo, orange, lime and lemon juices to evaluate whether their 
modulating effects on the CYP3A4-mediated metabolism of MDZ was dependent on 
the dominant flavonoid pattern and taxonomy of the citrus fruits. To date, this is the 
first comparative study of the citrus fruit juices using the commercial HIM system. 
 
Of the 5 fruit juices studied, grapefruit, pummelo and lemon juices exhibited 
inhibitory activity against the CYP3A4 activity. Of these three, grapefruit juice is 
well-established as an inhibitor of CYP3A4 while the inhibitory profile of pummelo 
juice on CYP3A4 activity has recently been confirmed (Egashira et al., 2004; Fujita et 
al., 2003; Grenier et al., 2006). The finding on lemon juice is therefore novel. Trivial 
amounts of bergamottin and GF-I-4, two of the furanocoumarins found in grapefruit 
juice (Fukuda et al., 2000; Guo et al., 2000, 2004), have been detected in lemon juice 
(Fukuda et al., 2000). GF-I-4 was found to be 100 times more potent than bergamottin 
in inhibiting CYP3A4 activity in vitro (Guo et al., 2000; Guo and Yamazoe, 2004; 
Tassaneeyakul et al., 2000). The presence of these potent furanocoumarins in lemon 
and grapefruit juices might explain their inhibitory action on CYP3A4 activity. As the 
grapefruit is believed to have originated from the pummelo, it is perhaps not 
surprising to observe inhibitory activity against CYP3A4 in the pummelo juice as 




well. Grapefruit and pummelo juices, at the concentrations employed, were not as 
potent as ketoconzole in inhibiting the CYP3A4-mediated metabolism of MDZ to 1’-
OH MDZ. Lemon juice was also less potent compared to ketoconazole, although it 
appeared to possess higher inhibitory action against the CYP3A4 metabolic activity 
compared to either grapefruit or pummelo juice.  
 
Arimori’s group had evaluated the CYP3A4-inhibitory effects of a variety of whole 
fruit juices using the human liver microsomes, and had classified grapefruit and 
pummelo juices as positive inhibitors of CYP3A4 activity (Fujita et al., 2003; Hidaka 
et al., 2004). They have shown that, at incubation times of up to 4 min, grapefruit and 
pummelo juices at 5% had reduced the 1’-OH MDZ formation to below 15 and 30%, 
respectively, compared to control. In the same study, orange juice was classified as a 
negative inhibitor on the basis that the 1’-OH MDZ production at 5% orange juice 
concentration was observed to occur at 64% of control level. Notwithstanding the 
disparity in enzyme activity, which could be due to the differences between the 
enzyme source in the HIM and the human liver microsomes (Paine et al., 2004), the 
classification of grapefruit, pummelo and orange juices in terms of their activity 
against the CYP3A4 enzyme are in agreement. The absence of the furanocoumarins, 
bergamottin and GF-I-4, in orange juice (Fukuda et al., 2000; Guo et al., 2000) has 
often been cited as the underlying reason for their lack of activity against the CYP3A4 
enzymes (Guo et al., 2000).  
 
To corroborate the data on the level of 1’-OH MDZ generated when MDZ was 
incubated with the HIM system for 10 min, we had also measured the amount of 
MDZ remaining. Thus, ketoconazole, as the putative CYP3A4 inhibitor, was found to 




reduce the amount of 1’-OH MDZ formed and to increase the amount of MDZ 
conserved. In the case of the fruit juices, however, the attenuation of 1’-OH MDZ 
formation by 5% of grapefruit, pummelo and lemon juices was not accompanied by 
an increase in the amount of MDZ conserved. The expected increase in the level of 
MDZ conserved was, nevertheless, observed when these fruit juices were applied at 
the higher concentration of 12.5%. An underlying reason could be that MDZ 
undergoes hydroxylation at two positions to yield a major metabolite, 1’-OH MDZ, 
and a minor primary metabolite, 4-hydroxymidazolam (4-OH MDZ) (Fig. 5.4) 


























Figure 5.4.   Metabolism of midazolam (Mw = 362.25) by CYP3A (Ref. 
Hosagrahara et al., 1999). 
 




2001; Khan et al., 2002; Kronbach et al., 1989; Paine et al., 1996). Both metabolites 
are rapidly converted to their glucoronide conjugates by secondary metabolism to 
yield a minor secondary metabolite, 1’,4-dihydroxymidazolam (Fig. 5.4). In a study of 
MDZ metabolism in the human liver microsomes, the Km values for 1’-OH MDZ and 
4-OH MDZ formations were 3.3 and 57.4 μM, respectively, while the corresponding 
Ki values for ketoconazole were 0.0037 and 0.047 μM (von Moltke et al., 1996b). 
Although the Km and Ki values are in no way reflective of those in the HIM, they do 
suggest that the formation and inhibition of 1’-OH MDZ, rather than 4-OH MDZ, was 
more favorable during MDZ metabolism. At low concentrations, grapefruit, pummelo 
and lemon juices, being less potent inhibitors compared to ketoconazole, might not be 
effective in inhibiting the transformation of MDZ to 4-OH MDZ, although they were 
capable of inhibiting the formation of 1’-OH MDZ. Consequently, while the level of 
1’-OH MDZ was reduced, the amount of unchanged MDZ was not conserved. At 
higher concentration, there was concomitant inhibition of 4-OH MDZ production, 
resulting in more MDZ being conserved.  
 
Lime juice has been reported to be an effective inhibitor of testosterone 6β-
hydroxylase activity in recombinant CYP3A4 systems (Bailey et al., 2003). However, 
lime juice administered at one-quarter strength, to produce equivalent concentration 
of bergamottin as found in grapefruit juice, did not elevate the bioavailability of 
felodipine as significantly as the grapefruit juice (Bailey et al., 2003). Two studies 
conducted by the Watkins’ group (Paine et al., 2004, 2005) subsequently found that 
the inhibitory potency of bergamottin was substrate-dependent. Bergamottin 
(contained at high concentration in lime juice; Bailey et al., 2003) was 8-fold more 
effective in inhibiting the hydroxylation of testosterone than in inhibiting the 




hydroxylation of MDZ (apparent Ki of 1.6 and 13.3 μM, respectively) in the HIM 
system. Because of its strong binding with the microsomal protein which may lead to 
a slow onset of inhibition, it was suggested that bergamottin had minimal interaction 
potential with a rapidly absorbed substrate, such as the MDZ, which is generally 
absorbed within 1 h (Dundee et al., 1984). This is consistent with our findings where 
lime juice at 5% showed less inhibitory potency as compared to grapefruit and even 
orange juice during the period of incubation.  However, when lime juice was applied 
at a concentration of 12.5%, it exhibited an apparent induction of the CYP3A4 
activity by elevating the amount of 1’-OH MDZ formed and reducing the amount of 
unchanged MDZ. This is the first report of such a finding for lime juice. However, as 
the experiment was conducted in only one sample, the data remained to be verified.  
 
The inhibition of CYP3A activity was by no means restricted only to citrus fruit 
juices. Compared with grapefruit juice, the juice of starfruit (Averrhoa carambola) 
was shown to exhibit stronger inhibitory effects (Hidaka et al., 2004), while the 
mulberry (Morus nigra) juice was recently reported to have significant, but lower, 
inhibitory effects (Kim et al., 2006), on human CYP3A activity. The mulberry juice 
was reported to exhibit similar mechanism-based inhibitory effects as the grapefruit 
juice. In contrast, the starfruit juice did not contain a mechanism-based inhibitor. 
Clinical studies have yet to be performed on the starfruit and mulberry juices, but the 
in vitro data on these non-citrus fruit juices suggest that the inhibition of CYP3A 
activity could be governed by constituents present in the grapefruit and lemon juices 
that were not unique to the Citrus genus 
 
 





Like the putative CYP3A4 inhibitor, ketoconazole, grapefruit, pummelo and lemon 
juices demonstrated inhibitory potency on 1’-OH MDZ formation and conserved the 
metabolism of MDZ at a concentration of 5%. Orange juice, on the other hand, 
showed poor inhibitory activity against the formation of 1’-OH MDZ by CYP3A4-
mediated metabolism of MDZ. Lime juice at a low concentration of 5% exhibited 
poor inhibitory effects against the CYP3A4 activity, but appeared to have an 
inductive effect on the enzyme activity at higher concentration of 12.5%. On the basis 
of their effects on the 1’-OH MDZ formation and MDZ metabolism, the 5 fruit juices 
may be broadly categorized into two groups, with grapefruit, pummelo and lemon 
juices in one group, and orange and lime juices in another. This grouping is consistent 
with the furanocoumarins content in the fruit juices, but it does not mirror the 
classification of the citrus fruits based on their dominant flavonoid pattern and 
taxonomy. 



















































6. FINAL CONCLUSIONS 
 
This project was initiated to test the hypothesis that the modulating activity of citrus 
fruit juices on cellular transport and metabolic pathways was dependent on the 
dominant flavonoid pattern and taxonomy of the citrus fruits. To verify the 
hypothesis, we set out to examine the effects of grapefruit, pummelo, orange, lime 
and lemon juices on various drug transport pathways and CYP3A4-mediated drug 
metabolism. On the basis of dominant flavonoid pattern, grapefruit and pummelo are 
classified under the neohesperidosyl species, while lime and lemon belong to the 
rutinosyl species. Taxonomic classification also places the grapefruit and pummelo 
into a group separate from lime and lemon. Orange appears to swaddle between the 
two groups as it is grouped with grapefruit and pummelo based on its taxonomy, but 
is classified as a rutinosyl species based on its dominant flavonoid glycosylation 
pattern. The inclusion of orange may therefore reveal the relative importance of these 
two classification principles in drug interactions.  
 
No conscious effort was made to standardize the constituent profile of any of the fruit 
juices used in the project, other than to use the same method for extracting the juice 
from freshly bought, unblemished fruits. In any case, it would have been a futile 
exercise to standardize the constituent profile, as demonstrated by preliminary 
experiments based on the HPLC analysis of the fruit juice constituents. Yet, despite 
the use of different batches of fruits over a 4-year period, we had been able to obtain 
consistent data when experiments had to be repeated months apart. More importantly, 
this project arrived at the same conclusions as those obtained by another student in the 
laboratory for the grapefruit, pummelo, lime and lemon juices, although fruits from 
different suppliers were used for the two projects (Lim and Lim, 2006 vs. Xu et al., 




2003). A comparison of data reported by different laboratories also showed this to be 
generally true, in that grapefruit and orange juices, whether employed in clinical, in 
vivo or in vitro studies, had shown similar P-gp and CYP3A4-inhibitory effects while 
the orange juice inhibits only the P-gp activity. It is unlikely for different laboratories 
to apply fruit juices of comparable constituent profiles to their experiments; therefore 
the similar findings lent further support to the hypothesis. 
 
Two passive diffusive transport pathways and the activities of 2 drug transporters 
were investigated. The passive transcellular diffusive pathway is the dominant route 
of absorption across the intestines for more than 80% of the clinically significant 
drugs with Mw > 200 Da and molecular radii > 15 Å (Brennan, 2000; Kerns, 2001). 
The paracellular route plays a minor role in drug translocation across normal intestinal 
tissues (Ward et al., 2000), but can become important when the intercellular tight 
junction is compromised (Sawada et al., 2003). This route is used to screen for 
potential permeation enhancers which promote the epithelial translocation of polar 
macromolecules, such as peptide-based drugs (Bernkop-Schnurch et al., 2003), by 
breaching the intercellular tight junction. The comparative effects of citrus fruit juices 
on both routes of transport were studied for the first time in this study.  
 
The P-gp efflux pump has significant clinical importance because of its influence on 
the oral bioavailability of a wide range of lipophilic drugs, and its role in multidrug 
resistance in cancer cells. The effects of citrus fruit juices, with the omission of 
orange juice, on P-gp-mediated digoxin transport in the Caco-2 cells have earlier been 
reported by our laboratory. However, Sawada et al. have raised doubts on our data 
involving the pummelo juice (Egashira et al., 2004). The current investigation aimed 




to validate our earlier findings by studying the uptake and cellular accumulation of a 
different P-gp substrate in the Caco-2 cells, and by evaluating digoxin transport in a 
different cell line, the L-MDR1 cells, which over-expressed the P-gp. The study was 
further extended to include P-gp expression, at both protein and mRNA levels, in cells 
and rodent tissues.  
 
Another transport pathway examined was that mediated by the uptake transporter, 
pOCT2, at both functional and expression levels, in the LLC-PK1 cells. This 
represents the first comparative study on fruit juice interaction with OCT2. OCT2 
mediates the absorption and secretion of approximately 50% of clinical drugs 
classified as OC (Jonker and Schinkel, 2004), and its inhibition is associated with 
renal tubular accumulation (Nierenberg, 1987; van Crugten et al., 1986) leading to 
adverse drug reactions and drug-drug interactions (King et al., 1987; Kremer and 
Hamilton, 1995; Maiche, 1986; Singh et al., 1986).  
 
Finally, the comparative effects of the citrus fruit juices on CYP3A4-mediated drug 
metabolism in the human intestinal microsomes were investigated. The CYP3A4 
contributes to the metabolism of approximately 50% of clinically available drugs 
(Guengerich, 1999; Gunaratna, 2000), and more than half of the drugs absorbed in the 
GIT (Benet et al., 1996a; Raeissi et al., 1999). Inhibition or induction of CYP3A4 
activity is consequently a common basis for clinically significant drug-drug and food-
drug interactions. Several fruit juices, namely the grapefruit, pummelo and orange 
juices, have been investigated for their effects on CYP3A4 activity. However, a 
comparative study of the citrus fruit juices, including lime and lemon juices, has not 
been carried out.  




In this project, the paracellular transport pathway was monitored through TEER 
measurements and [14C]-mannitol transport parameters. Of the 5 citrus fruit juices, 
lime and lemon juices at 10 and 30% consistently lowered the TEER and enhanced 
the [14C]-mannitol fluxes by several fold in the Caco-2, L-MDR1 and LLC-PK1 cell 
monolayers. This capacity to open up the intercellular tight junction could not be 
attributed to their strong acidity because the juices were adjusted to pH 7.4 prior to 
administration to the cells. Neither could it be attributed to the hypertonicity of the 
juice samples brought about by adjusting the samples to pH 7.4 with strong NaOH. 
The implication is that lime and lemon juices contained constituents capable of 
facilitating transport via the paracellular pathway. This capacity to modulate the cell 
monolayer integrity was reversible, at least for changes brought about by the juices at 
10% concentration, 24 h after removing the juice. Low concentrations of lime and 
lemon juices may therefore have the potential to serve as paracellular permeability 
enhancers (PPEs). Compared with synthetic PPEs, lime and lemon juices have the 
advantages of being natural, readily available and well tolerated at low 
concentrations. Nevertheless, more studies will have to be conducted to elucidate the 
modulation mechanisms and dose effects before lime and lemon juices can be applied 
clinically as PPEs. This is because the non-specific modulation of tight junctions can 
cause systemic toxicity and diseases like inflammatory bowel syndrome (Sawada et 
al., 2003; Ward et al., 2000). 
 
Unlike the lime and lemon juices, grapefruit and pummelo juices at up to 30% did not 
modulate the [14C]-mannitol transport profile significantly in all the 3 cell lines 
studied. Orange juice produced less consistent results across the cell types; it raised 
the mannitol fluxes to comparable level as the lime juice in the Caco-2 cell 




monolayers, but had minimal effects on mannitol transport in the L-MDR1 and LLC-
PK1 cells, like the grapefruit and pummelo juices. It may therefore be concluded that 
the classification of the 5 citrus fruit juices on the basis of their effects on the 
paracellular passive diffusive pathways is consistent with their classification based on 
taxonomy and dominant flavonoid pattern. Moreover, while the effects of lime, 
lemon, grapefruit and pummelo juices appeared to be more readily predictable, that of 
orange juice may well depend on cell type. 
  
The classification of the citrus fruit juices based on their effects on the passive 
transcellular transport of [3H]-propranolol across the Caco-2 cell monolayers was less 
definitive. This is because the 5 juices produced comparatively small effects on the 
transcellular absorption of propranolol compared to the juice-mediated changes in 
paracellular mannitol transport profiles. The BA [3H]-propranolol flux was more 
susceptible to modulation by the fruit juices. On this basis, lime and lemon juices 
could be categorized into a group that produced relatively higher attenuation of the 
BA [3H]-propranolol fluxes than grapefruit, pummelo and orange juices. Until the 
clinical significance of these findings can be established, it may be prudent to urge 
caution when drugs of narrow therapeutic index that are absorbed by the passive 
transcellular route are to be co-administered with lime or lemon juice.  
 
The findings of this project validated previous results reported by our laboratory on 
the citrus fruit juice-mediated P-gp activity. The groupings of the 5 citrus fruit juices 
according to their modulating effects on the P-gp activity were consistent, regardless 
of the P-gp substrate or cell model used.  Grapefruit and pummelo juices exhibited 
relatively strong inhibitory potency on the P-gp-mediated efflux of R-123 across the 




Caco-2 cells. They also abolished the polarized transport of [3H]-digoxin across the P-
gp-expressing L-MDR1 cells without affecting the passive transcellular transport of 
digoxin in the P-gp-deficient LLC-PK1 cells. Lime and lemon juices, on the other 
hand, facilitated the R-123 efflux and bi-directional [3H]-digoxin transport across the 
corresponding cell monolayers by opening up the paracellular transport pathways. 
Orange juice alone again exhibited anomalous behaviour, which was not entirely 
congruous with P-gp inhibitory activity. Compared with grapefruit and pummelo 
juices, it reduced to the smallest extent R-123 efflux across the Caco-2 cell 
monolayers, yet produced the greatest enhancement in R-123 cellular accumulation. 
In addition, orange juice elevated the AB [3H]-digoxin flux across the L-MDR1 cells 
without effecting a significant concomitant reduction of the BA [3H]-digoxin flux. In 
this respect, it differed from grapefruit and pummelo juices, which abolished the 
vectorial transport of digoxin by enhancing the AB flux and attenuating the BA flux, 
as was typical of P-gp inhibitors. Therefore, grapefruit and pummelo may be 
classified as agents that promote the absorption of P-gp substrates by inhibiting their 
efflux by the P-gp pump, while lime and lemon juices at corresponding concentrations 
promoted the paracellular transport of P-gp substrates. Orange juice enhanced the 
absorption of P-gp substrates like R-123 and digoxin, but the mechanism may involve 
the modulation of a transporter other than, or together, with the P-gp. This 
classification was again consistent with the classification of the fruits according to 
their taxonomy and major flavonoids. 
 
Grapefruit, pummelo and orange juices were again grouped together in alienation 
from lime and lemon juices based on their modulating effects on the pOCT2-mediated 
transport and cellular accumulation of R-123 in the LLC-PK1 cell monolayers. 




Grapefruit juice at 10%, pummelo and orange juices at 10 to 50% showed appearent 
inhibitory activity against the pOCT2 transporter by producing R-123 transport and 
cellular accumulation profiles comparable to those observed for TEA, an established 
OCT inhibitor. Lime and lemon juices, on the other hand, again increased the bi-
directional R-123 transport by opening up the intercellular tight junctions. It should be 
noted, however, that grapefruit juice at 30% and beyond also exerted the same effects 
as lime and lemon juices on R-123 transport across the LLC-PK1 cell monolayers.  
 
Of the 3 citrus fruit juices that might modulate the functional status of the P-gp, 
grapefruit and orange juices did not modify the P-gp protein level in the L-MDR1 
cells after 24 h of co-incubation. Neither did they affect the rodent P-gp and mdr1a 
mRNA levels following twice daily gavage for 10 days at a dose of 10 ml/kg. 
Pummelo juice, on other hand, down-regulated the P-gp level in the L-MDR1 cells 
when applied at 50% concentration. Pummelo juice also up-regulated the P-gp levels 
in the rat liver and kidney following twice daily dosing at 10 ml/kg for 10 days but 
did not modulate the P-gp level in the ileum, nor the mdr1a mRNA levels in all the rat 
organs tested. Therefore the taxonomy and dominant flavonoid pattern of the citrus 
fruit juices are not good predictors of their capacity to modulate the expression of 
cellular P-gp.  
 
Neither were the taxonomy and dominant flavonoid pattern of the citrus fruit juices 
good predictors of their capacity to modulate the expression of pOCT2 in the LLC-
PK1 cells. In this case, pummelo, orange and lime juices were shown to up-regulate 
the cellular pOCT2 protein level following 24 h incubation, while grapefruit and 
lemon juices did not modulate the pOCT2 level in the cells. This grouping of the 




citrus fruit juices was not consistent with their classification based on taxonomy or 
flavonoid content. 
 
The preliminary screening of the fruit juices for their modulating effects on the 
intestinal CYP3A4-mediated metabolism of MDZ provided yet another perspective 
into the fruit juice categorization. Of the 5 fruit juices studied, grapefruit, pummelo 
and lemon juices significantly inhibited the formation of 1’-OH MDZ by CYP3A4-
mediated metabolism of MDZ, while orange and lime juices showed poor inhibitory 
activity. On the basis of their effects on CYP3A4-mediated MDZ metabolism, 
grapefruit, pummelo and lemon juices may be broadly categorized in one group, and 
orange and lime juices in another. This grouping did not mirror the classification of 
the citrus fruits based on their dominant flavonoid pattern and taxonomy, but was 
consistent with the furanocoumarins content in the fruit juices. It underscores the 
furanocoumarins as the active components responsible for the modulating effects of 
the citrus fruit juices on the CYP3A4 activity (Edwards et al., 1996; Saito et al., 
2005).  
 
In vitro cytotoxicity profile established via the MTT assay consistently showed the 
lime and lemon juices to be the most cytotoxic in the concentration range of 10 to 
50%. Both juices invariably reduced the viability of all 3 cell lines to the greatest 
extent. Grapefruit and pummelo juices, on the other hand, tended to enhance the 
mitochondrial activity of the Caco-2 and L-MDR1 cells, but they had the same 
cytotoxic profiles against the LLC-PK1 cells as the lime and lemon juices. Orange 
juice exhibited anomalous behavior by modulating (increase or decrease) the viability 
of the Caco-2 cells at 10 to 30%, and the L-MDR1 cells at 10%. At higher 




concentrations, orange juice did not appear to affect the viability of these two cell 
lines. Orange juice also had comparable cytotoxic profile against the LLC-PK1 cells 
as the other 4 citrus fruit juices. On the basis of their cytotoxicity against the Caco-2 
and L-MDR1 cells, the citrus fruit juices may again be categorized into 3 groups 
consistent with their classification according to taxonomy and flavonoid content. This 
classification cannot be applied to the cyotoxicity of the fruit juices against the LLC-
PK1 cells due to a lack of differential cytotoxicity profiles. The cytotoxicity of the 
fruit juices could not be attributed to their acidity because all the juice samples were 
adjusted to pH 7.4 just prior to administration to the cells. Although the pH 
adjustment caused the samples to become hypertonic, the osmotic pressure of the 
juice samples was poorly correlated to their cytotoxicity. Moreover, the addition of 
NaCl to the HBSS-HEPES solution, to elevate its osmotic pressure to the highest level 
reached by the lime and lemon juice samples, also failed to produce the same degree 
of cytotoxicity.  
 
The anti-proliferative activity of the citrus fruit juices against the L-MDR1 and LLC-
PK1 cells were also assessed to determine whether the juices inhibited cell 
proliferation during the P-gp and OCT2 expression experiments, respectively. Only 
the grapefruit, pummelo and orange juices were evaluated against the L-MDR1 cells 
because of their application in the P-gp expression experiments. All 3 juices promoted 
the proliferation of L-MDR1 cells in the concentration range of 10 to 50%. Pummelo 
and orange juices were stronger promoters of L-MDR1 cell proliferation, giving cell 
viability in the ranges of 128-159% and 137-155%, respectively, than grapefruit juice 
(121-144%). Different anti-proliferation profiles were obtained for the 5 citrus fruit 
juices when evaluated against the LLC-PK1 cells. Grapefruit juice exhibited 




concentration-independent anti-proliferative activity, producing cell viability within 
the range of 55 to 61% for the concentration range tested. Lime and lemon juices, on 
the other hand, exhibited concentration-dependent anti-proliferation activity, severely 
reducing the viability of LLC-PK1 cells to less than 50% at high juice concentrations. 
Pummelo juice inhibited cell proliferation at low concentrations of up to 10%, but 
promoted cell proliferation at higher concentrations of 30 and 50%. Orange juice 
produced the smallest effect on LLC-PK1 cell proliferation, with cell viability varying 
within the narrow range of 89 to 110%.  On the basis of the juice effects on the cell 
viability and proliferation, the profiles are too varied to streamline the fruit juices into 
groups according to their taxonomy and flavonoid content. 
 
To summarize, on the basis of their effects on the TEER of all the cell lines studied; 
mannitol, propranolol and R-123 transport profiles in the Caco-2 cell model; digoxin 
transport profiles in the L-MDR1 and LLC-PK1 cell models; and R-123 transport and 
accumulation profiles in the LLC-PK1 cell model, the 5 fruit juices may be broadly 
categorized into two groups, with lime and lemon juices in one group, grapefruit and 
pummelo juices in another, and orange juice being the unique species that has certain 
characteristics in common with the two groups. The grouping is consistent with the 
categorization of the citrus fruits according to their dominant flavonoid pattern and 
taxonomy, suggesting that certain fruit juice-drug interactions may be predicted based 
on the dominant flavonoid pattern and/or taxonomy of the fruit. For such cases, the 
taxonomy of the citrus fruits appear to play a more important role as the orange juice 
tended to yield data that were in agreement with those produced by the grapefruit and 
pummelo juices. Examples included the juice-mediated changes in the paracellular 
and transcellular passive transport pathways as well as the P-gp and pOCT2 activities. 




The ability to predict fruit juice-drug interactions based on the dominant flavonoid 
pattern and taxonomy of the citrus fruits is obviously an advantage, because it 
precludes the need to know the complete constituent makeup of the fruit juices.  
 
However, the modulating effects of the fruit juices on the P-gp and pOCT2 protein 
level in the L-MDR1 and LLC-PK1 cells, respectively, and the P-gp and mdr1a 
mRNA levels in the rat tissues are not specific to the classification of the fruits. 
Although the underlying reasons for the differentiated modulating effects of the juices 
have not been established in the present study, the findings point to the need for more 
research into this area, in particular if the changes in transporter expression translate 
into significant changes in functional status of the respective transporter. The activity 
of the citrus fruit juices on the CYP3A4-mediated metabolism also could not be 
correlated to the dominant flavonoid pattern and taxonomy of the citrus fruits. Instead, 
it appears to be correlated to the furanocoumarin content in the fruit juice, thereby 
highlighting the functional differences between drug metabolic enzymes and drug 
transporters (Wacher et al., 1998) that lead to differences in inhibitory kinetics 
(Wandel et al., 1999).  
 
The data generated in this project also suggest that the 5 citrus fruit juices may 
increase the oral bioavailability of drugs by a number of mechanisms. Lime and 
lemon juices would enhance drug transport via the paracellular and transcellular 
diffusive pathways, while grapefruit, pummelo and orange juices could modulate the 
bioavailability of drug that are substrates of P-gp. The latter might be exploited as 
adjuvants in cancer chemotherapy, in particular in the MDR phenotypes (Gottesman 
et al., 1996; Ling, 1997). In addition, grapefruit, pummelo and lemon juices could 




cause clinical drug interactions by reducing the metabolism of CYP3A4 substrates 
such as saquinavir (James, 1995; Kupferschmidt et al., 1998), while grapefruit, 
pummelo and orange juices might increase the renal clearance of nephrotoxic OC 
such as cisplatin and cadmium by inhibiting their uptake by hOCT2 in the proximal 
tubules (Ciarimboli et al., 2005; Friberg, 1984). Extensive studies are warranted to 
determine the intensity of the bioavailability enhancement in relation to the amount of 
juices consumed in human. This is especially important for drugs with a narrow 
therapeutic window as adverse drug interactions could result, as have been reported 
for cyclosporine and terfenadine after its co-ingestion with grapefruit juice (Bailey, 
2004; Spence, 1997). Until such details emerged, it is recommended to avoid the co-
administration of grapefruit, pummelo, orange, lime or lemon juices with drugs of 
narrow therapeutic windows. 



















































7. FUTURE DIRECTIONS 
 
This project has successfully validated the hypothesis that the modulating effects of 
grapefruit, pummelo, orange, lime and lemon juices on the passive paracellular and 
transcellular transport pathways, P-gp-mediated efflux, and pOCT2 uptake transport 
can be predicted based on the dominant flavonoid pattern and/or taxonomy of the 
fruit. To strengthen the validity of the hypothesis, citrus fruits like mandarin, sour 
orange and citron could be included in a future study. Based on taxonomy, the 
mandarin (Citrus reticulata) and sour orange (Citrus aurantium) belong to the C1 
group, same as grapefruit, pummelo and orange, while citron (Citrus medica) belongs 
to the C2 group, same as lime and lemon (Barret and Rhodes, 1976).  However, 
according to the dominant flavonoid pattern, only sour orange is grouped with 
grapefruit and pummelo under the neohesperidosyl species, while citron, mandarin 
and orange belong to the rutinosyl species with lime and lemon (Kanes et al., 1993). 
The inclusion of these fruits will test the robustness of the hypothesis. If the 
hypothesis is correct, sour orange juice should behave like grapefruit and pummelo 
juices, while the juice of citron should act like the lime and lemon juices, and 
mandarin juice will resemble the sweet orange juice in the manner in which they 
modulate the various drug transport and metabolic pathways.  
 
This study has only performed a preliminary screening of the citrus fruit juices on the 
CYP3A4 activity. To substantiate the current findings that the modulating activities of 
the fruit juices are dependent on the furanocoumarins content rather than the dominant 
flavonoid pattern and/or taxonomy, more experimentation should be conducted. 
Experiment variables may include the application of other citrus fruits, a wider juice 
concentration range (Hidaka et al., 2004), variable incubation time, and longer 




preincubation times to explore the mechanism-based inhibitory potency of the fruit 
juices (Fujita et al., 2003). Alternative CYP3A4 substrates, like testosterone (Galetin 
et al., 2003; Hosea et al., 2000; Kenworthy et al., 1999; Schrag and Wienkers, 2001), 
could be used to test whether the inhibitory potencies of the juices are substrate-
dependent, like that of bergamottin (Paine et al., 2004, 2005).   
  
In terms of the modulating effects of citrus fruit juices on the P-gp activity, two in 
vitro studies using different P-gp substrates, R-123 and digoxin, respectively, on the 
Caco-2 cells which resemble the intestinal epithelial cells, and the L-MDR1 cells that 
overexpressed P-gp, were well-correlated. While valuable information was obtained 
from the in vitro studies, the modulating effects of the juices on the in vivo P-gp 
activity need to be evaluated. This could be performed by administering digoxin 
intravenously to the bile duct cannulated mdr1a (+/+) (wild-type) mice and comparing 
the intestinal secretion of digoxin from blood to intestinal lumen with mdr1a (-/-) 
(mdrla knocked-out) mice (Mayer et al., 1996). To evaluate the modulating effects of 
the juices, the fruit juices can be administered orally prior to the intravenous dosing of 
P-gp in the mdr1a (+/+) (wild-type) mice. Further experimentation on P-gp 
expression could also be conducted in Caco-2 cells or porcine to verify the attenuating 
effects of the pummelo juice on cellular P-gp levels, and to substantiate the absence of 
modulation effects of the grapefruit and orange juices.  
 
This study has also demonstrated disparities in the modulating effects of the fruit 
juices on the pOCT2 function and expression in the LLC-PK1 cells. For instance, 
lime juice at 5 and 10% was shown to induce the cellular pOCT2 level, but its 
modulating effects on the transporter function could not be demonstrated due to 




concomitant detrimental effects on the intercellular tight junction. On the other hand, 
grapefruit juice, which showed inhibitory activity against the pOCT2 function at 
concentrations of 10 and 30%, did not modulate pOCT2 protein level. The latter was 
attributed to the strong anti-cell proliferation activity of grapefruit juice at these 
concentrations. For both grapefruit and lime juices, it may be useful to repeat the 
experiments at lower juice concentrations to avoid the cytotoxic effects of the juices 
from influencing their modulating action on the cellular pOCT2 function and protein 
levels. It will also be interesting to use another OCT substrate, such as TEA (Wright 
and Dantzler, 2004), or experimental model, like the Xenopus laevis ooctyes 
(Gorboulev et al. 1997), to verify the modulating effects of the juices on the OCT2 
transport profiles. In vivo experiments that more closely simulate the physiological 
conditions, e.g. the disposition of OC in isolated perfused rat kidney can be performed 
in the presence of the juices (Masereeuw et al., 1997) to determine any changes 

























































Adson A., Burton P. S., Raub T. J., Barsuhn C. L., Audus K. L., and Ho N. F. H. 
Passive diffusion of weak organic electrolytes across Caco-2 cell monolayers: 
Uncoupling the contributions of hydrodynamic, transcellular, and paracellular 
barriers. J. Pharm. Sci. 84: 1197-1204 (1995). 
 
Albach R. F., and Redman G. H. Composition and inheritance of flavanones in citrus 
fruit. Phytochemistry 8: 127-143 (1969). 
 
Ameer B., and Weintraub R. A. Drug interactions with grapefruit juice. Clin. 
Pharmacokinet. 33: 103-121 (1997). 
 
Ameer B., Weintraub R. A., Johnson J. V., Yost R. A., and Rouseff R. L. Flavanone 
absorption after naringin, hesperidin, and citrus administration. Clin. 
Pharmacol. Ther.  60: 34-40 (1996). 
 
Ando H., Nishio Y., Ito K., Nakao A., Wang L., Zhao Y. L., Kitaichi K., Takagi K., 
and Hasegawa T. Effect of endotoxin on P-glycoprotein-mediated biliary and 
renal excretion of rhodamine-123 in rats. Antimicrob. Agents Chemother. 45: 
3462–3467 (2001). 
 
Arimori K., and Nakano M. Drug exsorption from blood into the gastrointestinal tract. 
Pharm. Res. 15: 371-376 (1998). 
 
Artursson P. Cell cultures as models for drug absorption across the intestinal mucosa. 
Crit. Rev. Ther. Drug Carrier Syst. 8: 305-330 (1991). 




Artursson P., and Karlsson J. Correlation between oral drug absorption in humans and 
apparent drug permeability coefficients in human intestinal epithelial (Caco-2) 
cells. Biochem. Biophys. Res. Comm. 175: 880-884 (1991). 
 
Artursson P., Karlsson J., Ocklind G., and Schipper N. Studying transport processes 
in absorptive epithelia, in Epithelial cell-culture: A practical approach, Oxford 
University Press, New York. pp. 111-133 (1996a). 
 
Artursson P., Palm K., and Luthman K. Caco-2 monolayers in experimental and 
theoretical predictions of drug transport. Adv. Drug Deliv. Rev. 22: 67-84 
(1996b). 
 
Ayesh S., Shao Y. M., and Stein W. D. Co-operative, competitive and non-
competitive interactions between modulators of P-glycoprotein. Biochim. 
Biophys. Acta. 1316: 8-18 (1996). 
 
Ayrton A., and Morgan P. Role of transport proteins in drug absorption, distribution 
and excretion. Xenobiotica 31: 469-497 (2001). 
 
Backman J. T., Mäenpää J., Belle D. J., Wrighton S. A., Kivistö K. T., and Neuvonen 
P. J. Lack of correlation between in vitro and in vivo studies on the effects of 
tangeretin and tangerine juice on midazolam hydroxylation. Clin. Pharmacol. 
Ther. 67: 382-390 (2000). 
 




Bailey D. G. Grapefruit juice-drug interaction issues, in Handbook of drug-nutrient 
interactions, Boullata J., and Armeni V. (Eds.), The Humana Press, Totawa, 
New Jersey. pp. 175-194 (2004). 
 
Bailey D. G., Arnold J. M., Bend J. R., Tran L. T., and Spence J. D. Grapefruit juice-
felodipine interaction: reproducibility and characterization with the extended 
release drug formulation. Br. J. Clin. Pharmacol. 40: 135-140 (1995). 
 
Bailey D. G., Arnold J. M., Munoz C., and Spence J. D. Grapefruit juice-felodipine 
interaction. Mechanism, predictability, and effect of naringin. Clin. Pharmacol. 
Ther.  53: 637-642 (1993a). 
 
Bailey D. G., Arnold J. M., and Spence J. D. Grapefruit juice and drugs: How 
significant is the interaction? Clin. Pharmacokinet. 26: 91-98 (1994). 
 
Bailey D. G., Arnold J. M., Strong H. A., Munoz C., and Spence J. D. Effect of 
grapefruit juice and naringin on nisoldipine pharmacokinetics. Clin. Pharmacol. 
Ther.  54: 589-594 (1993b). 
 
Bailey D. G., Dresser G. K., and Bend J. R. Bergamottin, lime juice, and red wine as 
inhibitors of cytochrome P450 3A4 activity: Compare with grapefruit juice. 
Clin. Pharmacol. Ther. 73: 529-537 (2003). 
 




Bailey D. G., Dresser G. K., Kreeft J. H., Munoz C., Freeman D. J., and Bend J. R. 
Grapefruit juice-felodipine interaction: Effect of unprocessed fruit and probable 
active ingredients. Clin. Pharmacol. Ther. 68: 468-477 (2000). 
 
Bailey D. G., Kreeft J. H., Munoz C., Freeman D. J., and Bend J. R. Grapefruit juice-
felodipine interaction: Effect of naringin and 6’, 7’-dihdroxybergamottin in 
humans. Clin. Pharmacol. Ther. 64: 248-256 (1998a). 
 
Bailey D. G., Malcolm J., Arnold O., and Spence J. D. Grapefruit juice-drug 
interactions. Br. J. Clin. Pharmacol. 46: 101-110 (1998b). 
 
Bailey D. G., Munoz C., and Arnold J. M. Grapefruit juice and naringin interaction 
with nitrendipine (abstract). Clin. Pharmacol. Ther.  51: 156 (1992). 
 
Bailey D. G., Spence J. D., Munoz C., and Arnold J. M. O. Interaction of citrus juices 
with felodipine and nifedipine. Lancet 337: 268-269 (1991). 
 
Balimane P. V., Patel K., Marino A., and Chong S. Utility of 96 well Caco-2 cell 
system for increased throughput of P-gp screening in drug discovery. Eur. J. 
Pharm. Biopharm. 58: 99-105 (2004). 
 
Banfield C., Gupta S., Marino M., Lim J., and Affrime M. Grapefruit juice reduces 
the oral bioavailability of fexofenadine but not desloratadine. Clin. 
Pharmacokinet. 41: 311-318 (2002). 
 




Barret H. C., and Rhodes A. M. A numerical taxonomic study of affinity relationship 
in cultivated Citrus and its close relatives. Syst. Bot. 1: 105-136 (1976). 
 
Basu T. K. Drug-nutrient interaction, in Drug-food interaction, Croom Helm, New 
York. pp. 107-114 (1998). 
 
Benet L. Z., and Cummins C. L. The drug efflux-metabolism alliance: biochemical 
aspects. Adv. Drug Del. Rev. 50: S3-S11 (2001). 
 
Benet L. Z., Cummins C. L., and Wu C. Y. Unmasking the dynamic interplay 
between efflux transporters and metabolic enzymes. Int. J. Pharm. 277: 3-9 
(2004). 
 
Benet L. Z., Izumi T., Zhang Y., Silverman J. A., and Wacher V. J. Intestinal MDR 
transport proteins and P-450 enzymes as barriers to oral drug delivery. J. 
Control Release 62: 25-31 (1999). 
 
Benet L. Z., Kroetz D. L., and Sheiner L. B. Pharmacokinetics: The dynamics of drug 
absorption, distribution, and elimination, in The pharmacologic basis of 
therapeutics (9th edition), Goodman and Gilman (Eds.), McGrawHill, New 
York. pp. 3-27 (1996a). 
 
Benet L. Z., Wu C-Y., Hebert M. F., and Wacher V. J. Intestinal drug metabolism and 
antitransport processes: A potential paradigm shift in oral drug delivery. J. 
Control Release 39: 139-143 (1996b). 




Benton R. E., Honig P. K., and Zamani K. Grapefruit juice alters terfenadine 
pharmacokinetics, resulting in prolongation of repolarization on the 
electrocardiogram. Clin. Pharmacol. Ther. 59: 383-388 (1996). 
 
Berhow M., Tisserat B., Kanes K., and Vandercook C. Survey of phenolic compounds 
produced in Citrus. Agric. Res. Ser. Technical Bulletin Number 1856. (1998). 
 
Bernkop-Schnurch A., Kast C. E., and Guggi D. Permeation enhancing polymers in 
oral delivery of hydrophilic macromolecules: thiomer/GSH systems. J. 
Control Release 93: 95-103 (2003). 
 
Brady J. M., Cherrington N. J., Hartley D. P., Buist S. C., Li N., and Klaassen C. D. 
Tissue distribution and chemical induction of multiple drug resistance genes in 
rats. Drug Metab. Dispos. 30: 838-844 (2002). 
 
Brennan M. B. Drug Discovery: Filtering out failures early in the game. Chem. & 
Eng. News. 78: 63-73 (2000). 
 
Buening M. K., Chang R. L., Huang M. T., Fortner J. G., Wood A. W., and Conney 
A. H. Activation and inhibition of benzo(a)pyrene and aflatoxin B1-metabolism 
in human liver microsomes by naturally occurring flavonoids. Cancer Res. 41: 
67-72 (1981). 
 
Burckhardt G., and Wolff N. A. Structure of renal organic anion and cation 
transporters. Am. J. Physiol. Renal Physiol. 278: F853-F866 (2000). 




Burton P. S., Ho N. F. H., Conradi R. A., and Hilgers A. R. The influence of 
molecular volume and hydrogen-bonding on peptide transport across epithelial 
membranes. Reply to the comments by Drs Potts and Guy. Pharm. Res. 10: 636-
637 (1993). 
 
Busch A. E., Karbach U., Miska D., Gorboulev V., Akhoundova A., Volk C., Arndt 
P., Ulzheimer J. C., Sonders M. S., Baumann C., Waldegger S., Lang F., and 
Koepsell H. Human neurons express the polyspecific cation transporter hOCT2, 
which translocates monoamine neurotransmitters, amantadine, and memantine. 
Mol. Pharmacol. 54: 342–352 (1998). 
 
Busch A. E., Quester S., Ulzheimer J. C., Waldegger S., Gorboulev V., Arndt P., 
Lang F., and Koepsell H. Electrogenic properties and substrate specificity of the 
polyspecific rat cation transporter rOCT1. J. Biol. Chem. 271: 32599–32604 
(1996). 
 
Cai Y., Bennett D., Nair R. V., Ceska O., Ashwood-Smith M. J., and DiGiovanni J. 
Inhibition and inactivation of murine hepatic ethoxy- and pentoxyresorufin O-
dealkylase by naturally occurring coumarins. Chem. Res. Toxicol. 6: 872-879 
(1993). 
 
Cavet M. E., West M., and Simmons N. L. Transport and epithelial secretion of the 
cardiac glycoside, digoxin, by human intestinal epithelial (Caco-2) cells. J. 
Pharmacol. 118: 1389-1396 (1996). 
 




Chan L. M., Lowes S., and Hirst B. H. The ABCs of drug transport in intestine and 
liver: efflux proteins limiting drug absorption and bioavailability. Eur. J. Pharm. 
Sci. 21: 25-51 (2004). 
 
Chang T., Benet L. Z., and Hebert M. F. Effect of water-soluble vitamin E on 
cyclosporine pharmacokinetics in healthy volunteers. Clin. Pharmacol. Ther. 
59: 297-303 (1996). 
 
Cheng K. J., Krishnamurty H. G., Jones G. A., and Simpson F. J. Identification of 
products produced by the anaerobic degradation of naringin by Butyrivibrio sp. 
C3. Can. J. Microbiol. 17: 129-131 (1971). 
 
Cheng K. L., Nafziger A. N., Peloquin C. A., and Amsden G. W. Effect of grapefruit 
juice on clarithromycin pharmacokinetics. Antimicrob. Agents Chemother. 42: 
927-929 (1998). 
 
Chin J. E., Soffir R., Noonan K. E., Choi K., and Roninson I. B. Structure and 
expression of the human MDR (P-glycoprotein) gene family. Mol. Cell. Biol. 9: 
3808-3820 (1989). 
 
Ciarimboli G., and Schlatter E. Regulation of organic cation transport. Pfulgers Arch-
Eur. J. Physiol. 449: 423-441 (2005). 
 
Ciarimboli G., Ludwig T., Lang D., Pavenstadt H., Koepsell H., Piechota H. J., Haier 
J., Jaehde U., Zisowsky J., and Schlatter E. Cisplatin nephrotoxicity is 




critically mediated via the human organic cation transporter 2. Am. J. Pathol. 
167: 1477-1484 (2005). 
  
Clarke R., van den Berg H. W., and Murphy R. F. Reduction of the membrane fluidity 
of human breast cancer cells by tamoxifen and 17 beta-estradiol. J. Natl. Cancer 
Inst. 82: 1702-1705 (1990). 
 
Cotreau M. M., von Moltke L. L., Beinfeld M. C., and Greenblatt D. J. Methodologies 
to study the induction of rat hepatic and intestinal cytochrome P 450 3A at the 
mRNA, protein, and catalytic activity level. J. Pharmacol. Toxicol. Methods 43: 
41-54 (2000). 
 
Crevoisier C., Ziegler W. H., and Eckert M. Relationship between plasma 
concentration and effect of midazolam after oral and intravenous administration. 
Br. J. Clin. Pharmacol. 16: 51-61 (1983). 
 
Dahan A., and Altman H. Food-drug interaction: grapefruit juice augments drug 
bioavailability-mechanism, extent and relevance. Eur. J. Clin. Nutr. 58: 1-9 
(2004). 
 
Dawson D. C. Principles of membrane transport, in Handbook of physiology, Rauner 
B. (Ed.), American Physiological Society, Bethesda. pp. 1-45 (1991). 
 




de Aizpurua H. J., and Russel-Jones G. J. Oral vaccination: Identification of classes of 
proteins that provoke an immune response upon oral feeding. J. Exp. Med. 167: 
440-451 (1988). 
 
Delie F., and Rubas W. A. human colonic cell line sharing similarities with 
enterocytes as a model to examine oral absorption: Advantages and limitations 
of the Caco-2 model. Crit. Rev. Ther. Drug Carrier Syst. 14: 221-286 (1997). 
 
Denizot F., and Lang R. Rapid colorimetric assay for cell growth and survival. 
Modifications to the tetrazolium dye procedure giving improved sensitivity and 
reliability. J. Immunol. Methods 89: 271-277 (1986). 
 
de Waziers I., Cugnenc P. H., Yang C. S., Leroux J. P., and Beaune P. H. Cytochrome 
P 450 isoenzymes, epoxide hydrolase and glutathione transferases in rat and 
human hepatic and extrahepatic tissues. J. Pharmacol. Exp. Ther. 253: 387-394 
(1990). 
   
Dey S., Ramachandra M., Pastan I., Gottesman M. M., and Ambudkar S. V. Evidence 
for two nonidentical drug-interaction sites in the human P-glycoprotein. Proc. 
Natl. Acad. Sci. U S A. 94: 10594-10599 (1997). 
 
Di Marco M. P., Edwards D. J., Wainer I. W., and Ducharme M. P. The effect of 
grapefruit juice and Seville orange juice on the pharmacokinetics of 
dextromethorphan: The role of gut CYP3A and P-glycoprotein. Life Sci. 71: 
1149-1160 (2002). 




Dintaman J. M., and Silverman J. A. Inhibition of P-glycoprotein by D-α-tocopheryl 
polyethylene glycol 1000 succinate (TPGS). Pharm. Res. 16: 1550-1556 (1999). 
 
Doherty M. M., and Charman W. N. The mucosa of the small intestine: how clinically 
relevant as an organ of drug metabolism? Clin. Pharmacokinet. 41: 235-253 
(2002). 
 
Dresser G. K., and Bailey D. G. The effects of fruit juices on drug disposition: a new 
model for drug interactions. Eur. J. Clin. Invest. 33: 10-16 (2003). 
 
Dresser G. K., Bailey D. G., Leake B. F., Schwarz U. I., Dawson P. A., Freeman D. 
J., and Kim R. B. Fruit juices inhibit organic anion transporting polypeptide-
mediated drug uptake to decrease the oral availability of fexofenadine. Clin. 
Pharmacol. Ther. 71: 11-20 (2002). 
 
Dresser M. J., Leabman M. K., and Giacomini K. M. Transporters involved in the 
elimination of drugs in the kidney: organic anion transporters and organic cation 
transporters. J. Pharm. Sci. 90: 397-421 (2001). 
 
Dresser M. J., Zhang L., and Giacomini K. M. Molecular and functional 
characteristics of cloned human organic cation transporters, in Membrane 
transporters as drug targets, Gordon L. A. and Wolfgang S. (Eds.), Kluwer 
Academic/ Plenum Publishers, New York. pp. 441-469 (2000). 
 




Ducharme M. P., Warbasse L. H., and Edwards D. J. Disposition of intravenous and 
oral cyclosporine after administration with grapefruit juice. Clin. Pharmacol. 
Ther.  57: 485-491 (1995) 
 
Dudley A. J., Bleasby K., and Brown C. D. A. The organic cation transporter OCT2 
mediates the uptake of beta-adrenoceptor antagonists across the apical 
membrane of renal LLC-PK1 cell monolayers. Br. J. Pharmacol. 131: 71 -79 
(2000).  
 
Dundee J. W., Halliday N. J., Harper K. W., and Brogden R. N. Midazolam: A review 
of its pharmacological properties and therapeutic use. Drugs 28: 519-543 
(1984). 
 
Eagling V. A., Profit L., and Back D. J. Inhibition of the CYP3A4-mediated 
metabolism and P-glycoprotein-mediated transport of the HIV-1 protease 
inhibitor saquinavir by grapefruit juice components. Br. J. Pharmacol. 48: 543-
552 (1999). 
 
Edgar B., Bailey D., Bergstrand R., Johnsson G., and Regardh C. G. Acute effects of 
drinking grapefruit juice on the pharmacokinetics and dynamics of felodipine--
and its potential clinical relevance. Eur. J. Clin. Pharmacol. 42: 313-317 (1992).  
 
Edwards D. J., Bellevue III F. H., and Woster P. M. Identification of 6’,7’-
dihydroxybergamottin, a cytochrome P450 inhibitor, in grapefruit juice. Drug 
Metab. Dispos. 24: 1287-1290 (1996). 




Edwards D. J., and Bernier S. M. Naringin and naringenin are not the primary CYP3A 
inhibitors in grapefruit juice. Life Sci. 59: 1025-1030 (1996). 
 
Edwards D. J., Fitzsimmons M. E., Schuetz E. G., Yasuda K., Ducharme M. P., 
Warbasse L. H., Woster P. M., Schuetz J. D., and Watkins P. 6’,7’-
Dihydroxybergamottin in grapefruit juice and Seville orange: effects on 
cyclosporine disposition, enterocyte CYP3A4, and P-glycoprotein. Clin. 
Pharmacol. Ther. 65: 237-244 (1999). 
 
Egashira K., Fukuda E., Onga T., Yogi Y., Matsuya F., Koyabu N., Ohtani H., and 
Sawada Y. Pomelo-induced increased in the blood level of tacrolimus in a renal 
transplant patient. Transplantation 75: 1057 (2003). 
 
Egashira K., Ohtani H., Itoh S., Koyabu N., Tsujimoto M., Murakami H., and Sawada 
Y. Inhibitory effects of pomelo on the metabolism of tacrolimus and the 
activities of CYP3A4 and P-glycoprotein. Drug Metab. Dispos. 32: 828-833 
(2004). 
 
Endo T., Kimura O., and Sakata M. Effects of P-glycoprotein inhibitors on cadmium 
accumulation in cultured renal epithelial cells, LLC-PK1, and OK. Toxicol. 
Appl. Pharmacol. 185: 166-171 (2002). 
 
Engel K., and Wang J. Interaction of organic cations with a newly identified plasma 
membrane monoamine transporter. Mol. Pharmacol. 68: 1397-1407 (2005).  
 




Enomoto A., Kimura H., Chairoungdua A., Shigeta Y., Jutabha P., Cha S. H., 
Hosoyamada M., Takeda M., Sekine T., and Igarashi T. Molecular identification 
of a renal urate-anion exchanger that regulates blood urate levels. Nature 417: 
447–452 (2002). 
 
Ernest S., and Bello-Reuss E. P-glycoprotein functions and substrates: possible roles 
of MDR1 gene in the kidney. Kidney Int. Suppl. 65: S11–S17 (1998). 
 
Evans A. M. Influence of dietary components on the gastrointestinal metabolism and 
transport of drugs. Ther. Drug Monit. 22: 131-136 (2000). 
 
Fardel O., Lecureur V., and Guillouzo A. The P-glycoprotein multidrug transporter. 
Gen. Pharmacol. 27: 1283-1291 (1996). 
 
Ferrec E. L., Chesne C., Artusson P., Brayden D., Fabre G., Gires P., Guillou F., 
Rousset M., Rubas W., and Scarino M. In vitro models of the intestinal barrier. 
ATLA 29: 649-668 (2001). 
 
Ferté J. Analysis of the tangled relationships between P-glycoprotein-mediated 
multidrug resistance and the lipid phase of the cell membrane. Eur. J. Biochem. 
267: 277-294 (2000). 
 
Fisher J. M., Wrighton S. A., Calamia J. C., Shen D. D., Kunze K. L., and Thummel 
K. E. Midazolam metabolism by modified Caco-2 cell monolayers: Effects of 
extracellular protein binding. J. Pharmacol. Exp. Ther. 289: 1143-1150 (1999). 




Fojo A. T., Ueda. K., Slamon D. J., Poplack D. G., Gottesman M. M., and Pastan I. 
Expression of a multidrug-resistance gene in human tumors and tissues. Proc. 
Natl. Acad. Sci. U.S.A. 84: 265-269 (1987). 
 
Fouda A. K., Fauth C., and Roch-Ramel F. Transport of organic cations by kidney 
epithelial cell line LLC-PK1. J. Pharmacol. Exp. Ther. 252: 286-292 (1990). 
 
Friberg L. Cadmium and the kidney. Environ. Health Perspect. 54: 1-11 (1984).  
 
Fricker G., Drewe J., Huwyler J., Gutmann H., and Beglinger C. Relevance of P-
glycoprotein for the enteral absorption of cyclosporin A: in vitro-in vivo 
correlation. Br. J. Pharmacol. 118: 1841-1847 (1996). 
 
Fromm M. F. P-glycoprotein: A defense mechanism limiting oral bioavailability and 
CNS accumulation of drugs. Int. J. Clin. Pharmacol. Ther. 38: 69-74 (2000).  
 
Fromm M. F. Importance of P-glycoprotein for drug disposition in humans. Eur. J. 
Clin. Invest. 33: 6-9 (2003). 
 
Fromm M. F., Kim R., Stein M., Wilkinson G. R., and Roden D. M. Inhibition of P-
glycoprotein-mediated drug transport. A unifying mechanism to explain the 
interaction between digoxin and quinidine. Circulation 99: 552-557 (1999). 
 
Fuhr U. Drug interactions with grapefruit juice: extent, probable mechanism and 
clinical relevance. Drug Saf. 18: 251-272 (1998). 




Fuhr U., and Kummert A. L. The fate of naringin in humans: a key to grapefruit juice-
drug interactions? Clin. Pharmacol. Ther. 58: 365-373 (1995). 
 
Fujita K-I., Hidaka M., Takamura N., Yamasaki K., Iwakiri T., Okumura M., Kodama 
H., Yamaguchi M., Ikenoue T., and Arimori K. Inhibitory effects of citrus fruit 
on cytochrome P450 3A (CYP3A) activity in humans. Biol. Pharm. Bull. 26: 
1371-1373 (2003). 
 
Fukuda K., Guo L., Ohashi N., Yoshikawa M., and Yamazoe Y. Amounts and 
variation in grapefruit juice of the main components causing grapefruit-drug 
interaction. J. Chromatogr. B.  741: 195-203 (2000). 
 
Fukuda K., Ohta T., Oshima Y., Ohashi N., Yoshikawa M., and Yamazoe Y. Specific 
CYP3A4 inhibitors in grapefruit juice: furanocoumarin dimers as components of 
drug interaction. Pharmacogenet. 5: 391-396 (1997). 
 
Galetin A., Clarke S. E., and Houston J.B. Multisite kinetic analysis of interactions 
between prototypical CYP3A4 subgroup substrates: midazolam, testosterone, 
and nifedipine. Drug Metab. Dispos. 31: 1108-1116 (2003). 
 
Gatmaitan Z. C., and Arias I. M. Structure and function of P-glycoprotein in normal 
liver and small intestine. Adv. Pharmacol. 24: 77-97 (1993). 
 




Ghosal A., Satoh H., Thomas P. E., Bush E., and Moore D. Inhibition and kinetics of 
cytochrome P4503A activity in microsomes from rat, human, and cDNA-
expressed human cytochrome P450. Drug Metab. Dispos. 24: 940-947 (1996). 
 
Gibbs M. A., Thummel K. E., Shen D. D., and Kunze K. L. Inhibition of cytochrome 
P-450 3A (CYP3A) in human intestinal and liver microsomes: comparison of Ki 
values and impact of CYP3A5 expression. Drug Metab. Dispos. 27: 180-187 
(1999). 
 
Goldstein L. J., Galski H., Fojo A., Willingham M., Lai S-L., Gazdar A., Pirker R., 
Green A., Crist W., Brodeur G. M., Lieber M., Cossma J., Gottesman M. M., 
and Pastan I. Expression of a multidrug resistance gene in human cancers. J. 
Natl. Cancer Inst. 81: 116-124 (1989). 
 
Gonzalez F. J. The molecular biology of cytochrome P450s. Pharmacol. Rev. 40: 
243-288 (1988). 
 
Gorboulev V., Ulzheimer J. C., Akhoundova A., Ulzheimer-Teuber I., Karbach U., 
Quester S., Baumann C., Lang F., Busch A. E., and Koepsell H. Cloning and 
characterization two human polyspecific organic cation transporters. DNA Cell 
Biol. 16: 871-881 (1997). 
 
Gorski J. C., Hall S. D., Jones D. R., Branden M. V., and Wrighton S. A. 
Regioselective biotransformation of midazolam by members of the human 




cytochrome P450 3A (CYP 3A) subfamily. Biochem. Pharmacol. 47: 1643-
1653 (1994). 
 
Gottesman M. M., and Pastan I. Biochemistry of multidrug resistance mediated by the 
multidrug transporter. Ann. Rev. Biochem. 62: 385-427 (1993). 
 
Gottesman M. M., Pastan I., and Ambudkar S. V. P-glycoprotein and multidrug 
resistance. Curr. Opin. Genet. Dev. 6: 610-667 (1996).  
 
Gray A. I. Structural diversity and distribution of coumarins and chromones in the 
rutales, in Chemistry and chemical taxonomy of the rutales, Academic Press, 
London. pp. 97-146 (1983). 
 
Greenblatt D. J., von Moltke L. L., Harmatz J. S., Chen G., Weemhoff J. L., Jen C., 
Kelley C. J., LeDuc B. W., and Zinny M. A. Time course recovery of 
cytochrome P450 3A after single doses of grapefruit juice. Clin. Pharmacol. 
Ther. 74: 121-129 (2003). 
 
Greenblatt D. J., Wright C. E., von Moltke L. L., Harmatz J. S., Ehrenberg B. L., 
Harrel L. M., Corbett K., Counihan M., Tobias S., and Shader R. I. 
Ketoconazole inhibition of triazolam and alprazolam clearance: differential 
kinetic and dynamic consequences. Clin. Pharmacol. Ther. 64: 237-247 (1998). 
 




Grenier J., Fradette C., Morelli G., Merritt G. J., Vranderick M., and Ducharme M. P. 
Pomelo juice, but not cranberry juice, affects the pharmacokinetics of 
cyclosporine in humans. Clin. Pharmacol. Ther. 79: 255-262 (2006). 
 
Gründemann D., Babin-Ebell J., Martel F., Örding N., Schmidt A., and Schömig E. 
Primary structure and functional expression of the apical organic cation 
transporter from kidney epithelial LLC-PK1 cells. J. Biol. Chem. 272: 10408-
10413 (1997). 
 
Gründemann D., Gorboulev V., Gambaryan S., Veyhl M., and Koepsell H. Drug 
excretion mediated by a new prototype of polyspecific transporter. Nature 372: 
549-552 (1994). 
 
Gstraunthaler G., Steinmassl D., and Pfaller W. Renal cell cultures: a tool for studying 
tubular function and nephrotoxicity. Toxicol. Lett. 53: 1-7 (1990). 
 
Guengerich F. P. Human cytochrome P450 enzymes, in Cytochrome P450: Structure, 
mechanism, and biochemistry (2nd edition), Plenum Press, New York. pp. 473-
535 (1995). 
 
Guengerich F. P. Cytochrome P450 3A4: Regulation and role in drug metabolism. 
Annu. Rev. Pharmacol. Toxicol. 39: 1-17 (1999). 
 




Guengerich F. P., and Kim D. H. In vitro inhibition of dihydropyridine oxidation and 
aflatoxin B1 activation in human liver microsomes by naringenin and other 
flavonoids. Carcinogenesis 11: 2275-2279 (1990). 
 
Gunaratna C. Drug metabolism and pharmacokinetics in drug discovery: A primer for 
bioanalytical chemists, Part 1. Curr. Sep. 19: 17-23 (2000).  
 
Guo L-Q., Fukuda K., Ohta T., and Yamazoe Y. Role of furanocoumarin derivatives 
on grapefruit juice-mediated inhibition of human CYP 3A activity. Drug Metab. 
Dispos. 28: 766-771 (2000). 
 
Guo L-Q, and Yamazoe Y. Inhibition of cytochrome P450 by furanocoumarins in 
grapefruit juice and herbal medicines. Acta Pharmacol. Sin. 25: 129-136 (2004). 
 
Hagenbuch B., and Meier P. J. The superfamily of organic anion transporting 
polypeptides. Biochim. Biophys. Acta 1609: 1–18 (2003). 
 
Haynes R., Sackett D., and Gibson E. Improvements of medication compliance in 
uncontrolled hypertension. Lancet 1: 1256-1268 (1976). 
 
He K., Iyer K. R., Hayes R. N., Sinz M. W., Woolf T. F., and Hollenberg P. F. 
Inactivation of cytochrome P450 3A4 by bergamottin, a component in grapefruit 
juice. Chem. Res. Toxicol. 11: 252-259 (1998). 
 




Hebert M. F., Roberts J. P., Prueksaritanont T., and Benet L. Z. Bioavailability of 
cyclosporine with concomitant rifampin administration is markedly less than 
predicted by hepatic enzyme induction. Clin. Pharmacol. Ther. 52: 453-457 
(1992). 
 
Heizmann P., Eckert M., and Ziegler W. H. Pharmacokinetics and bioavailability of 
midazolam in man. Br. J. Clin. Pharmacol. 16: 43-49 (1983). 
 
Heizmann P., and Ziegler W. H. Excretion and metabolism of 14C-midazolam in 
humans following oral dosing. Arzneimittelforschung. 31: 2220-2223 (1981). 
 
Hidaka M., Fujita K-I., Ogikubo T., Yamasaki K., Iwakiri T., Okumura M., Kodama 
H., and Arimori K. Potent inhibition by star fruit of human cytochrome P450 3A 
(CYP3A) activity. Drug Metab. Dispos. 32: 581-583 (2004). 
 
Hidalgo I. J., Raub T. J., and Borchardt R. T. Characterization of the human colon 
carcinoma cell line (Caco-2) as a model system for intestinal epithelial 
permeability. Gastroenterology 96: 736-749 (1989). 
 
Higgins C., Hiles I., Salmond G., Gill D., Downie J., Evans I., Holland I., Gray L., 
Buckel S., Bell A., and Hermodson M. A family of related ATP-binding 
subunits coupled to many distinct biological processes in bacteria. Nature 323: 
448-450 (1986). 
 




Higgins C. F., and Gottesman M. M. Is the multidrug transporter a flippase? Trends 
Biochem. Sci. 17: 18-21 (1992). 
 
Hirashima T., Eto T., and DenBesten L. Lactomer copolymer absorbable staples in 
gastrointestinal surgery. Am. J. Surg. 150: 381-385 (1985). 
 
Hirsch-Ernst K. I., Ziemann C., Rustenbeck I., and Kahl G. F. Inhibitors of mdr1-
dependent transport activity delay accumulation of the mdr1 substrate 
rhodamine 123 in primary rat hepatocyte cultures. Toxicology. 167: 47-57 
(2001). 
 
Ho G-T., Moodie F. M., and Satsangi J. Multidrug resistance 1 gene (P-glycoprotein 
170): an important determinant in gastrointestinal disease? Gut 52: 759-766 
(2003). 
 
Ho P-C., Chalcroft S. C., Coville P. F., and Wanwimolruk S.  Grapefruit juice has no 
effect on quinine pharmacokinetics. Eur. J. Clin. Pharmacol. 55: 393-398 
(1999). 
 
Ho P-C., Saville D. J., Coville P. F., and Wanwimolruk S. Content of CYP3A4 
inhibitors, naringin, naringenin and bergapten in grapefruit and grapefruit juice 
products. Pharma. Acta Helv. 74: 379-385 (2000). 
 




Ho P-C., Saville D. J., and Wanwimolruk S. Inhibition of human CYP3A4 activity by 
grapefruit flavonoids, furanocoumarins and related compounds. J. Pharm. 
Pharm. Sci. 4: 217-227 (2001). 
 
Hoen P. A. C., Bijsterbosch M. K., van Berkel T. J. C., Vermeulen N. P. E., and 
Commandeur J. N. M. Midazolam is a phenobarbital-like cytochrome P450 
inducer in rats. J. Pharmacol. Exp. Ther. 299: 921-927 (2001). 
 
Holmes J. A., and West R. R. The effect of MDR-1 gene expression on outcome in 
acute myeloblastic leukaemia. Br. J. Cancer. 69: 382-384 (1994). 
 
Holohan P. D., White K. E., Sokol P. P., and Rebbeor J. Photoaffinity labeling of the 
organic cation/H+ exchanger in renal brush border membrane vesicles. J. Biol. 
Chem. 267: 13513-13519 (1992). 
 
Holtbecker N., Fromm M. F., Kroemer H. K., Ohnhaus E. E., and Heidemann H. The 
nifedipine-rifampin interaction. Evidence for induction of gut wall metabolism. 
Drug Metab. Dispos. 24: 1121-1123 (1996). 
 
Honda Y., Ushigome F., Koyabu N., Morimoto S., Shoyama Y., Uchiumi T., Kuwano 
M., Ohtani H., and Sawada Y. Effects of grapefruit juice and orange juice 
component on P-glycoprotein- and MRP2-mediated drug efflux. Br. J. 
Pharmacol. 143: 856-864 (2004). 
  




Hosagrahara V. P., Hansen L. K., and Remmel R. P. Induction of the metabolism of 
midazolam by rifampin in cultured porcine hepatocytes: preliminary evidence 
for CYP3A isoforms in pigs. Drug Metab. Dispos. 27: 1512-1518 (1999). 
 
Hosea N. A., Miller G. P., and Guengerich F. P. Elucidation of distinct ligand binding 
sites for cytochrome P450 3A4. Biochemistry. 39: 5929-5939 (2000). 
 
Hou Y. C., Hsiu S. L., Tsao C. W., Wang Y. H., and Chao P. D. Acute intoxication of 
cyclosporin caused by coadministration of decoctions of the fruits of citrus 
aurantium and the pericarps of citrus grandis. Planta Med. 66: 653-655 (2000). 
 
Huang C., Wu M., Xu G., Li D., Cheng H., Tu Z., Jiang H., and Gu J. Overexpression 
of the MDR1 gene and P-glycoprotein in human hepatocellular carcinoma. J. 
Natl. Cancer Inst. 84: 262-264 (1992). 
 
Huisman M. T., Smit J. W., Wiltshire H. R., Hoetelmans R. M. W., Beijnen J. H., and 
Schinkel A. H. P-glycoprotein limits oral availability, brain, and fetal 
penetration of saquinavir even with high doses of ritonavir. Molec. Pharmacol. 
59: 806-813 (2001). 
 
Hull R. N., Cherry W. R., and Weaver G. W. The origin and characteristics of a pig 
kidney cell strain, LLC-PK. In Vitro. 12: 670-677 (1976). 
 




Hunter J., Hirst B. H., and Simmons N. L. Drug absorption limited by P-glycoprotein-
mediated secretory drug transport in human intestinal epithelial Caco-2 cell 
layers. Pharm. Res. 10: 743-749 (1993a). 
 
Hunter J., Jepson M., Tsuruo T., Simmons N. L., and Hirst B. H. Functional 
expression of P-glycoprotein in apical membranes of human intestinal Caco-2 
cells. Kinetics of vinblastine secretion and interaction with modulators. J. Biol. 
Chem. 268: 14991-14997 (1993b). 
  
Hyde S. C., Emsley P., Hartshorn M. F., Mimmack M. M., Gileadi U., Pearce S. R., 
Gallagher M. P., Gill D. R., Hubbard R. E., and Higgins C. F. Structural model 
of ATP-binding proteins associated with cystic fibrosis, multidrug resistance 
and bacterial transport. Nature 346: 362-365 (1990).  
 
Ikegawa T., Ushigome F., Koyabu N., Morimoto S., Shoyama Y., Naito M., Tsuruo 
T., Ohtani H., and Sawada Y. Inhibition of P-glycoprotein by orange juice 
components polymethoxyflavones in adriamycin-resistant human myelogenous 
leukemia (K562/ADM) cells. Cancer Lett. 160: 21-28 (2000). 
 
Ito K., Kusuhara H., and Sugiyama Y. Effects of intestinal CYP3A4 and P-
glycoprotein on oral drug absorption-Theoretical approach. Pharm. Res. 16: 
225-231 (1999). 
 
James J. S. Grapefruit juice and saquinavir. AIDS Treatment News 235: 5-6 (1995). 
 




Jonker J. W., and Schinkel A. H. Pharmacological and physiological functions of the 
polyspecific organic cation transporters: OCT1, 2, and 3 (SLC22A1-3). J. 
Pharmacol. Exp. Ther. 308: 2-9 (2004). 
 
Josefsson M., Zackrission A. L., and Ahlner J. Effect of grapefruit juice on the 
pharmacokinetics of amlodipine in healthy volunteers. Eur. J. Clin. Pharmacol. 
51: 189-193 (1996). 
 
Jung T., Kamm W., Breitenbach A., Kaiserling E., Xiao J. X., and Kissel T. 
Biodegradable nanoparticles for oral delivery of peptides: Is there a role for 
polymers to affect mucosal uptake? Eur. J. Pharm. Biopharm. 50: 147-160 
(2000). 
 
Kakar S. M., Paine M. F., Stewart P. W., and Watkins P. B. 6’7’-
Dihydroxybergamottin contributes to the grapefruit juice effect. Clin. 
Pharmacol. Ther. 75: 569-579 (2004). 
 
Kakumoto M., Sakaeda T., Takara K., Nakamura T., Kita T., Yagami T., Kobayashi 
H., Okamura N. and Okumura K. Effects of carvedilol on MDR1-mediated 
multidrug resistance: comparison with verapamil. Cancer Sci. 94: 81-86 (2003).  
 
Kamath A. V., Yao M., Zhang Y., and Chong S. Effect of fruit juices on the oral 
bioavailability of fexofenadine in rats. J. Pharm. Sci. 94: 233-239 (2005).  
 
 




Kaminsky L. S., and Fasco M. J. Small intestinal cytochromes P450. Crit. Rev. 
Toxicol. 21: 407-422 (1991). 
 
Kane G. C., and Lipsky J. J. Drug-grapefruit juice interactions. Mayo Clin. Proc. 75: 
933-942 (2000). 
 
Kanes K., Tisserat B., Berhow M., and Vandercook C. Phenolic composition of 
various tissues of rutaceae species. Phytochemistry. 32: 967-974 (1993). 
 
Kanto J., and Allonen H. Pharmacokinetics and sedative effect of midazolam. Int. J. 
Clin. Pharmacol. Ther. Toxicol. 21: 460-463 (1983). 
 
Kantola T., Kivisto K. T., and Neuvonen P. J. Grapefruit juice greatly increases serum 
concentrations of lovastatin and lovastatin acid. Clin. Pharmacol. Ther. 63: 397-
402 (1998). 
 
Kaplan J. G. Membrane cation transport and the control of proliferation of 
mammalian cells. Annu. Rev. Physiol. 40: 19-41 (1978). 
 
Karbach U., Kricke J., Meyer-Wentrup F., Gorboulev V., Volk C., Loffing-Cueni D., 
Kaissling B., Bachmann S., and Koepsell H. Localization of organic cation 
transporters OCT1 and OCT2 in rat kidney. Am. J. Physiol. Renal Physiol. 279: 
F679-F687 (2000). 
 




Katsura T., and Inui K-I. Intestinal absorption of drugs mediated by drug transporters: 
mechanisms and regulation. Drug Metab. Pharmacokin. 18: 1-15 (2003). 
 
Kekuda R., Prasad P. D., Wu X., Wang H., Fei Y-J., Leibach F. H., and Ganapathy V. 
Cloning and functional characterization of a potential-sensitive, polyspecific 
organic cation transporter (OCT3) most abundantly expressed in placenta. J. 
Biol. Chem. 273: 15971–15979 (1998). 
 
Kenworthy K. E., Bloomer J. C., Clarke S. E., and  Houston J. B. CYP3A4 drug 
interactions: correlation of 10 in vitro probe substrates. Br. J. Clin. Pharmacol. 
48: 716-727 (1999). 
 
Kerns E. H. High throughput physicochemical profiling for drug discovery. J. Pharm. 
Sci. 90: 1838-1858 (2001). 
 
Khan K. K., He Y. Q., Domanski T. L., and Halpert J R. Midazolam oxidation by 
cytochrome P450 3A4 and active-site mutants: an evaluation of multiple binding 
sites and of the metabolic pathway that leads to enzyme inactivation. Mol. 
Pharmacol. 61: 495-506 (2002). 
 
Kim H., Yoon Y. J., Shon J. H., Cha I. J., Shin J. G., and Liu K. H. Inhibitory effects 
of fruit juices on CYP3A activity. Drug Metab. Dispos. 34:521-523 (2006). 
 




Kim R. B., Fromm M. F., Wandel C., Leake B., Wood A. J. J., Roden D. M., and 
Wilkinson G. R.. The drug transporter P-glycoprotein limits oral absorption and 
brain entry of HIV-1 protease inhibitors. J. Clin. Invest. 101: 289-294 (1998). 
 
Kim R. B., Wandel C., Leake B., Cvetkovic M., Fromm M. F., Dempsey P. J., Roden 
M. M., Belas F., Chaudhary A. K., Roden D. M., Wood A. J. J., and Wilkinson 
G. R. Interrelationship between substrates and inhibitors of human CYP3A and 
P-glycoprotein.  Pharm. Res. 16: 408-414 (1999). 
 
Kim W. Y., and Benet L. Z.  P-glycoprotein (P-gp/MDR1)-mediated efflux of sex-
steroid hormones and modulation of P-gp expression in vitro. Pharm. Res. 21: 
1284-1293 (2004). 
 
Kimura O., Endo T., Hotta Y., and Sakata M. Effects of P-glycoprotein inhibitors on 
transepithelial transport of cadmium n cultured renal epithelial cells, LLC-PK1 
and LLC-GA5-COL 150. Toxicology 208: 123-132 (2005). 
 
King H. W., Macfarlane A. W., Graham R. M., and Verbov J. L. Near fatal drug 
interactions with methotrexate given for psoriasis. Br. Med. J. 295: 752–753 
(1987). 
 
Kioka N., Hosokawa N., Komano T., Hirayoshi K., Nagata K., and Ueda K. 
Quercetin, a bioflavonoid, inhibits the increase of human multidrug resistance 
gene (MDR1) expression caused by arsenite. FEBS Lett. 301: 307-309 (1992). 
 




Klein I., Sarkadi B., and Váradi A. An inventory of the human ABC proteins. 
Biochim. Biophys. Acta. 1461: 237-262 (1999).  
 
Koepsell H. Organic cation transporters in intestine, kidney, liver and brain. Annu. 
Rev. Physiol. 60: 243-266 (1998). 
 
Koepsell H. Polyspecific organic cation transporters: their functions and interactions 
with drugs. Trends Pharmacol. Sci. 25: 375-381 (2004). 
 
Koepsell H., Busch A., Gorboulev V., and Arndt P. Structure and function of renal 
organic cation transportes. News Physiol. Sci. 13: 11-16 (1998). 
 
Koepsell H., and Endou H. The SLC22 drug transporter family. Pflugers Arch. 447: 
666-676 (2004). 
 
Koepsell H., Gorboulev V., and Arndt P. Molecular pharmacology of organic cation 
transporters in kidney. J. Membrane Biol. 167: 103-117 (1999). 
 
Koepsell H., Schmitt B. M., and Gorboulev V. Organic cation transporters. Rev. 
Physiol. Biochem. Pharmacol. 150: 36-90 (2003). 
 
Kolars J. C., Awni W. M., Merion R. M., and Watkins P. B. First-pass metabolism of 
cyclosporin by the gut. Lancet. 338: 1488-1490 (1991). 
 




Kolars J. C., Schmiedlin-Ren P., Schuetz J. D., Fang C., and Watkins P. B. 
Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small 
bowel enterocytes. J. Clin. Invest. 90: 1871-1878 (1992). 
 
Kramer R., Weber T. K., Morse B., Arceci R., Staniunas R., Steele G., and 
Summerhayes I. C. Constitutive expression of multidrug resistance in human 
colorectal tumours and cell lines. Br. J. Cancer. 67: 959-968 (1993). 
 
Kremer J. M., and Hamilton R. A. The effects of nonsteroidal anti-inflammatory 
drugs on methotrexate (MTX) pharmacokinetics: Impairment of renal clearance 
of MTX at weekly maintenance doses but not at 7.5 mg. J. Rheumatol. 22: 
2072–2077 (1995). 
 
Kronbach T., Mathys D., Umeno M., Gonzalez F. J., and Meyer U. A. Oxidation of 
midazolam and triazolam by human liver cytochrome P450IIIA4. Mol. 
Pharmacol. 36: 89-96 (1989). 
 
Kuhnau J. The flavonoids: A class of semi-essential food components. Their role in 
human nutrition. World Rev. Nutr. Diet. 24: 117-191 (1976). 
 
Kunta J. R., and Sinko P. J. Intestinal drug transporters: In vivo function and clinical 
importance. Curr. Drug Metab. 5: 109-124 (2004). 
 
Kuo S-M. Transepithelial transport and accumulation of flavone in human intestinal 
Caco-2 cells.  Life Sci. 63: 2323-2331(1998). 




Kupferschmidt H. H., Fattinger K. E., Ha H. R., Follath F., and Krahenbuhl S. 
Grapefruit juice enhances the bioavailability of the HIV protease inhibitor 
saquinavir in man. Br. J. Clin. Pharmacol. 45: 355-359 (1998). 
Kupferschmidt H. H., Ha H. R., Ziegler W. H., Meier P. J., and Krähenbühl S. 
Interaction between grapefruit juice and midazolam in humans. Clin. 
Pharmacol. Ther. 58: 20-28 (1995). 
 
Li Q., Sai Y., Kato Y., Muraoka H., Tamai I., and Tsuji A. Transporter-mediated 
renal handling of nafamostat mesilate. J. Pharm Sci. 93: 262-272 (2004). 
 
Lilja J. J., Backman J. T., and Laitila J. Itraconazole increases but grapefruit juice 
greatly decreases plasma concentrations of celiprolol. Clin. Pharmacol. Ther. 
73: 192-198 (2003). 
 
Lilja J. J., Juntti-Patinen L., and Neuvonen P. J. Orange juice substantially reduces the 
bioavailability of the beta-adrenergic-blocking agent celiprolol. Clin. 
Pharmacol. Ther. 75: 184-190 (2004). 
 
Lilja J. J., Kivisto K. T., Backman J. T., and Neuvonen P. J.  Effect of grapefruit juice 
dose on grapefruit juice-triazolam interaction: repeated consumption prolongs 
triazolam half-life. Eur. J. Clin. Pharmacol. 56: 411-415 (2000a). 
 
Lilja J. J., Kivisto K. T., and Neuvonen P. J. Grapefruit juice-simvastatin interaction: 
effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA 
reductase inhibitors. Clin. Pharmacol. Ther. 64: 477-483 (1998). 




Lilja J. J., Kivisto K. T., and Neuvonen P. J. Duration of effect of grapefruit juice on 
the pharmacokinetic of the CYP3A4 substrate simvastatin. Clin. Pharmacol. 
Ther. 68: 384-390 (2000b). 
 
 Ling V. Multidrug resistance: molecular mechanisms and clinical relevance. Cancer 
Chemother. Pharmacol. 40: S3-S8 (1997). 
 
Litman T., Zeuthen T., Skovsgaard T., and Stein W. D. Competitive, non-competitive 
and cooperative interactions between substrates of P-glycoprotein as measured 
by its ATPase activity. Biochim. Biophys. Acta. 1361: 169-176 (1997). 
 
Lowes S., Cavet M. E., and Simmons N. L. Evidence for a non-MDR1 component in 
digoxin secretion by human intestinal Caco-2 epithelial layers. Eur. J. 
Pharmacol. 458: 49-56 (2003). 
 
Lown K. S., Bailey D. G., Fontana R. J., Janardan S. K., Adair C. H., Fortlage L. A., 
Brown M. B., Guo W., and Watkins P. B. Grapefruit juice increases felodipine 
oral availability in humans by decreasing intestinal CYP3A4 protein expression. 
J. Clin. Invest. 99: 2545-2553 (1997a). 
 
Lown K. S., Ghosh M., and Watkins P. B. Sequences of intestinal and hepatic 
cytochrome P450 3A4 cDNAs are identical. Drug Metab. Dispos. 26: 185-187 
(1998). 
 




Lown K. S., Kolars J. C., Thummel K. E., Barnett J. L., Kunze K. L., Wrighton S. A., 
and Watkins P. B. Interpatient heterogeneity in expression of CYP3A4 and 
CYP3A5 in small bowel. Lack of prediction by erythromycin breath test. Drug 
Metab. Dispos. 22: 947-955 (1994). 
 
Lown K. S., Mayo. R. R., Leichtman A. B., Hsiao H., Turgeon D. K., Schmiedlin-Ren 
P., Brown M. B., Guo W., Rossi S. J., Benet L. Z., and Watkins P. B. Role of 
intestinal P-glycoprotein (MDR1) in interpatient variation in the oral 
bioavailability of cyclosporine. Clin. Pharmacol. Ther. 62: 248-260 (1997b). 
 
Lundahl J. U. E., Regardh C. G., Edgar B., and Johnsson G. Relationship between 
time of intake of grapefruit juice and its effect on pharmacokinetics and 
pharmacodynamics of felodipine in healthy subjects. Eur. J. Clin. Pharmacol. 
49: 61-67 (1995). 
 
Lundahl J. U. E., Regardh C. G., Edgar B., and Johnsson G. Effects of grapefruit juice 
ingestion-pharmacokinetics and haemodynamics of intravenously and orally 
administered felodipine in healthy men. Eur. J. Clin. Pharmacol. 52: 139-145 
(1997). 
 
Lundahl J. U. E., Regardh C. G., Edgar B., and Johnsson G. The interaction effect of 
grapefruit juice is maximal after the first glass. Eur. J. Clin. Pharmacol. 54: 
75-81 (1998). 
  




Maiche A. G. Acute renal failure due to concomitant action of methotrexate and 
indomethacin. Lancet 1: 1390 (1986). 
 
 Maitra R., Halpin P. A., Karlson K. H., Page R. L., Paik D. Y., Leavitt M. O., Moyer 
B. D., Stanton B. A., and Hamilton J. W. Differential effects of mitomycin C 
and doxorubicin on P-glycoprotein expression. Biochem. J. 355: 617-624 
(2001). 
 
Makhey V. D., Guo A., Norris D. A., Hu P., Yan J., and Sinko P. J. Characterization 
of the regional intestinal kinetics of drug efflux in rat and human intestine and in 
Caco-2 cells. Pharm. Res. 15: 1160-1167 (1998). 
 
Malhotra S., Bailey D. G., Paine M. F., and Watkins P. B. Seville orange juice-
felodipine interaction: Comparison with dilute grapefruit juice and involvement 
of furocoumarins. Clin. Pharmacol. Ther. 69: 14-23 (2001).  
 
Mammen J. M., and Matthews J. B. Mucosal repair in the gastrointestinal tract. Crit. 
Care Med. 31: S532-S537 (2003). 
 
Mangano N. G., Cutuli V. M., Caruso A., De Bernardis E., and Amico-Roxas M. 
Grapefruit juice effects on the bioavailability of cyclosporin-A in rats. Eur. 
Rev. Med. Pharmacol. Sci. 5:1-6 (2001).  
 
 




Manthey J. A., and Grohmann K. Phenols in citrus peel byproducts: concentrations of 
hydroxycinnamates and polymethoxylated flavones in citrus peel molasses. J. 
Agric. Food Chem. 49: 3268-3273 (2001). 
 
Markowska M., Oberle R., Juzwin S., Hsu C-P., Gryszkiewicz M., and Streeter A. J. 
Optimizing Caco-2 cell monolayers to increase throughput in drug intestinal 
absorption analysis. J. Pharmacol. Toxicol. Mtds. 46: 51-55 (2001). 
 
Martel F., Calhau C., and Azevedo I. Characterization of the transport of the organic 
cation [3H]MPP+ in human intestinal epithelial (Caco-2) cells. Naunyn 
Schmiedebergs Arch. Pharmacol. 361: 505-513 (2000). 
 
Masereeuw R., Moons M. M., and Russel F. G. M. Rhodamine-123 accumulates 
extensively in the isolated perfused rat kidney and is secreted by the organic 
cation system. Eur. J. Pharmacol. 321: 315-323 (1997). 
 
Masereeuw R., and Russel F. G. M. Mechanisms and clinical implications of renal 
drug excretion. Drug Metab. Rev. 33: 299–351 (2001).  
 
Mayer U., Wagenaar E., Beijnen J. H., Smit J. W., Meijer D. K., van Asperen J., 
Borst P., and Schinkel A. H. Substantial excretion of digoxin via the intestinal 
mucosa and prevention of long-term digoxin accumulation in the brain by the 
mdr1a P-glycoprotein. Br. J. Pharmacol. 119: 1038-1044 (1996). 
 




Mealey K. L., Northrup N. C., and Bentjen S. A. Increased toxicity of P-glycoprotein-
substrate chemotherapeutic agents in a dog with the MDR1 deletion mutation 
associated with ivermectin sensitivity. J. Am. Vet Med. Assoc. 223: 1453-1455 
(2003). 
 
Meyer-Wentrup F., Karbach U., Gorboulev V., Arndt P., and Koepsell H. Membrane 
localization of the electrogenic cation transporter rOCT1 in rat liver. Biochem. 
Biophys. Res. Commun. 248: 673– 678 (1998). 
 
Miller D. S. Daunomycin secretion by killifish renal proximal tubules. Am. J. Physiol. 
269: R370– R379 (1995). 
 
Min D. I., Ku Y. M., Geraets D. R., and Lee H. Effect of grapefruit juice on the 
pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers. J. 
Clin. Pharmacol. 36: 469-476 (1996a). 
 
Min D. I., Ku Y. M., Perry P. J., Ukah F. O., Ashton K., Martin M. F., and Hunsicker 
L. G. Effect of grapefruit juice on cyclosporine pharmacokinetics in renal 
transplant patients. Transplantation  62: 123-125 (1996b). 
 
Miniscalco A., Lundahl J., Regardh C. G., Edgar B., and Eriksson U. G. Inhibition of 
dihydropyridine metabolism in rat and human liver microsomes by flavonoids 
found in grapefruit juice. J. Pharmacol. Exp. Ther. 261: 1196-1199 (1992). 
 




Mizelle J. W., Dunlap W. J., Hagen R. E., Wender S. H., Lime B. J., Albach R. F., 
Griffiths F. P. Isolation and identification of some flavanone rutinosides of the 
grapefruit. Anal. Biochem. 12: 316-324 (1965). 
 
Mohri K., Uesawa Y., and Sagawa K. Effects of long-term grapefruit juice ingestion 
on nifedipine pharmacokinetics: induction of rat hepatic P-450 by grapefruit 
juice. Drug Metab. Dispos. 28: 482-486 (2000).   
 
Molin L., Dahlström G., Nilsson M. I., Nyberg L., and Tekenbergs L. Solubility, 
partition, and adsorption of digitalis glycosides. Acta Pharm. Sci. 20: 129-144 
(1983). 
 
Mosmann T. Rapid colorimetric assay for cellular growth and survival: Application to 
proliferation and cytotoxicity assays. J. Immunol. Methods 65: 55-63 (1983). 
 
Motohashi H., Sakurai Y., Saito H., Masuda S., Urakami Y., Goto M., Fukatsu A., 
Ogawa O., and Inui K-I. Gene expression levels and immunolocalization of 
organic ion transporters in the human kidney. J. Am. Soc. Nephrol. 13: 866– 874 
(2002). 
 
Mouly P., Gaydou E. M., and Auffray A. Simultaneous separation of flavanone 
glycosides and polymethoxylated flavones in citrus juices using liquid 
chromatography. J. Chromatogr. A  800: 171-179 (1998).  
 




Mouly P., Gaydou E. M., and Estienne J. Column liquid chromatographic 
determination of flavanone glycosides in Citrus.  J. Chromatogr. 634: 129-134 
(1993). 
 
Muller C., Laurent G., and Ling V. P-glycoprotein stability is affected by serum 
deprivation and high cell density in multidrug-resistant cells. J. Cell Physiol. 
163: 538-544 (1995). 
 
Müller M. 49 Human ATP-binding cassette transporters. (2005) 
http://www.nutrigene.4t.com/humanabc.htm 
 
Nagel G., Volk C., Friedrich T., Ulzheimer J. C., Bamberg E., and Koepsell H. A re-
evaluation of substrate specificity of the rat cation transporter rOCT1. J. Biol. 
Chem. 272: 31953–31956 (1997). 
 
Nakamura T., Kakumoto M., Yamashita K., Takara K., Tanigawara Y., Sakaeda T., 
and Okumura K. Factors influencing the prediction of steady state 
concentrations of digoxin. Biol. Pharm. Bull. 24: 403-408 (2002). 
 
Nelson E. K. The occurrence of a pentamethyl flavonol in tangerine peel. J. Am. 
Chem. Soc. 56: 1392 (1934). 
 
Nierenberg D.W. Drug inhibition of penicillin tubular secretion: Concordance 
between in vitro and clinical findings. J. Pharmacol. Exp. Ther. 240: 712–716 
(1987). 




Ofer M., Wolffram S., Koggel A., Spahn-Langguth H., and Langguth P. Modulation 
of drug transport by selected flavonoids: Involvement of P-gp and OCT? Eur. J. 
Pharm. Sci. 25: 263-271 (2005).  
 
Ohnishi A., Matsuo H., Yamada S., Takanaga H., Morimoto S., Shoyamo Y., Ohtani 
H., and Sawada Y. Effect of furanocoumarin derivatives in grapefruit juice on 
the uptake of vinblastine by Caco-2 cells and on the activity of cytochrome P450 
3A4. Br. J. Pharmacol. 130: 1369-1377 (2000). 
 
Okuda M., Saito H., Urakami Y., Takano M., and Inui K-I. cDNA cloning and 
functional expression of a novel rat kidney organic cation transporter, OCT2. 
Biochem. Biophys. Res. Commun. 224: 500–507 (1996). 
 
Okuda M., Urakami Y., Saito H., and Inui K-I. Molecular mechanisms of organic 
cation transport in OCT2-expressing Xenopus oocytes. Biochim. Biophys. Acta 
1417: 224–231 (1999). 
 
Pade V., and Stavchansky S. Estimation of the relative contribution of the 
transcellular and paracellular pathway to the transport of passively absorbed 
drugs in the Caco-2 cell culture model. Pharm. Res. 14: 1210-1215 (1997). 
 
Paine M. F., Criss A. B., and Watkins P. B. Two major grapefruit juice components 
differ in intestinal CYP3A4 inhibition kinetic and binding properties. Drug 
Metab. Dispos. 32: 1146-1153 (2004). 
 




Paine M. F., Criss A. B., and Watkins P. B. Two major grapefruit juice components 
differ in time to onset of intestinal CYP3A4 inhibition. J. Pharmacol. Exp. Ther. 
312: 1151-1160 (2005). 
 
Paine M. F., Khalighi M., Fisher J. M., Shen D. D., Kunze K. L, Marsh C. L., Perkins 
J. D., and Thummel K. E. Characterization of interintestinal and intraintestinal 
variations in human CYP3A-dependent metabolism. J. Pharmacol. Exp. Ther. 
283: 1552-1562 (1997). 
 
Paine M. F., Shen D. D., Kunze K. L., Perkins J. D., Marsh C. L., McVicar J. P., Barr 
D. M., Gillies B. S., and Thummel K. E. First-pass metabolism of midazolam by 
the human intestine. Clin. Pharmacol. Ther. 60: 14-24 (1996). 
 
Pappenheimer J. R., and Reiss K. Z. Contribution of solvent drug through intercellular 
junctions to absorption of nutrients by the small intestine of the rat. J. Membr. 
Biol. 100: 123-136 (1987). 
  
Pascaud C., Garrigos M., and Orlowski S. Multidrug resistance transporter P-
glycoprotein has distinct but interacting binding sites for cytotoxic drugs and 
reversing agents. Biochem. J. 333: 351-358 (1998). 
  
Patki K. C., von Moltke L. L., and Greenblatt D. J. In vitro metabolism of midazolam, 
triazolam, nifedipine, and testosterone by human liver microsomes and 
recombinant cytochromes P450: role of CYP3A4 and CYP3A5. Drug Metab. 
Dispos. 31: 938-944 (2003). 




Pauli-Magnus C., Murdter T., Godel A., Mettang T., Eichelbaum M., Klotz U., and 
Fromm M. F. P-glycoprotein-mediated transport of digitoxin, α-methyldigoxin 
and β-acetyldigoxin. Naunyn-Schmiedeberg’s Arch. Pharmacol. 363: 337-343 
(2001). 
 
Pauli-Magnus C., Richter O. V., Burk O., Ziegler A., Mettang T., Eichelbaum M., and 
Fromm M. F. Characterization of the major metabolites of verapamil as 
substrates and inhibitors of P-glycoprotein. J. Pharmacol. Exp. Ther. 293: 376-
382 (2000).  
 
Penzak S. R., Acosta E. P., Turner M., Edwards D. J., Hon Y. Y., Desai H. D., and 
Jann M. W. Effect of Seville orange juice and grapefruit juice on indinavir 
pharmacokinetics. J. Clin. Pharmacol. 42: 1165-1170 (2002). 
 
Peters W. H., and Kremers P. G. Cytochromes P-450 in the intestinal mucosa of man. 
Biochem. Pharmacol. 38: 1535-1538 (1989). 
 
Pfaller W., Gstraunthaler G., and Loidl P. Morphology of the differentiation and 
maturation of LLC-PK1 epithelia. J. Cell Physiol. 142: 247-254 (1990). 
 
Pietruck F., and Ullrich K. J. Transport interactions of different organic cations during 
their excretion by the intact rat kidney. Kidney Int. 47: 1647-1657 (1995). 
 




Polli J. W., Wring S. A., Humphreys J. E., Huang L., Morgan J. B., Webster L. O., 
and Serabjit-Singh C. S. Rational use of in vitro P-glycoprotein assays in drug 
discovery.  J. Pharmacol. Exp. Ther. 299: 620-628 (2001). 
 
Pritchard J. B., and Miller D. S. Mechanisms mediating renal secretion of organic 
anions and cations. Physiol. Rev. 73: 765-796 (1993). 
 
Radtke. Intake and absorption of selected flavonoids. PhD Thesis. Department of food 
and nutrition, Technical University Munich. (2001). 
 
Raeissi S. D., Hidalgo I. J., Segura-Auguilar J., and P Artursson. Interplay between 
CYP3A4-mediated metabolism and polarized efflux of terfenadine in epithelial 
Caco-2 (TC7) cell monolayers. Pharm. Res. 16: 625-632 (1999). 
 
Rashid J., McKinstry C., Renwick A. G., Dirnhuber M., Waller D. G, and George C. 
F. Quercetin, an in vitro inhibitor of CYP3A, does not contribute to the 
interaction between nifedipine and grapefruit juice. Br. J. Clin. Pharmacol. 36: 
460-463 (1993). 
 
Rashid T. J., Martin U., Clarke H., Waller D. G., Renwick A. G., and George C. F. 
Factors affecting the absolute bioavailability of nifedipine. Br. J. Clin. 
Pharmacol. 40: 51-58 (1995). 
 




Rau S. E., Bend J. R., Arnold M. O., Tran L. T., Spence J. D., and Bailey D. G. 
Grapefruit juice-terfenadine single-dose interaction: magnitude, mechanism, and 
relevance. Clin. Pharmacol. Ther. 61: 401-409 (1997). 
 
Reves J. G., Fragen R. J., Vinik H. R., and Greenblatt D. J. Midazolam: 
pharmacology and uses. Anesthesiology. 62: 310-324 (1985). 
 
Rogers J. D., Zhao J., Liu L. D., Amin R. D., Gagliano K. D., Porras A. G., Blum R. 
A., Wilson M. F., Stepanavage M., and Vega J. M. Grapefruit juice has minimal 
effects on plasma concentrations of lovastatin-derived 3-hydroxy-3-
methylglutaryl coenzyme A reductase inhibitors. Clin. Pharmacol. Ther. 66: 
358-366 (1999). 
 
Romiti N., Tramonti G., Donati A., and Chieli E. Effects of grapefruit juice on the 
multidrug transporter P-glycoprotein in the human proximal tubular cell line 
HK-2. Life Sci. 76: 293-302 (2004). 
 
Sababi M., Borga O., and Hultkvist-Bengtsson U. The role of P-glycoprotein in 
limiting intestinal regional absorption of digoxin in rats. Eur. J. Pharm. Sci. 14: 
21-27 (2001). 
 
Sai Y. Biochemical and molecular pharmacological aspects of transporters as 
determinants of drug disposition. Drug Metab. Pharmacokinet. 20: 91-99 
(2005). 
 




Sai Y., and Tsuji A. Transporter-mediated drug delivery: recent progress and 
experimental approaches. Drug Discov. Today 9: 712-720 (2004). 
 
Saito M., Hirata-Koizumi M., Matsumoto M., Urano T., and Hasegawa R. 
Undesirable effects of citrus juice on the pharmacokinetics of drugs. Drug Saf. 
28: 677-694 (2005). 
 
Sakaeda T., Nakamura T., and Okumura K. MDR1 genotype-related pharmacokinetics 
and pharmacodynamics. Biol. Pharm. Bull. 25: 1391–1400 (2002). 
Sawada N., Murata M., Kikuchi K., Osanai M., Tobioka H., Kojima T., and Chiba H. 
Tight junctions and human diseases. Med. Electron Microsc. 36: 147-156 
(2003). 
 
Schäli C., Schild L., Overney J., and Roch-Ramel F. Secretion of 
tetraethylammonium by proximal tubules of rabbit kidneys. Am. Physiol. Renal 
Fluid Electrolyte Physiol. 245: F238–F246 (1983). 
 
Schinkel A. H. P-glycoprotein, a gatekeeper in the blood-brain barrier. Adv. Drug Del. 
Rev. 36: 179-194 (1999). 
 
Schinkel A. H., Roelofs E. M., and Borst P. Characterization of the human MDR3 P-
glycoprotein and its recognition by P-glycoprotein-specific monoclonal 
antibodies. Cancer Res. 51: 2628-2635 (1991).  
 




Schinkel A. H., Wagenaar E., van Deemter L., Mol C. A. A. M., and Borst P. 
Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and 
pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J. Clin. Invest. 
96: 1698-1705 (1995). 
 
Schmiedlin-Ren P., Edwards D. J., Fitzsimmons M. E., He K., Lown K. S., Woster P. 
K. M., Rahman A., Thummel K. E., Fisher J. M., Hollenberg P. F., and Watkins 
P. B. Mechanisms of enhanced oral availability of CYP3A4 substrates by 
grapefruit constituents: Decreased enterocyte CYP3A4 concentration and 
mechanism-based inactivation by furanocoumarins. Drug Metab. Dispos. 25: 
1228-1233 (1997). 
 
Schömig E., Babin-Ebell J., and Russ H. 1,1’-Diethyl-2,2’-cyanine (decynium 22) 
potently inhibits the renal transport of organic cations. Naunyn Schmiedebergs 
Arch. Pharmacol. 347: 379-383 (1993).  
 
Schrag M. L., and Wienkers L. C. Covalent alteration of the CYP3A4 active site: 
evidence for multiple substrate binding domains. Arch. Biochem. Biophys. 391: 
49-55 (2001). 
 
Schuetz E. G., Beck W. T., and Schuetz J. D. Modulators and substrates of P-
glycoprotein and cytochrome P450 3A4 coordinately up-regulate these proteins 
in human colon carcinoma cells. Mol. Pharmacol. 49: 311-318 (1996). 
 




Schwab D., Fischer H., Tabatabaei A., Poli S., and Huwyler J. Comparison of in vitro 
P-glycoprotein screening assays: Recommendations for their use in drug 
discovery. J. Med. Chem. 46: 1716-1725 (2003). 
 
Schwarz U. I., Seemann D., Oertel R., Miehlke S., Kuhlisch E., Fromm M. F., Kim R. 
B., Bailey D. G., and Kirch W. Grapefruit juice ingestion significantly reduces 
talinolol bioavailability. Clin. Pharmacol. Ther. 77: 291-301 (2005). 
 
Scora R. W. On the history and origin of Citrus. Bull. Torrey. Bot. Club. 102: 369-375 
(1975). 
Scudiero D. A., Shoemaker R. H., Paull K. D., Monks A., Tierney S., Nofziger T. H., 
Currens M. J., Seniff D., and Boyd M. R. Evaluation of a soluble tetrazolium/ 
formazan assay for cell growth and drug sensitivity in culture using human and 
other tumor cells lines. Cancer Res. 48: 4827-4833 (1988). 
 
Senior A. E., al-Shawi M. K., and Urbatsch I. L. The catalytic cycle of P-
glycoprotein. FEBS Lett. 377: 285-289 (1995). 
 
Shapiro A. B., and Ling V. Effect of quercetin on Hoechst 33342 transport by purified 
and reconstituted P-glycoprotein. Biochem. Pharmacol. 53: 587-596 (1997). 
 
Shapiro A. B., and Ling V. The mechanism of ATP-dependent multidrug transport by 
P-glycoprotein. Acta Physiol. Scand. Suppl. 643: 227-234 (1998). 
 




Shu Y., Bello C. L., Mangravite L. M., Feng B., and Giacomini K. M. Functional 
characteristics and steroid hormone-mediated regulation of an organic cation 
transporter in Madin-Darby canine kidney cells. J. Pharmacol. Exp. Ther. 299: 
392-398 (2001). 
 
Silverman R. B. Mechanism-based enzyme inactivation: chemistry and enzymology. 
Boca Raton (FL): CRC Press 1: 224 (1988a). 
 
Silverman R. B. Mechanism-based enzyme inactivation: chemistry and enzymology. 
Boca Raton (FL): CRC Press 2: 288 (1988b). 
 
Singh G. A possible cellular mechanism of cisplatin-induced nephrotoxicity. 
Toxicology. 58: 71-80 (1989). 
 
Singh R. R., Malaviya A. N., Pandley J. N., and Guleria J. S. Fatal interaction 
between methotrexate and naproxen. Lancet 1: 1390 (1986). 
 
Skowronek P., Haferkamp O., and Rodel G. A fluorescence-microscopic and flow-
cytometric study of HeLa cells with an experimentally induced respiratory 
deficiency. Biochem. Biophys. Res. Commun. 187: 991-998 (1992). 
 
Sladowski D., Steer S. J., Clothier R. H., and Balls M. An improved MTT assay. J. 
Immunol. Methods 157: 203-207 (1993). 
 




Smit J. W., Duin E., Steen H., Oosting R., Roggeveld J., and Meijer D. K. Interactions 
between P-glycoprotein substrates and other cationic drugs at the hepatic 
excretory level. Br. J. Pharmacol. 123: 361–370 (1998a). 
 
Smit J. W., Weert B., Schinkel A. H., and Meijer D. K. F. Heterologous expression of 
various P-glycoproteins in polarized epithelial cells induces directional transport 
of small (Type 1) and bulky (Type 2) cationic drugs. J. Pharmacol. Exp. Ther. 
286: 321-327 (1998b). 
 
Smith M. T., Eadie M. J., and Brophy T. O. The pharmacokinetics of midazolam in 
man. Eur. J. Clin. Pharmacol. 19: 271-278 (1981). 
 
Spahn-Langguth H., and Langguth P. Grapefruit juice enhances intestinal absorption 
of the P-glycoprotein substrate talinolol. Eur. J. Pharm. Sci. 12: 361-367 (2001). 
 
Spence J. D. Drug interactions with grapefruit: whose responsibility is it to warn the 
public? Clin. Pharmacol. Ther. 61: 395-400 (1997). 
 
Stephens R. H., Tanianis-Hughes J., Higgs N. B., Humphrey M., and Warhurst G. 
Region-dependent modulation of intestinal permeability by drug efflux 
transporters: in vitro studies in mdr1a (-/-) mouse intestine. J. Pharmacol. Exp. 
Ther. 303: 1095-1101 (2002). 
 
Sugawara-Yokoo M., Urakami Y., Koyama H., Fujikura K., Masuda S., Saito H., 
Naruse T., Inui K., and Takata K. Differential localization of organic cation 




transporters rOCT1 and rOCT2 in the basolateral membrane of rat kidney 
proximal tubules. Histochem. Cell Biol. 114: 175-180 (2000). 
 
Suhre W. M., Ekins S., Cheng C., Swaan P. W., and Wright S. H. Molecular 
determinants of substrate/inhibitor binding to the human and rabbit renal organic 
cation transporters hOCT2 and rbOCT2. Mol. Pharmacol. 67: 1067–1077 
(2005). 
  
Suzuki H., and Sugiyama Y. Role of metabolic enzymes and efflux transporters in the 
absorption of drugs from the small intestine. Eur. J. Pharm. Sci. 12: 3-12 
(2000). 
 
Sweet D. H., Bush K. T., and Nigam S. K. The organic anion transporter family: from 
physiology to ontogeny and the clinic. Am. J. Physiol. Renal Physiol. 281: 
F197-F205 (2001). 
 
Sweet D. H. and Pritchard J. B. The molecular biology of renal organic anion and 
organic cation transporters. Cell Biochem. Biophys. 31: 89-118 (1999). 
 
Swift L. J. TLC-spectrophotometric analysis for neutral fraction flavones in orange 
peel juice. J. Agri. Food Chem. 15: 99 (1967). 
 
Taipalensuu J., Tavelin S., Lazorova L., Svensson A. C., and Artursson P. Exploring 
the quantitative relationship between the level of MDR1 transcript, protein and 




function using digoxin as a marker of MDR1-dependent drug efflux activity. 
Eur. J. Pharm. Sci. 21: 69-75 (2004). 
 
Takanaga H., Ohnishi A., Matsuo H., and Sawada Y. Inhibition of vinblastine efflux 
mediated by P-glycoprotein by grapefruit juice components in Caco-2 cells. 
Biol.  Pharm. Bull. 21: 1062-1066 (1998). 
 
Takanaga H., Ohnishi A., Murakami H., Matsuo H., Higuchi S., Urae A., Irie S., 
Furuie H., Matsukuma K., Kimura M., Kawano K., Orii Y., Tanaka T., and 
Sawada Y. Relationship between time after intake of grapefruit juice and the 
effect on pharmacokinetics and pharmacodynamics of nisoldipine in healthy 
subjects. Clin. Pharmacol. Ther. 67: 201-214 (2000a).  
 
Takanaga H., Ohnishi A., Yamada S., Matsuo H., Morimoto S., Shoyamo Y., Ohtani 
H., and Sawada Y. Polymethoxylated flavones in orange juice are inhibitors of 
P-glycoprotein but not cytochrome P450 3A4. J. Pharmacol. Exp. Ther. 293: 
230-236 (2000b). 
 
Takara K., Kakumoto M., Tanigawara Y., Funakoshi J., Sakaeda T., and Okumura K. 
Interaction of digoxin with antihypertensive drugs via MDR1. Life Sci. 70: 
1491-1500 (2002). 
 
Takara K., Ohnishi N., Horibe S., and Yokoyama T. Expression profiles of drug-
metabolizing enzyme CYP3A and drug efflux transporter multidrug resistance 1 




subfamily mRNAS in small intestine. Drug Metab. Dispos. 31: 1235-1239 
(2003). 
 
Tanigawara Y., Okamura N., Hirai M., Yasuhara M., Ueda K., Kioka N., Komano T., 
and Hori R. Transport of digoxin by human P-glycoprotein expressed in a 
porcine kidney epithelial cell line (LLC-PK1). J. Pharmacol. Exp. Ther. 263: 
840-845 (1992). 
 
Tassaneeyakul W., Guo L. Q., Fukuda K., Ohta T., and Yamazoe Y. Inhibition 
selectivity of grapefruit juice components on human cytochromes P450. Arch. 
Biochem. Biophys. 378: 356-363 (2000). 
 
ter Horst P. G. J., Foudraine N. A., Cuypers G., van Dijk E. A., and Oldenhof N. J. J. 
Simultaneous determination of levomepromazine, midazolam and their major 
metabolites in human plasma by reversed-phase liquid chromatography. J. 
Chromatogr. B Analyt. Technol. Biomed. Life Sci. 791: 389-398 (2003). 
 
Terao T., Hisanaga E., Sai Y., Tamai I., and Tsuji A. Active secretion of drugs from 
the small intestinal epithelium in rats by P-glycoprotein functioning as an 
absorption barrier. J. Pharm. Pharmacol. 48: 1083-1089 (1996). 
 
Thiebaut F., Tsuruo T., Hamada H., Gottesman M. M., Pastan I., and Willingham M. 
C. Cellular localization of the multidrug-resistance gene product P-glycoprotein 
in normal human tissues. Proc. Natl. Acad. Sci. U.S.A. 84: 7735-7738 (1987). 
 




Thummel K. E., O'Shea D., Paine M. F., Shen D. D., Kunze K. L., Perkins J. D., and 
Wilkinson G. R. Oral first-pass elimination of midazolam involves both 
gastrointestinal and hepatic CYP3A-mediated metabolism. Clin. Pharmacol. 
Ther. 59: 491-502 (1996). 
 
Thummel K. E., and Wilkinson G. R. In vitro and in vivo drug interactions involving 
human CYP3A. Annu. Rev. Pharmacol. Toxicol. 38: 389-430 (1998). 
 
Tian R., Koyabu N., Takanaga H., Matsuo H., Ohtani H., and Sawada Y. Effects of 
grapefruit juice and orange juice on the intestinal efflux of P-glycoprotein 
substrates. Pharm. Res. 19:  802-809 (2002). 
 
Tirona R. G., and Kim R. B. Pharmacogenomics of organic anion-transporting 
polypeptides (OATP). Adv. Drug Deliv. Rev. 54: 1343-1352 (2002). 
Tran T. H., von Moltke L. L., Venkatakrishnan K., Granda B. W., Gibbs M. A., 
Obach R. S., Harmatz J. S., and Greenblatt D. J. Microsomal protein 
concentration modifies the apparent inhibitory potency of CYP3A inhibitors. 
Drug Metab. Dispos. 30: 1441-1445 (2002). 
 
Troutman M. D., and Thakker D. R. Rhodamine 123 requires carrier-mediated influx 
for its activity as a P-glycoprotein substrate in Caco-2 cells. Pharm. Res. 20: 
1192-1199 (2003a). 
 
Troutman M. D., and Thakker D. R. Novel experimental parameters to quantify the 
modulation of absorptive and secretory transport of compounds by P-




glycoprotein in cell culture models of intestinal epithelium. Pharm. Res. 20: 
1210-1224 (2003b). 
  
Tseng K. F. Nobiletin. Part I., an oil extracted by cold methyl alcohol from Citrus 
nobilis, Lour, affords nobiletin, a hexamethoxyflavone containing a veratryl 
nucleus. Chem. Soc. 1003-1004 (1938). 
 
Tsuji A., and Tamai I. Carrier-mediated intestinal transport of drugs. Pharm. Res. 13: 
963-977 (1996). 
 
Tsunoda S. M., Velez R. L., von Moltke L. L., and Greenblatt D. J. Differentiation of 
intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an 
in vivo probe: effect of ketoconazole. Clin. Pharmacol. Ther. 66: 461-471 
(1999). 
Tukker J. J. Characterization of transport over epithelial barriers, in Cell culture 
models of biological barriers: In vitro test systems for drug absorption and 
delivery, Lehr C-M (Ed.), Taylor and Francis, London and New York. pp. 52-61 
(2003). 
 
Ueda K., Cornwell M. M., Gottesman M. M., Pastan I., Roninson I. B., Ling V., and 
Riordan J. R. The mdr1 gene responsible for multidrug resistance codes for P-
glycoprotein. Biochim. Biophys. Res. Commun. 141: 956-962 (1986). 
 
Ueda K., Taguchi Y., and Morishima M. How does P-glycoprotein recognize its 
substrates? Sem. Cancer Biol. 8: 151-159 (1997). 




Ullrich K. J. Specificity of transporters for ‘organic anions’ and ‘organic cations’ in 
the kidney. Biochim. Biophys. Acta. 1197: 45-62 (1994). 
 
Ullrich K. J., and Rumrich G. Luminal transport system for choline+ in relation to the 
other organic cation transport systems in the rat proximal tubule. Kinetics, 
specificity: alkyl/arylamines, alkylamines with OH, O, SH, NH2, ROCO, RSCO 
and H2PO4-groups, methylaminostyryl, rhodamine, acridine, phenanthrene and 
cyanine compounds. Pflügers Arch-Eur. J. Physiol. 432: 471-485 (1996). 
 
Ungell A. L., Nylander S., Bergstrand S., Sjoberg A., and Lennernas H. Membrane 
transport of drugs in different regions of the intestinal tract of the rat. J. Pharm. 
Sci. 87: 360-366 (1998). 
 
Uno T., Ohkubo T., Sugawara K., Higashiyama A., Motomura S., and Ishizaki T. 
Effects of grapefruit juice on the stereoselective disposition of nicardipine in 
humans: evidence for dominant presystemic elimination at the gut site. Eur. J. 
Clin. Pharmacol. 56: 643-649 (2000). 
 
van Crugten J., Bochner F., Keal J., and Somogoyi A. Studies with anionic, cationic 
and zwitterionic Drugs. J. Pharmacol. Exp. Ther. 236: 481–487 (1986).  
 
van der Sandt I. C., Blom-Roosemalen M. C., de Boer A. G., and Breimer D. D. 
Specificity of doxorubicin versus rhodamine-123 in assessing P-glycoprotein 
functionality in the LLC-PK1, LLC-PK1: MDR1 and Caco-2 cell line. Eur. J. 
Pharm. Sci. 11: 207-214 (2000). 




van Meer G., and Simons K. The function of tight junctions in maintaining 
differences in lipid composition between the apical and the basolateral cell 
surface domains of MDCK cells. EMBO J. 5: 1455-1464 (1986). 
 
van Montfoort J. E., Muller M., Groothuis G. M., Meijer D. K., Koepsell H., and 
Meier P. J. Comparison of “type I” and “type II” organic cation transport by 
organic cation transporters and organic anion-transporting polypeptides. J. 
Pharmacol. Exp. Ther. 298: 110–115 (2001). 
 
Venkatakrishnan K., von Moltke L. L., and Greenblatt D. J. Effects of the antifungal 
agents on oxidative drug metabolism: clinical relevance. Clin. Pharmacokinet. 
38: 111-180 (2000). 
Verhaagh S., Schweifer N., Barlow D. P., and Zwart R. Cloning of the mouse and 
human solute carrier 22a3 (Slc22a3/SLC22A3) identifies a conserved cluster of 
three organic cation transporters on mouse chromosome 17 and human 6q26–
q27. Genomics 55: 209–218 (1999). 
 
Veronese M., Burke J., Dorval E.,  Pequignot E., Waldman S., and Greenberg H. 
Grapefruit juice (GFJ) inhibits hepatic and intestinal CYP3A4 dose-dependently 
(Abstract PIII-37). Clin. Pharmacol. Ther. 67: 151 (2000).  
 
Veronese M. L., Gillen L. P., Burke J. P., Dorval E. P., Hauck W. W., Pequignot E., 
Waldman S. A., and Greenberg H. E. Exposure-dependent inhibition of 
intestinal and hepatic CYP3A4 in vivo by grapefruit juice. J. Clin. Pharmacol. 
43: 831-839 (2003).  




Violini S., Sharma V., Prior J. L., Dyszlewski M., and Piwnica-Worms D. Evidence 
for a plasma membrane-mediated permeability barrier to Tat basic domain in 
well-differentiated epithelial cells: Lack of correlation with heparan sulfate. 
Biochemistry 41: 12652-12661 (2002). 
 
von Moltke L. L., Greenblatt D. J., Harmatz J. S., Duan S. X., Harrel L. M., Cotreau-
Bibbo M. M., Pritchard G. A., Wright C. E., and Shader R. I. Triazolam 
biotransformation by human liver microsomes in vitro: effects of metabolic 
inhibitors and clinical confirmation of a predicted interaction with ketoconazole. 
J. Pharmacol. Exp. Ther. 276: 370-379 (1996a). 
 
von Moltke L. L., Greenblatt D. J., Schmider J., Duan S. X., Wright C. E., Harmatz J. 
S., and Shader R. I. Midazolam hydroxylation by human liver microsomes in 
vitro: inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents. J. 
Clin. Pharmacol. 36: 783-791 (1996b). 
 
Wacher V. J., Salphati L., and Benet L. Z. Active secretion and enterocytic drug 
metabolism barriers to drug absorption. Adv. Drug Del. Rev. 20: 99-112 (1996). 
 
Wacher V. J., Silverman J. A., Zhang Y., and Benet L. Z. Role of P-glycoprotein and 
cytochrome P450 3A in limiting oral absorption of peptides and 
peptidomimetics. J. Pharm. Sci.  87: 1322-1330 (1998). 
 
Wacher V. J., Wu C. Y., and Benet L. Z. Overlapping substrate specificities and tissue 
distribution of cytochrome P450 3A and P-glycoprotein: implications for drug 




delivery and activity in cancer chemotherapy. Mol. Carcinog. 13: 129-134 
(1995). 
 
Wagner D., Spahn-Langguth H., Hanafy A., Koggel A., and Langguth P. Intestinal 
drug efflux: formulation and food effects. Adv. Drug Del. Rev. 50: S13-S31 
(2001). 
 
Walgren R. A., and Walle T. The influence of plasma binding on 
absorption/exsorption in the Caco-2 model of human intestinal absorption. J. 
Pharm. Pharmacol. 51: 1037-1040 (1999). 
 
Walters H. C., Craddock A. L., Fusegawa H., Willingham M. C., and Dawson P. A. 
Expression, transport properties, and chromosomal location of organic anion 
transporter subtype 3. Am. J. Physiol-Gastrointestinal Liver Physiol. 279: 
G1188-G1200 (2000). 
 
Wandel C., Kim R. B., Kajiji S., Guengerich F. P., Wilkinson G. R., and Wood A. J. 
J. P-glycoprotein and cytochrome P-450 3A inhibition: Dissociation of 
inhibitory potencies. Cancer Res. 59: 3944-3948 (1999). 
 
Wandel C., Kim R., Wood M., and Wood A. Interaction of morphine, fentanyl, 
sufentanil, alfentanil, and loperamide with the efflux drug transporter P-
glycoprotein. Anesthesiology. 96: 913-920 (2002). 
 




Wang E-J., Casciano C. N., Clement R. P., and Johnson W. W. Inhibition of P-
glycoprotein transport function by grapefruit juice psoralen. Pharm. Res. 18: 
432-438 (2001). 
 
Ward P. D., Tippin T. K., and Thakker D. R. Enhancing paracellular permeability by 
modulating epithelial tight junctions. Pharm. Sci. Technol. Today 3: 346-358 
(2000). 
 
Watkins P. B. The barrier function of CYP3A4 and P-glycoprotein in the small bowel. 
Adv. Drug Del. Rev. 27: 161-170 (1997). 
 
Watkins P. B., Wrighton S. A., Schuetz E. G., and Guzelian P. S. Identification of 
glucocorticoid-inducible cytochromes P450 in the intestinal mucosa of rats and 
man. J. Clin. Invest. 80: 1029-1036 (1987). 
 
Weber A., Jager R., Borner A., Klinger G., Vollanth R., Matthey K., and Balogh A. 
Can grapefruit juice influence ethinylestradiol bioavailability? Contraception 
53: 41-47 (1996). 
 
Wigler P.W. Cellular drug efflux and reversal therapy of cancer. J. Bioenerg. 
Biomembr. 28: 279-284 (1996). 
 
Woodland C., Verjee Z., Giesbrecht E., Koren G., and Ito S. The digoxin-propafenone 
interaction: Characterization of a mechanism using renal tubular cell 
monolayers. J. Pharmacol. Exp. Ther. 283: 39-45 (1997). 




Wright S. H. Role of organic cation transporters in the renal handling of therapeutic 
agents and xenobiotics. Toxicol. Appl. Pharmacol. 204: 309-319 (2005). 
 
Wright S. H., and Dantzler W. H. Molecular and cellular physiology of renal organic 
cation and anion transport. Physiol. Rev. 84: 987-1049 (2004).  
 
Wright S. H., Wunz T. M., and Wunz T. P. Structure and interaction of inhibitors with 
the TEA/H+ exchanger of rabbit renal brush border membranes. Pflugers Arch. 
429: 313–324 (1995). 
 
Wrighton S. A., and Ring B. J. Inhibition of human CYP3A catalyzed 1'-hydroxy 
midazolam formation by ketoconazole, nifedipine, erythromycin, cimetidine, 
and nizatidine. Pharm. Res. 11: 921-924 (1994). 
 
Wu C. Y., Benet L. Z., Hebert M. F., Gupta S. K., Rowland M., Gomez D. Y., and 
Wacher V. J. Differentiation of absorption and first-pass gut and hepatic 
metabolism in humans: studies with cyclosporine. Clin. Pharmacol. Ther. 58: 
492-497 (1995). 
 
Wu X., Prasad P. D., Leibach F. H., and Ganapathy V. cDNA sequence, transport 
function and genomic organization of human OCTN2, a new member of the 
organic cation transporter family. Biochem. Biophys. Res. Commun. 246: 589–
595 (1998). 
 




Xu J., Go M. L., and Lim L-Y. Modulation of digoxin transport across Caco-2 cell 
monolayers by citrus fruit juices: Lime, Lemon, Grapefruit, and Pummelo. 
Pharm. Res. 20: 169-176 (2003). 
 
Yasui N., Kondo T., Furukori H., Kaneko S., Ohkubo T., Uno T., Osanai T., 
Sugawara K., and Otani K. Effects of repeated ingestion of grapefruit juice on 
the single and multiple oral dose pharmacokinetics and pharmacodynamics of 
alprazolam. Psychopharmacology (Berl) 150: 185-190 (2000). 
 
Yee G. C., Stanley D. L., and Pessa L. J. Effect of grapefruit juice on blood 
cyclosporine concentration. Lancet 345: 955-956 (1995). 
Yee S. In vitro permeability across Caco-2 cells (colonic) can predict in vivo (small 
intestinal) absorption in man-fact or myth. Pharm. Res. 14: 763-766 (1997). 
 
Yee S. Y., and Day W. W. Applications of Caco-2 cells in drug discovery and 
development, in Handbook of drug metabolism, Marcel Dekker, Inc. pp. 507-
522 (1999). 
 
Yuan R., Flockhart D. A., and Balian J. D. Pharmacokinetic and pharmacodynamic 
consequences of metabolism-based drug interactions with alprazolam, 
midazolam, and triazolam. J. Clin. Pharmacol. 39: 1109-1125 (1999). 
 
Yuan R., Madani S., Wei X-X., Reynolds K., and Huang S-M. Evaluation of 
cytochrome P450 probe substrates commonly used by the pharmaceutical 




industry to study in vitro drug interactions. Drug Metab. Dispos. 30: 1311-1319 
(2002). 
 
Yumoto R., Murakami T., Nakamoto Y.,  Hasegawa R.,  Nagai J.,  and Takano  M. 
Transport of rhodamine 123, a P-glycoprotein substrate, across rat intestine and 
Caco-2 cell monolayers in the presence of cytochrome P-450 3A-related 
compounds. J. Pharmacol. Exp. Ther. 289: 149-155 (1999). 
 
Zaidenstein R., Soback S., Gips M., Avni B., Dishi V., Weissgarten Y., Golik A., and 
Scapa E. Effect of grapefruit juice on the pharmacokinetics of losartan and its 
active metabolite E3174 in healthy volunteers. Ther. Drug Monit. 23: 369-373 
(2001). 
 
Zastre J., Jackson J., Bajwa M., Liggins R., Iqbal F., and Burt H. Enhanced cellular 
accumulation of a P-glycoprotein substrate, rhodamine-123, by Caco-2 cells 
using low molecular weight methoxypolyethylene glycol-block-
polycaprolactone diblock copolymers. Eur. J. Pharm. Biopharm. 54: 299-309 
(2002). 
 
Zhang L., Brett C. M., and Giacomini K. M. Role of organic cation transporters in 
drug absorption and elimination. Annu. Rev. Pharmacol. Toxicol. 38: 431-460 
(1998). 
 
Zhou S., Lim L. Y., and Chowbay B. Herbal modulation of P-glycoprotein. Drug 
Metab. Rev. 36: 57-104 (2004). 






























































































































                                                           (b) 
Figure 9.1.  Standard curves of (a) MDZ and (b) 1’-OH MDZ concentrations versus 
peak areas relative to internal standard, IS (10 μM norclomipramine HCl). 
 
 
 
 
 
